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Abstract
In this thesis, metabolic routes were developed for the production of hydroxyacids and
their lactones in multiple microbial systems. These compounds see widespread use in the
production of pharmaceuticals, polymers, and fine chiral intermediates. First in this
thesis, strategies and tools for metabolic pathway design are discussed. This is followed
by the descriptions of and data for each microbial production system.
The compounds produced in this thesis and their highest titers obtained are shown below:
3-Hydroxybutyrate (3HB) 2.9 g/L
3-Hydroxyvalerate (3HV) 5.3 g/L
4-Hydroxyvalerate (4HV) 27.1 g/L
4-Valerolactone (4VL) 8.2 g/L
3,4-Dihydroxybutyrate (DHBA) 3.2 g/L
3-Hydroxybutyrolactone (3-HBL) 2.2 g/L
The production of the two hydroxyvalerates was accomplished through the reduction of
the renewable substrate levulinate in Pseudomonas putida by endogenous host enzymes
followed by the liberation of the hydroxyvalerate product through the recombinant
expression of thioesterase B (tesB). The production of 4VL was accomplished from
levulinate by adding the lactonase paraoxonase I (PON1) to the P. putida
hydroxyvalerate production system. Because 4VL was found to exist in a pH-dependent
equilibrium with 4HV, the lactonase was expressed extracytosolically in acidic media to
achieve significant titers of 4VL. The addition of a second resin phase to 4VL-producing
cultures with a high affinity for 4VL substantially enhanced lactone production.
3HB, 3HV, DHBA, and 3-HBL were all produced in Escherichia coli through the
expression of an acetoacetyl-CoA thiolase (thil, bktB, or phaA), a 3-hydroxybutyryl-CoA
reductase (phaB or hbd), and tesB. Supplying glucose to E. coli expressing these
enzymes resulted in 3HB production, while supplying glucose and propionate results in
3HV production. Supplying glucose and glycolate resulted in DHBA production with
some 3-HBL, but only with the help of a fourth gene - propionyl-CoA transferase (pct).
Removing the tesB gene from this four-gene system substantially increases 3-HBL titers
at the expense of DHBA. This work represents the first successful production of DHBA
and 3-HBL in a biological system from carbohydrate-based substrates.
In each of these systems, several broadly-applicable tools and strategies were developed
to enhance product titer or discover new metabolic activities. In the P. putida system,
cytosolic and extracytosolic biocatalysis were combined in a single metabolic pathway to
realize lactone production. This catalytic strategy, termed integrated bioprocessing, is
applicable to other metabolic pathways whose production suffers due to a suboptimal
cytosolic enzyme. Also in the P. putida system, two-phase cultures were used to
sequester the lactone product away from the lactonase, helping to drive lactone-
hydroxyacid equilibrium towards the lactone. This methodology allows one to overcome
equilibrium-based limitations of product titer. Finally in the E. coli work, a promiscuous
pathway normally used for polyhydroxyalkanoate synthesis was exploited to give a wide
range of hydroxyacid products. This substrate promiscuity was critical in achieving the
production of new compounds biologically and thus substrate promiscuity was identified
as a key component for metabolic pathway design and construction.
Thesis Supervisor: Kristala Jones Prather
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Chapter 1: Introduction
Motivation and Obiectives
Biotechnology is rapidly becoming a major industry for the production of chemicals,
fuels, and pharmaceuticals. Several modem medicines are made biologically, including
the antimalarial compound artemisinin (Ro et al., 2006) and human insulin (Goeddel et
al., 1979). Recently, the Energy Policy Act of 2005 (Public Law 109-58) mandated the
increasing production and blending of biofuels in gasoline. The costs of non-renewable
supplies of material for chemical and fuel production, namely oil, are rising as
environmental and security concerns over these resources mount while the quantity of the
resources dwindles. Biotechnology is being turned to not only to produce the more
intricate and complex compounds for humanity, but also the everyday commodity
chemicals that impact the lives of everyone daily. First and foremost, this thesis was
done as a small contribution to this growing shift towards biotechnology.
More specifically, the main objective of this thesis was to develop novel, unnatural
metabolic pathways for the biosynthesis of hydroxyacids and lactones. Hydroxyacids are
versatile, chiral compounds that contain both a carboxyl and a hydroxyl moiety, readily
allowing for the modification of this class of compounds into several useful derivatives
(Lee et al., 2002; Chen and Wu, 2005). Specifically, hydroxyacids see use in the
synthesis of antibiotics (Chiba and Nakai, 1985), P- and y-aminoacids and peptides (Park
et al., 2001; Seebach et al., 2001), and as chiral synthetic building blocks (Lee, 2002).
Hydroxyacids can also be used directly as nutritional supplements (Tasaki et al., 1999)
and can be polymerized into biodegradable polyesters (polyhydroxyalkanoates, or PHAs)
with interesting physical properties (Hazer and Steinbiichel, 2007). Figure 1.1 depicts the
various uses of hydroxyacids.
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4. Verlinden et at, J. Appl. Microbiol, 2007, 102:1437-1449.
Figure 1.1: Applications of hydroxyacids for the synthesis of antibiotics (A), synthetic aminoacids (B),
and plastics (C and D).
Of the lactones, 4-valerolactone (4VL), has been reported to be an ideal compound for
use as a fuel and in the production of carbon-based chemicals (Horvith et al., 2008). It
has also seen extensive use as a component of block-copolymers for drug delivery
(Attwood et al., 2007; Chang and Chu, 2008), as a precursor for acrylic compounds
(Manzer, 2004), and can be used as a precursor for the production of "bio-nylon"
polymers (Lange et al., 2007). Another lactone, 3-hydroxybutyrolactone (3-HBL), is
widely used in the pharmaceutical industry as a building block for the class of
cholesterol-reducing drugs called statins such as Crestor(R) and Lipitor(R) as well as the
antibiotic Zybox(R) and the anti-hyperlipidemic medication Ezetimibe(R) (Lee et al., 2008;
Lee and Park, 2009). 3-HBL has been listed as one of the top ten value-added chemicals
by the U.S. Department of Energy (Werpy and Peterson, 2004). Figure 1.2 below (taken
from Werpy and Peterson, 2004) illustrates a variety of derivitization routes available for
3-HBL.
9Buteny-Iactone
3-Hydroxytetrahydrfura Cp M= MW
HO Epoxy4actane
H2 3-Hydroxybutyrolacton C4 A W=
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0 Acrylate-actone
tetrahydrofuran 4 M= 15BA4
Figure 1.2: Routes for derivitization of 3-HBL into other compounds of use proposed by Werpy and
Peterson (2004). Compounds circled in yellow currently see commodity-scale commercial use.
There exists no natural, complete biochemical route for the synthesis of 3-HBL or its
hydroxyacid form 3,4-dihydroxybutyrate (DHBA), nor has one yet been engineered.
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Currently 3-HBL costs about $20-50 per gram (depending on quantity and enantiopurity)
and is made chemically through high-pressure hydrogenation of carbohydrates over
ruthenium-based catalysts (Hollingworth and Wang, 2000). This method produces many
byproducts that are difficult to separate from 3-HBL, driving up the cost of the product.
Other synthetic methods employ bacterial dehalogenation of the expensive chlorinated
precursor 4-chloro-3-hydroxybutyrate (Suzuki et al., 1999; Nakagawa et al., 2006). A
combination chemical and biological production scheme has been developed to reduce
malic acid to 3-HBL using hydrogenation over a zinc catalyst, benzyl chloride, and
immobilized lipase (Lee et al., 2008). The goal of this thesis was to create a novel
completely biological route for 3-HBL synthesis. This method also suffers from the need
for expensive reagents and purification. A summary of current methods for producing 3-
HBL is shown in Figure 1.3 below.
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Figure 1.3: Summary of current methods for producing 3-HBL, with their drawbacks highlighted with
various colors.
Because the primary thesis goal was microbial lactone production, two different
strategies for lactonization were examined. First, a system was engineered in
Pseudomonas putida for the production of 4-valerolactone (4VL) from levulinate. In this
system, the lactonization strategy was to make 4VL from its free hydroxyacid, 4-
hydroxyvalerate (4HV). 4HV and 4VL exist in a pH-dependent equilibrium with one
another (Teiber et al., 2003), so the P. putida cell system was engineered to exploit this
equilibrium by performing the lactonization reaction extracytosolically in acidic medium
to enhance lactone production. To further increase production, a two-phase reaction
system was employed to sequester the lactone away from the cells, further driving the
equilibrium towards lactone production. The second lactone production system was the
3-hydroxybutyrolactone (3-HBL) production system in Escherichia coli. Here, 3-HBL
was produced from the activated precursor 3,4-dihydroxybutyryl-CoA. A thioesterase
was employed to control production - with a thioesterase present 3,4-dihydroxybutyrate
(DHBA) was produced, while without it 3-HBL was produced. Since in this system there
was no lactonase, there was no appreciable equilibrium between DHBA and 3-HBL.
Rather, the coenzyme A (CoA) moiety on DHBA-CoA activates the DHBA for
spontaneous lactonization.
The secondary objective of this thesis was to discover pathway design or implementation
strategies for enabling new metabolic routes and enhancing product titers. Given the
sheer number of known enzymes (both natural and engineered) and enzyme-catalyzed
reactions available, there almost certainly exists many possible metabolic pathways
towards a given target compound or class of compounds (Li et al., 2004; Hatzimanikatis
et al., 2005; Prather and Martin, 2008; Martin et al., 2009). How does one sort through
these possibilities and identify promising pathways? What experimental issues must be
addressed to construct and implement these pathways? As a part of this thesis, a database
of enzyme-catalyzed reactions called the Retro-Biosynthetic Tool (ReBiT) was
constructed to assist in metabolic pathway design by identifying enzymes that carry out a
desired chemical reaction.
Organization and Summary
This thesis is organized into three distinct sections. First, metabolic pathway design and
construction are discussed in Chapter 2. This chapter, which contains primarily
background information on the field of metabolic pathway construction, reviews the
various experimental and computational methods available for pathway design and
discusses in detail the ReBiT database of enzyme-catalyzed transformations. This insight
into pathway design is then put to practice experimentally in the next two sections. These
sections describe two different metabolic systems constructed for the biosynthesis of two
different lactones.
Chapters 3 and 4 describe the engineering of P. putida for the synthesis of 4VL from
levulinate (Figure 3.6 and 4.1). To overcome a pH-dependent equilibrium limitation on
making 4VL from its hydroxyacid in aqueous media, the lactonization reaction was
catalyzed outside of the cytosol at an acidic pH. By performing the lactonization reaction
outside of the cell, the pH at which the reactor occurs can be manipulated to give higher
titers of lactones. Chapter 3 discusses the biosynthesis of 4HV from levulinate in P.
putida. Different culturing conditions were tested for this process, and a maximum of
13.9 + 1.2 g L-1 of 4HV could be produced from levulinate in shake flasks. This process
was also found to make 3HV, and a maximum titer of 5.3 ± 0.1 g L' of this compound
could be made at the shake flask scale. Chapter 4 builds upon the 4HV-producing system
from Chapter 3 by expressing the lactonase paraoxonase I (PON1) extracytosolically.
The expression of PON1 outside of the cytosol was established in E. coli and P. putida
(Table 4.1), and using this system 2.1 ± 0.1 g L and 8.2 g L-' of 4VL could be produced
from levulinate at the shake-flask and bioreactor scales respectively (Figures 4.5 and 4.6,
respectively).
Chapters 5 and 6 describe the production of 3-hydroxyacids in E. coli through the 3-
hydroxyalkanoic acid pathway (Figures 5.1 and 6.1). Chapter 5 details the production of
the simplest 3-hydroxyacid, 3-hydroxybutyrate (3HB), as well as the CoA-manipulation
tools needed to produce this molecule and the analytical methods developed to determine
its chirality. Here it was found that by feeding recombinant E. coli glucose 2.9 + 0.2 g L-
1 of (R)-3HB and 2.0 ± 0.1 g L-' of (S)-3HB could be produced at the shake-flask scale.
Chapter 6 focuses on the application of the 3-hydroxyalkanoic acid pathway to the
production of 3-hydroxyvalerate (3HV), DHBA and 3-HBL. Specifically, this chapter
describes the successful condensation of acetyl-CoA with propionyl-CoA to form 3HV or
glycolyl-CoA to form DHBA and 3-HBL. The highest titers of 3HV produced were 537
g L-' of (R)-3HV and 522 mg L-1 of (S)-3HV. The highest titers obtained for DHBA and
3-HBL were 3.2 g L' and 2.2 g L', respectively (Figures 6.9). This chapter also
discusses how to alter the product profiles of DHBA and 3-HBL through the expression
of the tesB thioesterase and through an acidic post-treatment of the culture broth.
Finally, Chapter 7 first summarizes all of the pathways, products, and titers presented in
Chapters 2-6 and draws broader conclusions about the case studies presented in these
chapters. Generalities for pathway design are discussed, and this discussion is applied
specifically to the problem of in vivo lactonization. This chapter concludes by providing
discussion and outlook for the field of metabolic engineering - specifically the subfields
of novel pathway construction and synthetic biology.
Chapter 2: Metabolic Pathway Design
This chapter contains material published in Prather and Martin, 2008 and Martin et al., 2009.
Synthetic biology has emerged as a powerful discipline for the creation of novel
biological systems (Endy, 2005; Pleiss, 2006), particularly within the subfield of
metabolic pathway and product engineering (Keasling, 2008; Savage et al., 2008).
Continuing efforts to characterize and understand natural enzymes and pathways have
opened the door for the building of synthetic pathways towards exciting and beneficial
compounds such as the anti-malarial drug precursor artemisinic acid (Ro et al., 2006) and
several branched-chain alcohols for use as biofuels (Atsumi et al., 2007). The need for
synthetic metabolic routes is a consequence of the fact that the array of compounds of
interest for biosynthesis vastly outnumbers the availability of characterized pathways and
enzymes. Several key building blocks can be made biologically (Patel et al., 2006);
however, a recent report from the U.S. Department of Energy highlighted twelve
biomass-derived chemical targets, only half of which have known biochemical routes
(Werpy and Petersen, 2004).
With the lack of characterized natural pathways to synthesize many high-value
compounds, one must learn to forge metabolic routes towards these molecular targets.
Logically, it follows that for unnatural pathways, new and unnatural enzymes will be
needed to compose these pathways. The parts-devices framework of synthetic biology
lends itself well to this dual-sided problem of synthetic pathway creation (Endy, 2005);
that is, pathways can be thought of as metabolic devices composed of individual enzyme-
catalyzed reaction parts. Implicit within this framework is the idea that the challenges of
pathway creation are best approached at both the part and device levels. In this Chapter,
efforts at the protein-level for broadening the array of enzyme parts that can be recruited
for use in synthetic pathways are reviewed. The discussion is then expanded to pathway-
level synthetic biology, where the tools available for designing metabolic pathways from
enzyme-level parts and the implementation strategies for realizing these pathways
experimentally are described. The overall process of pathway creation (Figure 2.1)
combines experimental and theoretical components of synthetic biology at both scales.
The chapter concludes with a description of the Retro-Biosynthesis Tool (ReBiT), a
database of enzyme-catalyzed chemical reactions for use in the design of novel metabolic
pathways.
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Figure 2.1: Overall scheme for metabolic pathway creation. The creation process includes protein-level
recruitment and reengineering of enzymes and pathway-level efforts to design and assemble these enzymes
into an unnatural pathway.
Building Novel Metabolic Routes at the Protein Level
Through natural evolution, organisms have acquired the capacity to catalyze a multitude
of diverse chemical reactions as a means to proliferate in a wide range of unique
I -- I - -- _ i;
microenvironments. Although only a small fraction of the earth's biodiversity (and an
even smaller subset of its composite enzymes) has been characterized, the identification
and isolation of novel proteins with unique properties or enzymatic function is a
laborious procedure. One particularly promising source of new enzymes and enzymatic
activities is the emerging field of metagenomics (Handelsman, 2004). Nonetheless, the
physical and catalytic properties of natural enzymes often render them as incompatible
or, at the very least, unoptimized for use in engineered pathways and strains. In cases
where natural evolution has fallen short of industrial needs, the tools and practices of
synthetic biology can be applied to aid in the creation of designer enzymes and cellular
phenotypes. The challenge of building new enzymes and reengineering natural ones has
been approached with the development of predictive theoretical frameworks and a range
of experimental techniques (Figure 2.2).
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Figure 2.2: Flowchart for the creation of new enzymes with experimental techniques and computational
tools. New enzymes generated with these methods are examined for desired properties and either further
reengineered or adapted for use in unnatural pathways.
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Theoretical Approaches
Computational tools exist to adapt the natural array of proteins for use in an increasing
number of applications. For example, the effects of codon bias on expression levels
(Kane, 1995; Gustafsson et al., 2004) can be resolved by design tools such as Gene
Designer (Villalobos et al., 2006). Other effects such as Shine-Dalgarno sequences,
promoter strength, and mRNA stability can be similarly optimized. Nonetheless, the
application of these tools is still limited to the biochemical diversity found in nature. To
increase the number and efficiency of biologically-catalyzed reactions, more
sophisticated in silico techniques are needed. While full-scale protein folding and ab
initio protein design and modeling are neither trivial nor currently practical, the use of
solved protein structures, strong physical models and experimentally derived libraries
allow for the design and improvement of enzymes. These theoretically designed proteins
in turn have significant potential to impact pathway-level synthetic metabolism
(Yoshikuni et al., 2008).
An empirical approach to synthetic protein design includes an understanding of the
protein sequence/function relationship. One example is the use of a linguistic metaphor
to describe a protein sequence (Searls, 1997; Searls, 2002). In language, a sentence is
composed of a sequence of words whose parsed meaning is a function of not only their
individual definitions but their connotations which are encoded by their type (part of
speech) and their relative location to other words. Similarly, a protein 'sentence' is
composed of residues that have not only a definitive identity but also possess chemical
properties and a relative position that affect the subsequent fold and function of the
resultant protein (Przytycka et al., 2002). Building on the successes of a putative protein
grammar (Przytycka et al., 2002; Naoki and Hiroshi, 1997), Loose et al. (2006) recently
demonstrated its use in the design of new antimicrobial peptides. Using the TEIRESIAS
algorithm (Rigoutsos and Floratos, 1998), a library with homology to known sequences
restricted to below 60% was generated with approximately 50% of designs showing some
antimicrobial activity. An alternative approach to modeling protein sequence/function
relationships involves the use of folded protein scaffolds and quantum transition state
models. Through detailed crystal structures and transition state models, Hederos et al.
(2004) noted that the active site of a glutathione transferase was of the appropriate size
and structure to stabilize the transition state complex of the hydrolytic degradation of a
thioester. By introducing a histidine residue within the active site they were able to
impart significant thioesterase activity. Finally, physics based free energy approaches
have been developed to predict protein structure/function relationships in the context of
antibody binding strength. While total free energy models were not a good predictor,
Lippow et al. (2007) found that the electrostatic interaction contributions to total energy
were well correlated with antibody binding affinity. Using this relationship, they were
able to generate an improved lysozyme antibody design which demonstrated a 140-fold
increase in binding. While neither of these examples fully describe protein
structure/function relationships, each does offer a unique insight into the problem.
Namely, they drastically reduced the sequence space of potential modifications to a
manageable subset with a high probability of success. In this manner, such empirical
models serve as an important tool in the design and improvement of enzymes.
Using a quantum transition state framework, great strides have been made in the in silico
development of enzyme activities (Jiang et al., 2008; Rothlisberger et al., 2008; Kaplan
and Degrado, 2004). At the heart of these efforts is a strong understanding of the desired
catalytic mechanism and its associated transition states and reaction intermediates. Once
compiled, this information can be used to generate an active site of the appropriate
dimensions with critical residues incorporated into appropriate locations for catalysis. At
this point, the designer has two options: try to identify a suitable folded scaffold that can
accommodate the active site with minimal mutations or generate a protein backbone with
correctly folded active site de novo. Each method has its inherent advantages and
challenges. While finding a host scaffold would appear to be the simpler of the two, it
requires extensive searches of protein structure libraries with tools such as RosettaMatch
(Zanghellini et al., 2006). Nonetheless, this approach has had some success with the
catalysis of unnatural reactions such as the retro-aldol catalysis of 4-hydroxy-4-(6-
methoxy-2-naphthyl)-2-butanone (Jiang et al., 2008) and the Kemp elimination
(Rothlisberger et al., 2008). Coupled with experimental techniques, in silico designed
enzymes can have activity levels comparable to that of evolved natural enzymes
(Rothlisberger et al., 2008). In contrast, de novo protein scaffold development requires
significant computational effort to not only consider the stability of the desired
conformation of the backbone and active site but also the likelihood of destabilization.
Nonetheless, Kaplan and DeGrado (2004) have successfully used such an approach to
generate an 0 2-dependent phenol oxidase. Despite the computational overhead
associated with these methods, their feasibility points to an improving and functional
understanding of protein structure/function relationships, leading to increased
possibilities for the rational design of enzymes and proteins.
In the absence of rational insight, theoretical tools can assist experimental techniques in
generating new and improved proteins. One common technique is protein recombination
or in vitro shuffling which combines the best traits of two or more individual enzymes
(Stemmer, 1994a; Stemmer, 1994b). However, successful recombination is contingent
on shuffling at domain boundaries to ensure proper folding of each domain. The
predictive algorithm SCHEMA, developed by Voigt et al. (2002), was designed to aid in
the screening process of such chimeric proteins. By analyzing the nature and number of
the disruptions of the intermolecular interactions, Voigt et al. were able to generate a
metric correlated with the probability of active p-lactamase hybrids of TEM-1 and PSE-4
(2002). Subsequent studies by Meyer et al. (2003) have confirmed this correlation and
used SCHEMA-guided recombination to derive functional and diverse libraries of
cytochrome P-450s (Otey et al., 2004) and p-lactamases (Meyer et al., 2006). Another
available predictive algorithm is FamClash (Saraf et al., 2004), which analyzes chimeras
for the conservation of charge, volume and hydrophobicity at a given residue. Generated
sequence scores have been demonstrated to be well correlated with the activities of
hybrid dihydrofolate reductases. While experimental techniques are important generators
of diverse protein libraries, tools such as FamClash, SCHEMA and other related
sequence analysis programs enrich such chimeric libraries and vastly improve their value
in the development of new and improved proteins. Currently, these tools are incapable of
predicting hits a priori; however, their importance in successful protein design should not
be underestimated.
Experimental Approaches
Rather than focusing on the prediction of protein structure and function, experimental
techniques allow the improvement or modification of existing enzymes, in some
instances creating entirely new enzymes and enzyme activities. These techniques include
mutagenesis, enzyme engineering and evolution, and gene synthesis technology, with
each boasting their own distinct advantages and inherent limitations (Bonomo et al.,
2006; Alper and Stephanopoulos, 2007). Collectively, they comprise a powerful set of
tools for the efficient generation of enzymes with user-specified properties. Protein
recombination, for example, provides a means by which secondary structural elements,
from natural or evolved proteins, can be rationally assembled in a modular fashion to
integrate domains featuring desired attributes (Otey et al., 2004).
The construction of synthetic pathways typically involves the recruitment of genes from
an array of sources to provide the required enzymatic function and activity (Figure 2.1).
However, heterologously expressed proteins, particularly those originating from a source
organism belonging to a different kingdom than that of the expression host, often suffer
from poor activity as a result of dissimilarities in codon usage. In such cases, the use of
synthetic genes with codon optimized sequences has been frequently employed to
achieve sufficient levels of functional expression. Synthesis of a codon optimized
xylanase gene from Thermomyces lanuginosus DSM 5826 led to a 10-fold improvement
in expression level in E. coli (Yin et al., 2008). Plant genes are often found to be poorly
expressed in E. coli (Martin et al., 2001). Martin et al. (2003) synthesized a codon
optimized variant of amorpha-4,11-diene synthase from the Artemisia annua to catalyze
the conversion of farnesyl pyrophosphate to amorphadiene, a precursor used for the
production of the anti-malarial drug artemisinin. As the cost associated with gene
synthesis continues to decrease, imaginable applications of synthetic genes and artificial,
designer proteins to include increased elements of rational design become increasingly
plausible.
The versatility of directed evolution for engineering desired enzyme attributes is
highlighted by a multitude of recent works employing this approach for a diverse
assortment of applications, including the enhancement of thermal stability (Asako et al.,
2008; Shi et al., 2008) and acid tolerance (Liu et al., 2008); promoting higher chemo-,
regio-, and enantio-selectivity towards substrates (Asako et al., 2008); elimination of
undesired biochemical activities (e.g., side reactions; Kelly et al., 2008); and improving
heterologous expression (Mueller-Cajar et al., 2008). In the example of the stereospecific
reduction of 2,5-hexanedione to (2S,5S)-hexanediol by alcohol dehydrogenase (AdhA)
from the thermophillic bacteria Pyrcoccus furiosus, laboratory evolution was used by
Machielsen et al. (2008) to alter the enzyme's optimum temperature and improve its
activity in recombinant E. coli under moderate culture conditions. Meanwhile, Aharoni
et al. (2004) have achieved functional expression of mammalian paraoxonases PON and
PON3 in E. coli through a directed evolution scheme that incorporated family DNA
shuffling (shuffling of DNA encoding homologous genes from different genetic sources)
and random mutagenesis to achieve the first active microbial expression of recombinant
PON variants. As a tool, directed evolution continues to benefit from refinements aimed
at improving the efficiency at which desired mutations can be obtained from a minimal
number of iterations while also reducing screening efforts (Reetz et al., 2007; Reetz et al.,
2008).
In addition to improving expression and altering the thermal properties of heterologous
enzymes, novel biochemical activities can be similarly engineered by the aforementioned
strategies. For example, cytochrome P450 BM3 from Bacillus megaterium has been
engineered via directed evolution using several sequential rounds of mutagenesis to alter
its regioselectivity for the hydroxylation of n-alkanes from subterminal positions to that
of the terminus (Meinhold et al., 2006). The approach has been employed to convert
several different n-alkanes to their corresponding n-alcohols, including the hydroxylation
of ethane to ethanol as a means for producing more tractable transportation fuels from
petrochemical feedstocks (Meinhold et al., 2005). To promote high end-product
specificity while maximizing metabolite flux, the preferential activity of an enzyme
between multiple competing substrates can also be tailored. For instance, the substrate
specificity of pyruvate oxidase (PoxB) from E. coli was altered via localized random
mutagenesis to decrease its activity on pyruvate in favor of an alternative endogenous
metabolite, 2-oxo-butanoate (Chang and Cronan, 2000). Synthetic pathways
incorporating this PoxB mutant will accordingly display preferential synthesis of
products from the four-carbon precursor. Meanwhile, Tsuge et al. (2003) utilized site
directed mutagenesis to shift the substrate specificity of PhaJ, an R-specific enoyl-CoA
hydratase from Aeromonas caviae from short-chain 3-hydroxyacyl-CoA precursors
towards those with longer carbon chain lengths (8 to 12). When incorporated into an
engineered polyhydroxyalkanoate (PHA) synthesis pathway in E. coli, increased molar
fractions of C8 and Clo 3-hydroxyacid monomer units were found to be incorporated into
PHA. In this case, the capacity to distinctly manipulate the composition of PHAs makes
possible the synthesis of novel bio-plastics with customizable physical properties to meet
commercial requirements. The ability to finely tune the substrate specificity of an
engineered enzyme is of particular importance for promoting high selectivity and product
yield, as well as for reducing the ill-effects of molecular cross-talk between engineered
and endogenous pathways.
At the protein level, synthetic biology aims to expand the catalog of well-characterized
enzymes while also engineering novel biochemistries. Subsequent incorporation of
engineered enzymes into synthetic pathways leads to the construction of devices that can
be implemented to achieve a user-specified function, such as the production of biofuels or
high-value pharmaceutical compounds. The design and construction of new metabolic
routes from individual enzymes represents synthetic biology at the next scale, the
pathway scale, and has unique challenges of its own.
Building Novel Metabolic Routes at the Pathway Level
Pathway-scale synthetic biology aims to create novel metabolic routes towards both
existing metabolites and unnatural compounds. Traditionally, pathway engineering has
been synonymous with metabolic engineering and its toolbox has been composed of the
same tools: gene knockouts, flux optimization, gene overexpression, and the like. The
ability to manipulate natural metabolism has seen many useful applications, such as
improving ethanol production in Saccharomyces cerevistiae (Bro et al. 2006),
solventogenesis in Clostridium acetobutylicum (Mermelstein et al., 1993; Woods, 1995),
and penicillin production in Penicillium chrysogenum (Casqueiro et al., 2001). A key
limitation in all of these examples is the confinement of pathway engineering to the
manipulation of natural metabolism. Continuing advances in characterizing, modifying,
and even creating enzymes (several of them discussed in the previous section of this
review) now allow us to build unnatural pathways for the biological production of
compounds. Understanding synthetic biology at the protein scale affords us the
opportunity to apply it at the pathway scale.
As at the protein scale, pathway-level synthetic biology has been approached from both
theoretical and experimental fronts. The theoretical work centers on the concept of
pathway design - assembling a logical series of enzyme-catalyzed reactions to convert an
accessible substrate into a valued final compound. Theoretical pathway design probes
what conversions are possible and what enzyme parts need to be assembled to create a
functional metabolic device. In contrast, experimental efforts focus on the construction
and application of unnatural pathways and serve as powerful real-world examples of what
these pathways can accomplish. Experimental approaches enable the exploration of
enzyme behaviors such as substrate promiscuity and activity, both useful properties for
creating unnatural pathways that cannot readily be predicted with theoretical approaches.
Theoretical Approaches
Before an unnatural metabolic pathway can be built in the laboratory, it must first be
designed. The goal of pathway design is to use a series of biochemically-catalyzed
reactions to connect a target product molecule to either a cellular metabolite (such as
acetyl-CoA, a-ketoglutarate, or L-alanine) or to a feasible feedstock (such as glucose or
glycerol). This can be accomplished using either natural enzymes or engineered ones.
The sheer number of known enzymes (both natural and engineered) and enzyme-
catalyzed reactions available means that there will almost certainly exist many possible
theoretical pathways towards a given target compound (Li et al., 2004; Hatzimanikatis et
al., 2005). Identifying and ranking these different possibilities are the central challenges
in pathway design.
One of the first steps in pathway design is obtaining knowledge of the enzymes and
enzyme-catalyzed reactions available for use in a pathway. Comprehensive protein and
metabolism databases, such as BRENDA (Schomburg et al., 2004), KEGG (Kaneshisa et
al., 2006), Metacyc (Capsi et al., 2006), and Swiss-Prot (Wu et al., 2006), provide a
wealth of information on the pool of natural, characterized enzymes that can be recruited.
More importantly, these databases reveal chemical conversions that are achievable with
enzymes. As of the preparation of this thesis, there are approximately 398,000 protein
entries in Swiss-Prot (build 56.2), from which the enzymes are organized into 4757 four-
digit enzyme classification (E.C.) groups in the most recent version of BRENDA (build
2007.2). Because of the large number of characterized enzymes, those performing
similar reaction chemistries are typically organized into generalized enzyme-catalyzed
reactions for the purposes of pathway construction (Li et al., 2004). A generalized
enzyme-catalyzed reaction is defined as the conversion of one functional group or
structural pattern in a substrate into a different group or structure in its product (Figure
2.3). Structural information about the non-reacting portions of the substrate is ignored,
making the identification of enzymes to carry out a desired chemical conversion a much
more tractable problem. However, the logical rules for assigning enzymes to a
generalized reaction can be subjective (Figure 2.3). One could for instance differentiate
between reactions solely on the reacting functional groups (i.e. aldehyde to alcohol) as Li
and coworkers (2004) did, or one could also include information about conserved
patterns of molecular structure between similar enzyme-catalyzed reactions.
Furthermore, generalized enzymatic reactions do not all fall cleanly into the existing E.C.
system (Figure 2.3c).
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Despite the need for a universal standard in reaction generalization, several publically-
available tools utilize this approach to address the problem of pathway design. The
BNICE (Biochemical Network Integrated Computational Explorer) framework allows for
the discovery of numerous possible metabolic routes between two compounds (Li et al.,
2004; Hatzimanikatis et al., 2005). This framework was applied to aromatic amino acid
biosynthesis to find over 400,000 theoretical biochemical pathways between chorismate
and phenylalanine, tyrosine, or tryptophan (Hatzimanikatis et al., 2005) and it was used
to explore hundreds of thousands of novel linear polyketide structures (Gonzilez-Lergier
et al., 2005). As part of this thesis, the ReBiT database of over 600 conserved structure
generalized enzyme-catalyzed reactions was developed and made freely available to the
public at http://www.retro-biosynthesis.com. ReBiT accepts as input a molecular or
functional group structure and returns as output all 3-digit E.C. groups capable of
reacting with or producing that structure. The University of Minnesota
Biocatalysis/Biodegradation Database (UM-BBD) uses a series of generalized reaction
rules to propose pathways step by step, with particular emphasis on analyzing the
degradation trajectories of xenobiotics (Ellis et al., 2006; Fenner et al., 2008).
Typically multiple, and indeed in some cases, several thousand, metabolic routes can be
proposed for a given compound. How does one distinguish logical, feasible pathways
from frivolous, improbable ones? What metrics can be applied to judge one
computationally-generated pathway as superior (i.e. more likely to be functionally
constructed) to another? One way of narrowing the choice of pathways is to apply
natural precedent to filter out unlikely pathway steps. In this strategy, a large set of
experimentally validated enzyme-catalyzed reactions are examined for patterns of
structural change and a series of rules are developed to give preference to reaction steps
containing structural changes that follow these rules. This methodology is implemented
in the UM-BBD to avoid the "combinatorial explosion" that results when considering all
the possible pathways that any given compound can take (Fenner et al., 2008). Another
ranking strategy is to calculate the thermodynamic favorability of the steps and to
penalize pathways involving steps which are energetically unfavorable. This approach is
taken by the BNICE framework (Hatzimanikatis et al., 2005) using a functional group
contribution method (Jankowski et al., 2008) to compute the overall change in Gibbs
energy for each individual pathway step. A new pathway modeling tool, DESHARKY,
quantifies and employs metabolic burden as a metric for judging unnatural pathways and,
in particular, how they are connected to cellular metabolism (Rodrigo et al., 2008).
DESHARKY is a Monte Carlo-based algorithm that estimates the transcriptomic and
metabolic loads on cells expressing unnatural pathways and calculates the decrease in
specific growth rate as a result of these additional burdens. There are still other
possibilities for pathway ranking, such as the number of pathway steps taken, the known
substrate specificities (or lack thereof) of the enzymes involved in each pathway, or the
availability and diversity of homologous enzymes to test at each pathway step. One of
the key challenges in pathway design is scoring pathways in a robust and balanced
manner, and only as more non-natural pathways are designed and built will there be a
better understanding as to which of these metrics are relevant and useful.
Experimental Approaches
With a target compound and a proposed metabolic route to reach that compound in hand,
one is now ready to begin experimental implementation of that pathway. Synthetic
pathway construction occurs over several shades of novelty - from recreating natural
pathways in heterologous hosts to creating synthetic pathways that parallel natural ones
to building completely novel metabolic routes towards unnatural compounds from
multiple, ordinarily unrelated enzymes (Figure 2.4). Here situations in which non-natural
pathways prove useful and several general strategies for creating these pathways are
discussed.
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Figure 2.4: Strategies for synthetic pathway creation arranged in increasing degrees of departure from
nature. A, B, C, D, F, a, P, y, and A represent metabolites, E represents an enzyme catalyzing a reaction,
and r represents an engineered enzyme catalyzing a reaction. In (1), a natural pathway in its native host is
transferred to a heterologous host, decoupling it from native regulation. This strategy is limited to the
production of natural products using natural pathways. In (2), new pathways are made in parallel to natural
ones through the use of promiscuous enzymes (2a), enzyme engineering (2b), or combinations of natural
pathways (2c). Strategies 2a and 2b allow for the synthesis of new, non-natural products, while 2c allows
for the creation of new metabolic routes between natural metabolites. Strategy 3 represents de novo
pathway construction, where individual unrelated enzymes are recruited to form entirely unnatural
pathways. This can be done using native enzyme activities (3a), promiscuous enzymes (3b), engineered
enzymes (3c), or combinations thereof.
Through the course of evolution, nature has assembled many pathways towards several
useful compounds, such as the biofuel and solvent 1-butanol in Clostridium
acetobutylicum (Jones and Woods, 1986; Diirre et al., 2002; Lee et al., 2008), the C5
terpenoid building block isopentenyl pyrophosphate (IPP) in Saccharomyces cerevisiae
(Seker et al., 2005), and the biopolymer polyhydroxybutyrate (PHB) in Ralstonia
eutropha (Wang and Yu, 2007). These pathways have physiological roles within their
native hosts; for example, the butanol pathway from acetyl-CoA in C. acetobutylicum
serves as an electron sink to regenerate NAD+ for glycolysis while deacidifying its
environment (Jones and Woods, 1986). Pathways in nature are optimized through
evolution to accomplish their physiological objectives, yet in most cases of pathway
engineering, it is desired to maximize the production of a target molecule in a pathway
rather than to accomplish a physiological goal. Butanol production in C. acetobutylicum,
for instance, is constricted by cellular regulation tying it to pH, redox conditions, and
sporulation (Diirre et al., 2002; Lee et al., 2008). The transference of natural pathways
into heterologous hosts isolates these pathways from their regulatory elements and
represents a first small step towards the creation of non-natural metabolism. While
heterologous pathway expression is limited to only pathways found in nature, it
nonetheless has proven effective in enhancing product titers and/or deregulating
compound production for a wide array of products, including the compounds in the
examples above (Atsumi et al., 2007; Kang et al., 2008; Martin et al., 2003; Pitera et al.,
2007).
The next level of novelty in synthetic pathway construction is creating metabolic routes
that parallel natural pathways, typically by capitalizing on enzymatic promiscuity or
enzyme engineering to operate natural or near-natural pathways on non-natural
substrates. This pathway construction strategy allows for the biosynthesis of truly
unnatural compounds. Returning to the PHB example, recombinant R. eutrophia have
been shown to incorporate sulfur-containing short- and medium-chain length thioacids
into polythioester co-polymers (Ewering et al., 2002). The synthesis of these completely
unnatural polymers was made possible by taking advantage of the relatively broad
substrate specificity of polyhydroxyalkanoate (PHA) synthases (Hazer and Steinbiichel,
2007), and because of that broad substrate specificity, hundreds of different monomer
units of various sizes (C3-C1 6) and substituents have been incorporated into PHA co-
polymers (Steinbiichel and Valentin, 1995). Another example of parallel pathway
construction is the synthesis of triacetic acid lactone from acetyl-CoA by expressing an
engineered fatty acid synthase B from Brevibacterium ammoniagenes (Zha et al., 2004).
This multifunctional enzyme has many domains designed to catalyze the various
reductions and condensations necessary for fatty acid synthesis (Meurer et al., 1991). By
specifically inactivating the ketoacyl-reductase domain of this fatty acid synthase, the
enzyme could no longer use NADPH to reduce its acetyl-CoA condensation products,
causing them to circularize into triacetic acid lactone rather than forming linear fatty
acids. Finally, natural products can be synthesized by arranging whole or partial
pathways to form a mixed, synthetic metabolic route. For example, the theoretical yield
of L-glutamate was improved from 1 mol glutamate per mol glucose to 1.2 mol per mol
by augmenting the native Corynebacterium glutamicum pentose phosphate pathway with
a phosphoketolase from Bifidobacterium lactis (Chinen et al., 2007). This strategy
allowed for the production of acetyl-CoA without the loss of carbon caused by pyruvate
decarboxylation to acetyl-CoA and resulted in increased glutamate titers and
productivity.
One of the most promising (and challenging) strategies for building synthetic pathways is
de novo pathway construction: the creation of pathways using disparate enzymes to form
entirely unnatural metabolic routes towards valuable compounds. This method of
pathway building does not rely upon natural precedent, but rather allows one to build
entirely new metabolite conduits from individual enzymatic pieces. As a result, this
approach allows for the biosynthesis of the widest array of compounds. On the other
hand, this strategy is the most difficult to realize given that for a completely unnatural
pathway, there may not be a complete set of appropriate known enzymes in nature to
build it. De novo pathway construction illustrates the need for a more complete set of
enzymatic tools for use in building synthetic pathways, and frequently this strategy is
coupled with enzyme engineering or the exploitation of enzymatic promiscuity to
compensate for the absence of a natural enzyme to execute a desired conversion step.
Because of the challenge in creating functional de novo pathways, few examples exist.
However, those that are available describe the biosynthesis of a wide range of useful
compounds and illustrate the utility of the approach. For instance, a pathway for the
biosynthesis of 1,2,4-butanetriol from D-xylose and L-arabinose was assembled using
pentose dehydrogenases and dehydratases from Pseudomonas fragi and E. coli and
benzoylformate decarboxylase from Pseudomonas putida (Nui et al., 2003). In this case,
multiple decarboxylases were screened to find a promiscuous decarboxylase from P.
putida capable of acting on a 3-deoxy-glyceropentulosonic acid intermediate in the
pathway. Another example of exploiting substrate promiscuity in de novo pathway
design is in the synthesis of several higher biofuels such as 2-methyl-l-butanol,
isobutanol, and 2-phenylethanol from glucose in E. coli (Atsumi et al., 2007). Here,
several 2-keto-acid decarboxylases were screened to identify one from Lactococcus lactis
for use in creating alcohols from 2-ketoacids (when combined with native E. coli alcohol
dehydrogenase activity). In a third example, a synthetic pathway for the unnatural
aminoacid phenylglycine from phenylpyruvate was made by combining
hydroxymandelate synthase, hydroxymandelate oxidase, and D-(4-
hydroxy)phneylglycine aminotransferase activities from Amycolatopsis orientalis,
Streptomyces coelicolor, and P. putida (Miiller et al., 2006). Finally, engineered
enzymes can be employed to create de novo pathways, as in the recent case of the
synthesis of 3-hydroxypropionic acid from alanine in E. coli (Liao et al., 2007). Here, a
lysine 2,3-aminomutase from Porphyromonas gingivalis (Brazeau et al., 2006) was
evolved to have alanine 2,3-aminomutase activity, allowing for the biosynthesis of 3-
alanine. Combining this evolved enzyme with p-alanine aminotransferase and
endogenous alcohol dehydrogenase activities afforded the final 3-hydroxypropionic acid
product. Another very recent work utilizes engineered pyruvate decarboxylase and 2-
isopropylmalate synthase for the synthesis of non-natural alcohols from 2-ketoacids in E.
coli (Zhang et al., 2008). By engineering the enzymes responsible for elongating 2-
ketoacids and carrying out their decarboxylation and reduction, the production of a
broader array of longer-chain alcohols was enabled.
Outlook for Pathway Design
The design and assembly of unnatural metabolic pathways represents a young and
exciting field with the potential to supplement, expand upon, or even replace current
industrial processes for the production of fine and commodity chemicals. Synthetic
pathway engineering integrates many components and consequently is highly
interdisciplinary (Figure 2.1). Key issues that need to be overcome in pathway design are
(1) establishing a standard for generalized enzyme-catalyzed reactions, (2) capturing
enzyme substrate preferences in these generalized reactions, and (3) determining the
pathway metrics that correlate with successful pathway construction. Overcoming the
first two challenges will allow for the creation of the next generation of pathway design
tools that better account for enzyme behavior, while conquering the last challenge will
afford us the ability to rank and choose metabolic pathways and refine the results from
design tools. For experimentally implementing unnatural pathways, the central challenge
is the limited number of characterized enzymes for the construction of new pathways. In
particular, there is great demand for both promiscuous natural enzymes and engineered
enzymes to perform specific desired reactions.
The need for new enzymes has given rise to several theoretical frameworks for relating
protein sequence, structure, and function. These frameworks each address a piece of the
problem - energetics, active site catalysis, and protein backbone structure, etc. - but the
ability to routinely build whole enzymes is still in the distant future. In the meantime,
mimicking active sites, backbones, and protein linguistics from nature has proven fruitful
in creating novel proteins. Experimental evolution and chimeragenesis of enzymes are
standard ways of imparting unnatural properties, particularly in the absence of detailed
information about the protein. The power of these experimental techniques is primarily
limited by the size of the resulting enzyme libraries and the throughput of the screen to
analyze them. Computational tools such as SCHEMA (Voigt et al., 2002) and Famclash
(Saraf et al., 2004) can assist in focusing and enriching these libraries.
As biotechnology is increasingly relied upon as a means for chemical production,
progress on the creation of new enzymes and unnatural pathway design and construction
will flourish. These new pathways must still be expressed within a cellular context, thus
improving and understanding unnatural pathway efficacy at a systems level will be
important for shattering barriers in pathway expression and product titer. For example,
application of flux balance analysis (Edwards et al., 2002) can guide systems-level
integration of non-natural pathways with host metabolism. Furthermore, redox balancing
and cofactor regeneration with respect to new pathways are critical to minimize their
burden on the host cell (Endo and Koizumi, 2001). Systems-level functionality can also
be coupled with unnatural pathways, for instance in the delivery of recombinant microbes
to a cancerous tumor (Anderson et al., 2006). Such microbes could be engineered to
simultaneously produce and deliver a drug. Established and recent advances in metabolic
engineering, such as global transcription machinery engineering (Alper and
Stephanopoulos, 2007), can complement synthetic biology in this regard, leading to
improved performance of novel pathways.
The ReBiT Database for Pathway Design
As part of this thesis, ReBiT (Retro-Biosynthetic Tool) was developed as a biochemical
pathway design tool to identify enzymes catalyzing specific functional group
transformations in their substrates. ReBiT allows researchers to query for enzymes that
convert one specific functional group, an alcohol for instance, into another, such as an
aldehyde. Combinations or clusters of multiple functional groups, like diols, ketoacids,
or hydroxyamines, may also be queried using ReBiT. Rather than having to manually
search each individual enzyme or enzyme class for a desired biochemical conversion,
ReBiT allows such searches to be executed in a single query. Thus ReBiT allows the
researcher to rapidly identify candidate enzymes for constructing specific arrangements
of functional groups present in a desired final product. This functionality would be
valuable to researchers interested in the construction of unnatural biochemical pathways
towards high-value products.
Enzymatic synthesis of chemical compounds represents a powerful alternative to
chemical synthesis, particularly in the case of chiral or highly functionalized molecules
(Johannes, 1996). With the advent of recombinant DNA technology and the development
of the field of metabolic engineering, it is now possible to assemble whole biochemical
pathways using enzymes from multiple organisms. Furthermore the enzymes themselves
are remarkable biocatalysts: specific to generally a small range of substrates yet
surprisingly promiscuous when given the right reactants and conditions. This enzymatic
promiscuity can be extended to unnatural substrates and amplified through genetic
engineering techniques (e.g., enzyme evolution) to obtain custom-made biocatalysts for
the biochemical production of a given target molecule (Farinas et al., 2001; Tao and
Cornish, 2002).
Of interest here however is assembling enzymes (whether engineered or native) into
unnatural reaction pathways. This new field of pathway development combines the
breadth and catalytic power of enzymes and the potential of enzyme engineering with the
field of metabolic engineering to realize the vision of efficient, versatile, and
environmentally-friendly synthesis. This vision, a world where chemicals, drugs, fuels,
etc. are largely produced by renewable, programmable microbes, is only just beginning to
materialize. With sustained work in these fields, the barriers between robust pathway
design, pathway construction, and reality will eventually fade.
Before any enzymatic pathway can be built, however, it must be designed. The goal of
"retro-biosynthetic" pathway design is to connect a target small molecule product to the
metabolism of the host cell through a series of enzyme-catalyzed reactions. One starts
the design process at the desired target molecule and then finds enzymes that will
produce that target molecule from various other substrates. These enzymes then lead the
designer backwards up a hypothetical biochemical pathway to new intermediate
compounds from which the process of finding enzymes and moving to new compounds is
repeated, until the pathway is connected to either cellular metabolism or to a substrate to
be supplied. The design process is analogous to playing a game of chess on a giant
metabolic chessboard, with the goal of moving a playing piece from a starting square on
the board to one or more end squares. Each possible substrate or metabolite represents a
square where the designer can place his piece and each enzyme represents a piece that
can only make certain moves, constraining the designer's ability to go from one place to
another. Furthermore, enzyme engineering serves to open up new moves for the designer
by bridging two squares on the board that would otherwise be disconnected. Pathway
design itself then is the process of figuring out how to get from one point on this board to
another quickly and efficiently.
The most difficult part of the pathway design process lies in identifying enzymes that (1)
allow you to make valid moves on this chessboard and (2) that move you in the right
direction. The breadth and range of chemistries that enzymes catalyze is diverse enough
that for many molecules, several different reactions are possible. This enzymatic
diversity also means that there are almost certainly many different combinations of
enzymes that can theoretically bridge two compounds with one another over the course of
a pathway (Li et al., 2004). A tool is thus needed to assist the designer in sifting through
this diversity, so that enzymes best connecting a target molecule to cellular metabolism
can be readily identified.
Popular enzyme databases like BRENDA (Schomburg et al., 2004), MetaCyc (Capsi et
al., 2006), and KEGG (Kanehisa et al., 2006) however do not readily lend themselves to
pathway design, because the information contained within these databases cannot be
easily queried based on the chemical or functional group transformations that the
enzymes themselves catalyze. Specifically, while these databases do allow users to query
their contents based on static substructures, they do not allow querying for dynamic
chemical changes that either create or convert a given substructure. This type of query
would be useful when identifying enzymes that create structures and compounds of
interest, i.e. in finding what moves on the metabolic chessboard are possible from a given
molecule. To address this issue, ReBiT, a database of enzymatic transformations, was
created to assist synthetic biologists and metabolic engineers in designing and assembling
novel pathways towards valuable target compounds.
ReBiT (http://www.retro-biosynthesis.com) allows a user to query molecular structures
against a database of enzyme-catalyzed chemical transformations. ReBiT returns hits
(enzyme-catalyzed chemical transformations) in which the queried structure is produced,
consumed, or changed in some way. Selecting a particular transformation lists all three-
digit Enzyme Classification (E.C.) numbers that contain enzymes catalyzing that
transformation as well as links to the ExPASy database (Gasteiger, 2003) for more
detailed enzyme-specific information. ReBiT also displays graphical representations of
all structures involved in each transformation and any cofactors or co-substrates used.
Methods
ReBiT allows a user to query enzyme-catalyzed reactions by the "canonical" substrates or
products involved in the reaction. For example, if a hypothetical group of enzymes
catalyze the conversion of propionate into n-propanol and butyrate into n-butanol, two
structures would be placed in ReBiT, one for a carboxylate (the canonical substrate) and
one for a primary alcohol (the canonical product). Parts of molecules that are not
canonical or that are not directly conjugated with the reacting portion of the molecule are
not included in the database. ReBiT is thus a searchable repository of dynamic molecular
changes in enzyme-catalyzed reactions.
Figure 2.3 illustrates the process of mapping enzymes and E.C. numbers to the chemical
structures on which they catalyze reactions. Figure 2.3a represents the relatively simple
case of a subset of E.C. 1.1.1 reductases that interconvert primary alcohols and
aldehydes. In generating the canonical reaction for this set of enzymes, all of the
reactions catalyzed within this 3-digit E.C. class were compared and it was determined
(1) what types and patterns of structural changes take place in the substrates participating
in each reaction and (2) what non-reacting structural elements are conserved across each
type of conversion within these reactions. For the reactions shown in Figure 2.3a, the
pattern of structural change is the interconversion of an alcohol (R-OH) and an aldehyde
(R-CH=O), while the conserved element across each reaction is the need for at least one
carbon to be attached to the reacting group. The generalized reaction placed in ReBiT to
represent these enzymes then is A-CH 2-OH +- A-CH=O, where A is a wildcard, and
ReBiT records this reaction as the canonical structures A-CH2-OH and A-CH=O linked
to each other by these E.C. 1.1.1 enzymes. Figure 2.3b depicts a somewhat more
complicated example of canonical reaction deduction with a set of interconversions
between 3-hydroxyaminoacids and 2-ketoacids that occur within E.C. 4.3.1. In these
reactions, the pattern of structural change is the loss of the hydroxyl group at the 3-
position and the conversion of the 2-amino group into a ketone. The carboxylate group in
each of these reactions remains unchanged, yet this functional group is conserved across
each of the reactions. This carboxylate group is thus included in the canonical structures
placed in ReBiT to represent these reactions.
Typically a given 3-digit E.C. class contains multiple types of functional group
conversions. For situations like this one canonical structure-reaction mapping would be
stored in ReBiT for each different pattern of conversion that was seen. Figure 2.3c
illustrates this process for E.C. 2.5.1. Within this enzyme class there exists a set of
enzymes that thiolate the ester bond of an aminoacid substrate (E.C. 2.5.1.47-2.5.1.49)
and a set of enzymes that adds an aminoacid group to a nitrogen atom in a heteroaromatic
ring (E.C. 2.5.1.51 and 2.5.1.52). Since these two groups of enzymes each produce
substantially different functional groups (thiols and thioesters vs. heteroaromatic
aminoacids) a canonical structure-reaction mapping was generated in ReBiT for each
group. The ReBiT interface notes the 4-digit E.C. numbers of the enzymes in each group
to clearly distinguish these two groups and the chemical conversions that they catalyze.
The ReBiT database itself is organized into two tables. The first table, an Enzymes table,
matches each stored structure with one or more three-digit E.C. numbers. The structures
are stored in the database as SMILES text strings (Weininger, 1988). The Enzymes table
also associates each E.C. number with additional information such as cofactors and
commentary for each reaction. The second table is a Functional Groups table that
associates each SMILES structure in ReBiT with a descriptive chemical name and a list
of all functional groups (alcohol, aldehyde, etc.) contained within each structure. These
two tables, taken together, allow a user to search ReBiT by specifying a SMILES string,
or a structure or substructure (which is subsequently converted into a SMILES string).
All functional groups can also be browsed by either structure or name.
The molecular structures in ReBiT were generated by manually examining each enzyme-
catalyzed reaction in BRENDA (Schomburg et al., 2004) and MetaCyc (Capsi et al.
2006) and deducing canonical structures for both the substrates and products associated
with these reactions. These structures were then gathered into a table, associated with the
enzyme class or classes that generate or consume the structures, and purged of any
duplicate structures or entries. A web-based interface was developed to give the central
database a user-friendly form and to allow its contents to be queried. The web interface
integrates the MySQL database with ChemAxon's JChem software (Csizmadia, 2000) to
execute searches of ReBiT's two tables by first converting the user's structure query into
a SMILES string and then comparing the converted query to the SMILES strings stored
in ReBiT's database. JChem also normalizes SMILES queries since a given structure can
be represented with multiple SMILES notations. After this comparison, the web interface
displays any matches found to the user in an organized and easy-to-read manner.
Currently the ReBiT database contains 605 unique canonical structures derived from
approximately 4,700 enzyme classes representing almost 90,000 enzymes. The 605
canonical structures are associated with each other through 637 unique enzymatic
conversions in ReBiT. The definition of the E.C. nomenclature means that all enzymes
with a specific 3-digit number should catalyze the same type of reaction but with
different substrates (Li et al., 2004). However, there are only 246 3-digit E.C. classes as
of the preparation of this manuscript, meaning that there are on average 2.6 unique
enzyme-catalyzed reactions per 3-digit E.C. class. As a specific example of this
phenomenon, note that cysteine synthase (E.C. 2.5.1.47) fixes sulfur from hydrogen
sulfide to form cysteine while thiamine pyridinylase (E.C. 2.5.1.2) acts as an N-
transferase between aromatic heterocycles. Both enzymes catalyze markedly different
chemistries yet both are classified under the same 3-digit E.C. heading (E.C. 2.5.1).
Further examples of discrepancies between E.C. number and enzyme chemistry are E.C.
1.2.3.3 (pyruvate oxidase, which simultaneously decarboxylates and phosphorylates
pyruvate) vs. most other enzymes in E.C. 1.2.3 (which oxidize aldehydes into carboxylic
acids) and E.C. 4.2.1.22 (cystathionine beta-synthase, which forms a thioether from the
alcohol group of serine and the thiol group of homocysteine) vs. E.C. 4.2.1.4, 4.2.1.62,
4.2.1.96, and others which dehydrate an alcohol into an alkene. These examples illustrate
that while the E.C. system is helpful in organizing and cataloging the breadth of known
enzymes, it cannot be relied upon to distinguish between enzyme groups on the basis of
the functional group transformations that they catalyze. As new enzymes are created or
identified, the weaknesses of this system will be amplified.
The E.C. system nonetheless serves as a common nomenclature that most researchers
invoke when referring to various characterized enzymes. Because of this, the enzyme-
reaction mappings encoded in ReBiT are referenced back to specific 3-digit E.C.
numbers. An important consequence of this is that some of ReBiT's enzyme-reaction
mappings span multiple 3-digit E.C. classes, while several 3-digit E.C. classes contain
multiple enzyme-reaction mappings. The former statement highlights ReBiT's utility in
identifying similar enzyme chemistries dispersed across several E.C. classes - when
queried for chemical conversions present in multiple E.C. classes ReBiT will present the
user with hits from each E.C. class found to contain the queried conversion. The issue of
multiple chemistries in one 3-digit E.C. class is addressed in ReBiT by the citation of
specific 4-digit E.C. numbers with each mapping, so that the user is not misdirected to an
enzyme within the 3-digit E.C. class that does not catalyze the queried conversion.
Implementation
The ReBiT homepage presents four different ways to access the information on enzyme
conversions. Structures of interest are found either by browsing the functional groups or
submitting a specific query to ReBiT. Users may also browse all 605 structures, or
browse a list of names associated with the functional groups. Currently the structures in
ReBiT may be searched by drawing the (sub)structure in a Java applet window, or by
inputting the structure as a SMILES text string.
* Browse Functional Groups returns a table containing all 605 structures currently stored
within ReBiT. Highlighting a particular functional group and choosing "Find Enzymes"
will open a new window listing the enzymes, other substrates or products and co-factors
involved in the reactions that consume or create the structure. This table is described in
more detail below. The Query Structure and Query SMILES options can also be accessed
from within the table of functional groups.
* Browse Names brings up an alphabetical listing of all functional groups in ReBiT.
Selecting a particular name will return a secondary list with more detailed naming and
structural information. For example, selection of "Diol" produces a list of several 1,2-
and 1,3-diols with structures. Selection of the text string corresponding to a particular
structure returns the table of corresponding enzymes.
* Query Structure brings up a drawing board that allows one to directly draw a skeletal
structure (Figure 2.5). After drawing the desired structure, the user selects a search
strategy (substructure, superstructure, similarity, exact match, etc.) from the drop-down
menu on the left-hand side of the screen. More stringent search strategies return fewer
hits closer to the queried structure, while less stringent searches return more hits
consisting of a broader array of structures. Selecting the search button initiates the query
for the drawn structure.
* Query SMILES brings up a text box where SMILES code may be input. After inputting
the desired SMILES string, the user can again select a search strategy and press the
search button to initiate the query.
Figure 2.5: Submission page for a structural query to ReBiT. The box in the center of the screen is used to
draw a structure to query, while the menu on the left allows the user to specify the search type
(substructure, superstructure, exact match, etc.), search time, and other conditions on the hits returned by
ReBiT. In the structure drawn in the palette, wildcard A atoms are used in a generic query for disubstituted
primary amines.
After querying ReBiT by structure or SMILES, a list of matching structures will be
displayed (Figure 2.6). The user can then select the structure of interest and press the
"Find Enzymes" button on the menu. A table of all enzyme-catalyzed reactions
involving the selected structure will be shown, along with 3-digit E.C. numbers
corresponding to each of the reactions (Figure 2.7). In parenthesis below each 3-digit
E.C. group is the total number of enzymes in that 3-digit group. This number serves as
an initial assessment of substrate diversity, an important metric for choosing enzymes for
new pathways. Additionally for each enzyme group, graphical representations of all
ReBiT structures involved in the canonical reaction are shown as well as any co-factors
or co-substrates involved. Comments (typically suggestions as to what specific 4-digit
E.C. numbers catalyze each reaction) are also displayed for each reaction. Selecting a
particular E.C. number directs the user to an ExPASy database (Gasteiger, 2003) page
listing all enzymes in the enzyme class selected. Clicking on a specific enzyme from this
list redirects the user to a webpage containing additional information about the selected
enzyme class can be found. Links to other enzyme databases (BRENDA, MetaCyc,
KEGG, etc.) may also be found here.
Figure 2.6: Results of a similarity search for the disubstituted primary amine structure drawn in the
structural query palette shown in Figure 2.5. The structure exactly matching the query in Figure 2.5 is
indicated with a dark rectangle. Other structures similar to the queried structure are also displayed in
similarity searches like this one for the user's consideration.
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Figure 2.7: Enzyme-catalyzed reactions returned by ReBiT which have as their product the disubstituted
primary amine structure illustrated in Figure 2.5. For each reaction, graphical representations of the
structures involved are shown along with any cofactors or co-substrates. Commentary for each reaction
(typically a recommendation as to one or more specific 4-digit E.C. numbers that catalyze a given reaction)
is also shown. Clicking on any 3-digit E.C. number hyperlink redirects the user to the ExPASy database
for detailed enzyme information for the selected reaction. The numbers in the parentheses below each 3-
digit E.C. hyperlink represent the total number of enzymes in that enzyme group.
Conclusions
ReBiT provides a new means of searching through enzyme chemistry in order to identify
potential transformations that can produce or consume specific functional groups. Such a
tool should be useful in selecting targets for single-step bioconversions (in whole cell or
free enzyme systems), especially for those enzymes that may need to be engineered to
increase substrate specificity. A database such as ReBiT is an important tool to enable
metabolic engineers and synthetic biologists to begin to design new pathways for
biological synthesis of small molecules. A retro-biosynthetic approach that mimics the
retrosynthesis performed by organic chemists necessarily requires access to knowledge of
the transformational potential of enzymes. ReBiT serves to complement other
computational tools such as BNICE (Hatzimanikatis et.al. 2005) that seek to move
biosynthesis towards rational design--or re-design--of pathways towards specific
targets.
Chapter 3: Hydroxyvalerate Production in P. putida
This chapter contains material published in Martin and Prather, 2009.
Hydroxyacids represent an important class of compounds that see application in the
production of polyesters, biodegradable plastics and antibiotics, and that serve as useful
chiral synthetic building blocks for other fine chemicals and pharmaceuticals. In this
chapter, an economical, high-titer method for the production of 4-hydroxyvalerate (4HV)
and 3-hydroxyvalerate (3HV) from the inexpensive and renewable carbon source
levulinic acid is described. These hydroxyvalerates were produced by periodically
feeding levulinate to Psuedomonas putida KT2440 expressing a recombinant thioesterase
II (tesB) gene from Escherichia coli K12. The titer of 4HV in shake flask culture
reached 13.9 + 1.2 g L- from P. putida tesB+ cultured at 320 C in LB medium periodically
supplemented with glucose and levulinate. The highest 3HV titer obtained was 5.3 ± 0.1
g L' in M9 minimal medium supplemented with glucose and levulinate.
Background
Hydroxyacids are versatile, chiral compounds that contain both a carboxyl and a
hydroxyl moiety, readily allowing for their modification into several useful derivatives
(Lee et al., 2002; Chen and Wu, 2005). Specifically, hydroxyacids are used in the
synthesis of antibiotics (Chiba and Nakai, 1985), j- and y-aminoacids and peptides (Park,
et al. 2001; Seebach et al., 2001), and as chiral synthetic building blocks (Lee et al.,
2002). Hydroxyacids can also be used directly as nutritional supplements (Tasaki et al.,
1999) and can be polymerized into biodegradable polyesters (polyhydroxyalkanoates, or
PHAs) with interesting physical properties (Hazer and Steinbiichel, 2007).
Hydroxyacids are found in nature primarily polymerized as intracellular PHAs for energy
storage in numerous organisms (Lenz and Marchessault, 2005). Of all the hydroxyacids,
3-hydroxybutyrate (3HB) is the most prolific, and several papers describe different means
of producing monomeric 3HB (Lee et al., 1999; Gao et al., 2002; Liu et al., 2007; Tseng
et al., 2009). Longer chain length hydroxyacids, mainly 3-hydroxyvalerate (3HV), 4-
hydroxyvalerate (4HV), 3-hydroxyhexanate and other medium chain length 3-
hydroxyacids have been produced as constituents of various intracellular PHA co-
polymers (Lee et al., 1999; Gorenflo et al., 2001; Park et al., 2002; Park and Lee, 2004).
However, efficient production of these longer chain hydroxyacid monomers is
complicated by issues such as low yields--typically less than 10% on a g hydroxyacid
per g PHA basis for in vivo depolymerization from PHAs (Lee et al., 1999)--or the need
for complicated chemical synthesis (Jaipuri et al., 2004) or purification (De Roo et al.,
2002) procedures, most of which involve the use of large quantities of organic solvents.
Currently there exist three fundamental routes to the production of monomeric
hydroxyacids: chemical synthesis, in vivo production of PHA polymers followed by
depolymerization, and biological synthesis through non-PHA pathways. Chemical routes
to hydroxyacid production are hampered by the high number of chemically reactive
moieties in the hydroxyacid structure and the presence of a chiral center, and very few
reports on their chemical synthesis are published (Jaipuri et al., 2004). There are,
however, several reports on hydroxyacid production by depolymerizing PHAs through
chemical or biological means (Lee et al., 2002 and references contained within).
Chemical depolymerization of PHAs (Seebach et al., 1998) typically yields derivatives of
hydroxyacids such as alkyl esters (De Roo et al., 2002). The subsequent chemical steps
required to remove the chemical modifications from the hydroxyacids make this option
for depolymerization unattractive. In vivo depolymerization can result in hydroxyacid
dimer production and other products of incomplete depolymerization (Lee et al., 1999).
Furthermore, both chemical and biological depolymerization methods require the initial
production of a microbial PHA, which potentially complicates the process of hydroxyacid
production. This additional step in the process may also result in poor product yields.
Typical yields for PHA production are 0.3-0.5 g PHA per g carbon source, while typical
yields for the recovery of hydroxyacids from depolymerized PHAs range from 6.7% to
87.5%, depending on the composition of the PHA and the specific depolymerization
method employed (Wang and Lee, 1997; Lee et al. 1999; Gorenflo et al., 2001; Ren et al.,
2007).
Direct biological production of hydroxyacid monomers has been successfully
demonstrated for 3HB, and titers of 3 g L- and 12 g L on the shake flask and fed-batch
scales have been reported (Gao et al., 2002; Tseng et al., 2009). In these reports, 3-
hydroxybutyrate is made from acetyl-CoA through the use of acetyl-CoA
acetyltransferase (phbA), 3-hydroxybutyryl-CoA dehydrogenase (phbB),
phosphotransbutyrylase (ptb), and butyrate kinase (buk) (Liu and Steinbiichel, 2000a; Liu
and Steinbiichel, 2000b; Gao et al., 2002). The last two of these enzymes were chosen to
remove the CoA moiety from 3-hydroxybutyryl-CoA to yield free 3HB and were taken
from Clostridium acetobutylicum, where they participate in the production of butyrate
from butyryl-CoA (Liu and Steinbiichel, 2000b). Recently, thioesterase II (tesB) from
Escherichia coli K12 (Naggert et al., 1991) was successfully employed to directly
hydrolyze the acyl-thioester of 3HB-CoA (Liu et al., 2007). While this pathway allows
for the production of 3HB from glucose, it does not efficiently make higher chain length
hydroxyacids and cannot produce hydroxyacids with the hydroxyl group at different
positions.
Here the production of high titers of higher chain length hydroxyacids from inexpensive
and renewable carbon sources was sought. It was reported that Pseudomonas putida
accumulates PHA copolymers containing 4HV and 3HV when fed levulinic acid
(Gorenflo et al., 2001). Levulinic acid is an inexpensive ketoacid that can be readily and
renewably produced by treating wheat straw (Chang et al., 2007), corn starch (Cha and
Hanna, 2002), cellulose (Hayes et al., 2006) and other agricultural feedstocks with dilute
acid at modestly elevated temperatures and pressures. In this chapter, a bioprocess for
the production of monomeric 4HV and 3HV from levulinic acid in P. putida shake flask
cultures is described. Two strains of P. putida were tested: a commercially available
strain (KT2440) and a PHA synthase knockout strain (GPpl04; Huisman et al., 1991).
Two enzyme systems for removing CoA acyl carriers from intracellular hydroxyacids
were tested: the ptb/buk system and tesB. Once a suitable strain and enzyme system was
found, the process was improved at the shake flask scale in minimal and rich media for
the high-titer production of both 4HV and 3HV. As of the writing of this thesis, this
study represents the first time that these higher chain length hydroxyacids have been
produced from a renewable feedstock in shake flasks at the g L' scale.
Results
Initial Cellular System Optimization
Recombinant P. putida KT2440 or GPpl04 harboring the plasmid pRK415 (empty
plasmid control), pRK415-ptb/buk, or pRK415-tesB was grown in 50 mL LB shake flask
cultures at 30 0C. The cultures were fed with 1.25 mL of a 2.0 M levulinate stock solution
at t = 0, 6, 22, 29, and 49 hours. Levulinate was supplied to the cultures in smaller doses
over time because it was found that extremely high initial concentrations of levulinate
were inhibitory to cell growth. The resulting titers of 4HV and 3HV reached 4.08 g L 1
and 1.11 g L respectively in the KT2440 (pRK415-tesB) culture after 72 hours (Table
3.1). The molar yields of 4HV and 3HV from the levulinate consumed in this culture
were 15.3% and 4.2%, respectively, at 72 hours.
Table 3.1: Hydroxyvalerate accumulation in shake flask culture media after 72 hours by recombinant P.
putida KT2440 or GPpl04 grown at 300 C in LB and harboring different gene combinations on the pRK415
plasmid. Levulinate was fed to these cultures from a 2.0 M stock solution in 1.25 mL increments at t = 0,
6, 22, 29, and 49 hours. Productivity is calculated on a per gram dry cell mass basis.
KT2440 GPpl04 KT2440 GPp104 KT2440 GPp104
ptb + buk ptb + buk tesB c tesB
Cell Density (g L-1): 4.85 1.55 2.61 2.32 2.51 1.44
Total Levulinate Consumed (g L-'): 28.8 9.5 25.3 13.6 27.1 7.2
4HV Titer (g L-1): 1.50 0.42 0.53 0.53 4.08 1.58
3HV Titer (g L-'): 0.51 0.00 0.56 0.00 1.11 0.00
4HV Productivity (g g-L): 0.31 0.34 0.20 0.29 1.63 1.37
3HV Productivity (g g-1): 0.11 0.00 0.21 0.00 0.44 0.00
4HV Molar Yield: 5.3% 4.5% 2.1% 4.0% 15.3% 22.3%
3HV Molar Yield: 1.8% 0.0% 2.2% 0.0% 4.2% 0.0%
The expression of tesB leads to a substantial increase in both 4HV and 3HV
concentration in the culture media while the ptb and buk genes do not improve either of
the titers (Table 3.1). Furthermore, P. putida GPp104 in all cases had lower 4HV titers
than KT2440 and did not produce detectable amounts of 3HV. GPpl04 4HV
productivity was comparable with KT2440, suggesting that PHA accumulation is not
competing significantly with 4HV production in KT2440; the differences in titer between
KT2440 and GPpl04 are due to differences in stationary phase cell density rather than
the presence or absence of PHA synthase activity. These results indicated that KT2440
overexpressing tesB was a superior strain for the production of hydroxyvalerates, and
consequently all future investigations were done with KT2440 tesB+.
Production of Hydroxyvalerates in LB medium
Recombinant P. putida KT2440 harboring the plasmid pRK415-tesB was grown in 50
mL LB shake flask cultures at 300 C or 320C. Where indicated, cultures were initially
supplemented with 0.4% glucose, followed by an additional 1 mL of 20% glucose
solution at t = 21, 42 and 70 hours. Glucose supplementation was done periodically
because it was found that glucose, like levulinate, was inhibitory to cell growth at high
concentrations. Levulinate was added to the cultures from a 2.0 M stock solution as
follows: 2.5 mL at t = 0 and 70 hours and 3.75 mL at t = 21 and 42 hours.
The highest 4HV titer obtained (13.9 ± 1.2 g L') was from the culture incubated at 320C
and supplemented with glucose (Figure 3.1). The molar yield of 4HV from levulinate in
this culture was 25 ± 1%. The highest 3HV titer in this experiment was observed in the
300 C culture without glucose supplementation and was 3.1 ± 0.4 g L-1 , corresponding to a
yield of 7 ± 1% from levulinate. Glucose supplementation did not have a significant
effect on hydroxyvalerate production in the 300C cultures, but did have a marked effect in
the 32oC cultures (Figure 3.1). The total hydroxyvalerate productivities per gram dry cell
mass for the 30'C, 30'C with glucose supplementation, 320C, and 320C with glucose
supplementation LB cultures were 4.7 + 0.4, 5.0 ± 0.4, 4.3 ± 0.2 and 7.8 ± 1.9 g g-1
respectively after 114 hours.
A probable explanation for the differences in hydroxyvalerate titers with respect to
temperature is that the tesB enzyme is more active at 320C. This enzyme is native to E.
coli, an organism whose metabolism is optimum at 370C, so tesB could be more active at
temperatures closer to that of its native host. A more active tesB would cause P. putida
to release more hydroxyvalerates, giving rise to the observed higher hydroxyvalerate
titers. However, higher hydroxyvalerate titers in LB medium at 320 C were only observed
when glucose was supplemented into the medium, suggesting that other factors such as
metabolic burden may be affecting the titers.
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Figure 3.1: Time-course of 4-hydroxyvalerate (top) and 3-hydroxyvalerate (bottom) accumulation in shake
flask culture media by recombinant P. putida KT2440 harboring pRK415-tesB grown at 300C or 32oC in
LB. Glucose was added to some cultures from a 20% stock solution where indicated, in 1 mL portions at t
= 0, 21, 42, and 70 hours. Levulinate was fed to the cultures from a 2.0 M stock solution as follows: 2.5
mL at t = 0 and 70 hours and 3.75 mL at t = 21 and 42 hours. The values shown are the average of three
independent cultures with the error bars representing the standard deviation.
Production of Hydroxyvalerates in M9 Minimal Medium
Recombinant P. putida KT2440 harboring the plasmid pRK415-tesB was grown in M9
minimal medium in 50 mL shake flasks at 300C or 320C. The M9 medium was
supplemented with 0.4% (w/v) glucose and a 1:1000 dilution of ATCC trace mineral
supplement. Levulinate was added to these cultures from a 2.0 M stock solution in
portions of 0.625, 0.625, 1.25, 1.25, and 1.25 mL at t = 0, 21, 52, 75, and 98 hours
respectively. To some cultures where indicated, additional glucose was added from a
20% glucose stock solution in portions of 0.375 mL at t = 21, 52, 75, and 98 hours.
The highest titers of 4HV and 3HV in this experiment, 2.1 + 0.0 g L (9 ± 0% molar
yield of 4HV from levulinate) and 5.3 ± 0.1 g L- (24 + 0%), were both observed in the
320C culture with periodic glucose supplementation (Figure 3.2). The total
hydroxyvalerate productivities per gram dry cell mass for the 30'C, 300C with glucose
supplementation, 320C, and 320C with glucose supplementation M9 cultures were 2.1 ±
0.1, 2.8 ± 0.1, 3.3 ± 0.6 and 5.2 ± 0.1 g g-1 respectively after 120 hours. In M9 medium,
higher incubation temperature and periodic glucose supplementation had a cumulative
positive effect on the titer of both hydroxyvalerates. The yield of 4HV from levulinate
increased slightly by increasing the incubation temperature or adding additional glucose,
while the 3HV yield increased substantially with these changes in culture condition.
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Figure 3.2: Time-course of 4-hydroxyvalerate (top) and 3-hydroxyvalerate (bottom) accumulation in shake
flask culture media by recombinant P. putida KT2440 harboring pRK415-tesB grown at 300C or 320C in
M9 minimal media supplemented with ATCC trace mineral solution and 0.4% glucose. Additional glucose
was added to some cultures from a 20% stock solution where indicated, in 0.375 mL portions at t = 21, 52,
75, and 98 hours. Levulinate was fed to the cultures from a 2.0 M stock solution as follows: 0.625 mL at t
= 0 and 21 hours and 1.25 mL at t = 52, 75, and 98 hours. The values shown are the average of three
independent cultures with the error bars representing the standard deviation.
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Interestingly, while growth in M9 minimal medium does not yield a higher total
hydroxyvalerate titer than growth in LB medium, the relative amounts of each
hydroxyvalerate differ significantly between the two media. A comparison of Figures 1
and 2 indicates that more 4HV is produced in LB medium relative to 3HV, while in M9
medium more 3HV is made relative to 4HV. The ratio varied across almost two orders of
magnitude, from as high as 21.4 ± 9.5 in LB medium at 320C with periodic glucose
supplementation to as low as 0.35 + 0.07 in M9 medium at 320 C with periodic glucose
supplementation (Figure 3.3). The choice of culture medium had the most dramatic
effect on the 4HV-to-3HV ratio. In general, increasing the incubation temperature,
supplementing the medium periodically with glucose, and increasing the culture time all
caused the ratio to increase in LB medium and decrease in M9 medium. The underlying
causes of the shifts in the 4HV-to-3HV ratio should be rooted in the expression and
kinetics of the enzymes in P. putida that create and consume the hydroxyvalerates, and
thus without further study these causes are subject only to speculation. Nonetheless, the
effects of various culture conditions on the 4HV-to-3HV ratio provide a convenient
means of controlling the relative amounts of each hydroxyvalerate produced.
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Figure 3.3: Ratios of 4HV-to-3HV titers produced by P. putida tesB cultured under the different culture
conditions from Figures 1 and 2. The conditions tested were LB or M9 media, 300C or 32 0C incubation,
and periodic glucose feeding (glc) or no periodic glucose feeding.
Mass Spectrometry Confirmation of Hydroxyvalerate Production
To confirm that hydroxyvalerates were being produced from levulinate, supernatants
from cultures of P. putida tesB+ supplemented with levulinate were analyzed by LC/MS
and the mass spectra of each experimental hydroxyvalerate peak were compared to 4HV
and 3HV standards. The mass spectra of the 4HV and 3HV peaks found in the P. putida
cultures matches the spectra of the 4HV and 3HV standards extremely well (Figure 3.4).
In the 4HV spectra (Figures 3.4a and 3.4b), the molecular ion (M ) peak of 118.1
(118.134 theoretical mass) is observed as well as an M + H peak of 119.1. The small
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peak of 136.2 is likely M + NH4+, given that the mobile phase for this LC/MS analysis
used ammonium formate as a buffer (by the same logic, the 118.1 peak likely also
represents the [M+ - H20] + NH4 ion). The 101.2 peak is consistent with [M - H20] + H+
and is likely the result of dehydration of 4HV into its lactone form upon sample
vaporization. The 3HV spectra (118.134 theoretical mass) consist of only a single peak
at 136.2, representing M + NH4+ (Figures 3.4c and 3.4d). As expected, there is no
dehydration peak in the 3HV spectra, as 3HV cannot form a stable lactone.
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Figures 3.4a-b: See figure caption on page 73.
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Figure 3.4: Positive mode electrospray mass spectra of 4HV produced by P. putida from levulinate (A), a
4HV standard (B), 3HV produced by P. putida from levulinate (C), and a 3HV standard (D),. The
theoretical mass of both 4HV and 3HV (M+) is 118.134. The additional peaks in the spectra are believed to
be M + H+ (119.142), M + NH4+ (136.173), and [M + H ] - H20 (101.126). The ammonium ion that gives
rise to the M + NH4+ peak at 136.1 originates from the ammonium formate buffer used in the mobile phase.
The [M + H+] - H20 peak at 101.2 peak is likely due to lactonization induced by sample vaporization in the
mass spectrometer.
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Investigation of Levulinate Metabolism in P. putida
To gain insight into how hydroxyvalerates are made in P. putida, P. putida tesBi was
grown in M9 minimal medium at 300C with 0.4% (w/v) glucose used as a carbon source.
This culture was then fed a bolus of either 3.0 g L-1' 4HV after 24 hours or 4.0 g L-
levulinate after 17 hours. The 4HV bolus caused the production of 3HV, establishing that
3HV is produced from 4HV in P. putida (Figure 3.5, top). No levulinate was detected
throughout the 4HV bolus experiment. The concentration of 3HV began to fall after a
single day, suggesting that 3HV is metabolized by P. putida. One likely avenue for 3HV
is odd-chain fatty acid metabolism, in which 3HV-CoA would be oxidized to 3-
ketovaleryl-CoA and then split into acetyl-CoA and propionyl-CoA.
In the levulinate bolus experiment, 4HV production in the hours following the bolus was
significantly more rapid than 3HV production, suggesting that 4HV is produced from
levulinate before 3HV (Figure 3.5, bottom). After the concentration of 4HV reaches
about 0.15 g L, 3HV levels begin to rapidly rise, eventually overtaking 4HV. About a
day after the levulinate bolus, 4HV increases more slowly while 3HV levels rapidly rise,
consistent with the observation that 4HV is consumed to form 3HV. The 4HV
concentration rapidly declines once levulinate is depleted from the medium, providing
further evidence that levulinate is reduced first to 4HV in P. putida. Finally, the decline
of 3HV levels between t = 69 and 94 hours after 4HV and levulinate are both depleted
further establishes that P. putida metabolizes 3HV.
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Figure 3.5: Concentration profiles of levulinate, 4HV, and 3HV in a M9 shake flask culture of P. putida
expressing tesB after a 3.0 g L- bolus of 4HV at t = 24 hours (top) or a 4.0 g L-1 bolus of levulinate at t =
16.7 hours (bottom). The values shown are the average of three independent cultures with the error bars
representing the standard deviation.
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The observations from the 4HV and levulinate bolus experiments support the levulinate
metabolism pathway shown in Figure 3.6. First, levulinate is reduced by a reductase
activity native to P. putida to 4HV. This 4HV is then isomerized into 3HV by one or
more enzymes also native to P. putida. Finally, 3HV itself is metabolized by P. putida,
likely by way of odd-chain fatty acid metabolism. The differences in the relative ratios of
the individual hydroxyvalerates produced are likely a consequence of the effect of
various culture conditions on the rates of the reaction steps in the levulinate metabolism
pathway, particularly the isomerization of 4HV to 3HV.
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Figure 3.6: Proposed model of levulinate metabolism in P. putida based on the experimental results shown
in Figure 3.5.
Discussion
In this chapter, it was demonstrated that high concentrations of 4HV and 3HV can be
made from levulinate in recombinant P. putida KT2440 by overexpressing the tesB gene.
Through careful modulation of the culture and feeding conditions, maximum titers of 14
g L-1 4HV and 5 g L-' 3HV at the shake flask scale were achieved.
Hydroxyvalerate production in both rich and minimal media was investigated and it was
found that the choice of culture medium substantially affects the relative amounts of each
hydroxyvalerate produced. LB medium was found to be superior for 4HV production
while M9 medium was better for 3HV production. The total hydroxyvalerate titer
however is higher in LB medium relative to M9 medium, an expected result given the
relative richness of the two media. Additionally the total hydrQxyvalerate productivity on
a per gram dry cell weight basis was consistently higher in LB (4.3-7.8 g g-') than in M9
(2.1-5.2 g g-') and was generally dependent on temperature and glucose supplementation.
Despite these differences, both hydroxyvalerates were produced in g L-' quantities at the
shake flask scale in both kinds of media.
While the hydroxyvalerate titers in this report are high at the shake flask scale, they are
not necessarily optimal. Both the total hydroxyvalerate titer and ratio of the individual
hydroxyvalerate produced were found to be strongly dependent on medium composition
and temperature. The temperature effect may be due to increased tesB activity, since
increased temperatures generally increased the concentrations of both hydroxyvalerates.
Medium composition heavily influences the conversion of 4HV to 3HV, since the ratio of
hydroxyvalerates produced by P. putida changes dramatically between rich and minimal
media. Specifically, the gene or genes responsible for this conversion appear to be
upregulated in defined media.
Because hydroxyvalerate levels were heavily influenced by culture conditions, analyzing
a wider variety of culture conditions would almost certainly lead to even higher product
titers. Furthermore, the ratio of hydroxyvalerates could be further controlled by taking
advantage of the levulinate pathway structure shown in Figure 3.6. For instance, 3HV
could be made by P. putida without any 4HV by first allowing the cells to accumulate
both hydroxyvalerates by feeding the culture levulinate and then subsequently depriving
the cells of levulinate, allowing them to convert the 4HV left in the medium to 3HV.
Care would need to be taken to harvest the 3HV from the culture medium immediately
after 4HV is depleted as the cells do consume 3HV. The 69 hour time point from the
levulinate bolus experiment in Figure 3.5 illustrates this strategy. At this time point 0.44
± 0.16 g L-1 of 3HV was present in the culture media as a result of the 4.0 g L1 levulinate
bolus while no 4HV was detected at this time point.
If the specific enzymes responsible for the steps in the levulinate metabolism pathway are
found, the pathway could likely be engineered to produce even higher titers of 4HV or
3HV from levulinate. Additionally, discovery of the levulinate pathway enzymes would
allow the reconstruction of the pathway in other organisms such as Escherichia coli that
are easier to engineer and could allow pathway expression at higher temperatures where
tesB may be more active. A likely candidate for both the reduction of levulinate and the
isomerization of 4HV to 3HV is the enzyme complex encoded by the P. putida fadBA
operon (Olivera et al., 2001). This multifunctional complex possesses hydroxyacyl-CoA
dehydrogenase, enoyl-CoA hydratase and enoyl-CoA isomerase activities that could both
reduce levulinate to 4HV and isomerize 4HV to 3HV. The high titers of
hydroxyvalerates produced by P. putida from levulinate suggest that the enzymes
responsible for levulinate metabolism in P. putida are highly active, making them
attractive choices for use in biosynthetic pathways involving similar reaction steps.
Given that total hydroxyvalerate titers in excess of 15 g L-1 could be made in 50 mL
shake flasks, one future study of immediate interest is hydroxyvalerate production in
larger stirred tank reactors. Large-scale production in a better aerated reaction vessel
should afford even higher'titers of 4HV and 3HV with improved economic margins.
Another future study of interest is the production of other hydroxyacids with tesB in P.
putida. In particular, it is known that supplying P. putida with oleic acid results in the
accumulation of a PHA containing 3-hydroxyalkanoic acids from six to fourteen carbon
atoms in length (De Roo et al., 2002). Given that tesB is known to accept longer-chain
fatty acid CoA thioesters such as decanoyl-CoA as substrates (Naggert et al., 1991), it is
likely that tesB will be able to liberate these C6-C14 3-hydroxyacids from their
intracellular CoA carriers prior to their incorporation as a PHA. This would result in the
accumulation of these novel, longer-chain hydroxyacids in the culture media.
In conclusion, a method was developed for producing high titers of the high-value
hydroxyacids 4HV and 3HV from the renewable and inexpensive substrate levulinate in
P. putida KT2440 at the shake flask scale by overexpressing the tesB gene.
Hydroxyvalerate titers of several grams per liter were achieved in both rich and minimal
media. Modulation of culture conditions such as temperature, feed profile, and media
yielded increased hydroxyvalerate titers as well as control over the relative amounts of
4HV and 3HV produced. Chapter 4 covers the further transformation of 4HV into 4-
valerolactone (4VL) using this cellular system.
Materials and Methods
Strains and Plasmids
Psuedomonas putida KT2440 (ATCC 47054; American Type Culture Collection,
Manassas, VA, USA) and GPpl04 (Huisman et al., 1991) were used to produce
hydroxyvalerate monomers from levulinic acid. GPpl04 is a polyhydroxyalkanoate
(PHA) synthase deficient mutant of P. putida KT2442. Escherichia coli thioesterase II
(tesB) was amplified from the E. coli K12 MG1655 (ATCC 47076) genome by PCR.
The primers used were purchased from Sigma-Genosys (St. Louis, MO, USA) and were
as follows (restriction sites used for cloning are underlined): EcoRI-tesB-FP (5'-
GAATTCTACTGGAGAGTTATATGAGTCAGG-3') and SalI-tesB-RP (5'-
GTCGACTTAATTGTGATTACGCATC-3'). HotStar HiFidelity DNA polymerase was
purchased from Qiagen (Valencia, CA, USA) and used according to the manufacturer's
instructions. The tesB gene was first cloned into the pGEM-T Easy vector (Promega,
Madison, WI, USA) to produce the plasmid pGEM-tesB. pGEM-tesB was then digested
with EcoRI and Sall and cloned into a similarly digested broad-host-range expression
vector pRK415 (Keen et al., 1988) to produce the plasmid pRK415-tesB. Molecular
biology manipulations were performed using standard cloning protocols (Sambrook and
Russell, 2001).
The phosphotransbutyryrase (ptb) and butyrate kinase (buk) genes were amplified as an
operon by PCR from the genomic DNA of Clostridium acetobutylicum (ATCC 824)
using the primers EcoRI-ptb/buk-FP (5'-
GAATTCACCAGTGATTAAGAGTTTTAATG-3') and PstI-ptb/buk-RP (5'-
GTCGACGGTACTGGTTATATTATATTATTTATG-3'). These two genes were
cloned into the pGEM-T Easy vector to yield the plasmid pGEM-ptb/buk. pGEM-
ptb/buk was then digested with EcoRI and PstI and cloned into similarly digested
pRK415 to produce the plasmid pRK415-ptb/buk.
Chemicals and Growth Media
Dehydrated LB broth (Miller formulation) was purchased from BD Biosciences (San
Jose, CA, USA) and D-glucose was purchased from Mallinckrodt Chemicals
(Phillipsburg, NJ, USA). M9 minimal medium was prepared as described elsewhere
(Sambrook and Russell, 2001). LB and M9 media were autoclaved prior to use, while D-
glucose was prepared as a 20% (w/v) stock solution and sterile filtered. Levulinic acid
was purchased from Acros Organics (Morris Plains, NJ, USA) and was neutralized to a
pH of 7.0 with 10N NaOH and sterile-filtered prior to use. ATCC Trace Mineral
Supplement (ATCC MD-TMS) was added to M9 cultures where indicated. 3-
Hydroxyvalerate was purchased from Epsilon Chimie (Brest, FRANCE) and was used as
an HPLC standard. 4-Hydroxyvalerate was made by saponification of y-valerolactone
purchased from Alfa Aesar (Ward Hill, MA, USA) and was used as an HPLC standard.
Culturing of P. putida
50 mL of M9 or LB media was added to a 250 mL shake flask. The medium was
supplemented with 10 pg mL-' tetracycline for plasmid maintenance, 1.0 mM IPTG for
induction of gene expression, and various levulinic acid concentrations. M9 cultures
were given a 1000x dilution of ATCC Trace Mineral Supplement. The inocula for all
cultures was prepared from P. putida KT2440 or GPpl04 grown overnight from frozen
stock in LB at 300C, centrifuged at 2,000 x g and 4oC for 5 min, and washed and
resuspended in 0.9% (w/v) sodium chloride. All experimental cultures were inoculated
with this resuspension to an initial optical density at 600nm (OD 600 ) of 0.05 and were
incubated at 30 or 320 C with shaking at 250 rpm. Samples were periodically withdrawn
from these cultures for OD 600 and HPLC analysis.
Analytics
Culture cell density was monitored by measuring optical density at 600 nm (OD600 ) on a
Beckman Coulter DU800 UV/Vis spectrophotometer. Optical density readings of cell
concentration were correlated to dry cell weight (DCW) per unit volume by measuring
the OD 600 of several P. putida KT2440 or GPpl04 cultures, filtering a known culture
volume through a pre-weighed Whatman 0.45 jm cellulose acetate filter, and drying the
retained cells for several days in a 370C oven. A calibration curve for both KT2440 and
GPp104 was constructed to convert OD 600 values to g DCW-L-1 and conversion factors of
0.42 g L-' OD 600-1 and 0.53 g L-' OD 600-1 were found for KT2440 and GPpl04,
respectively.
High-performance liquid chromatography (HPLC) samples were prepared by
centrifuging 1 mL of culture at 14,000 x g for 10 min at room temperature and
withdrawing the supernatant for analysis. HPLC samples were analyzed on an Agilent
1100 Series instrument equipped with an Agilent ZORBAX SB-Aq reverse phase column
(4.6 x 150mm, 3.5jm). The column temperature was maintained at 650C. Levulinic acid
and hydroxyvalerate concentrations were measured with a refractive index detector. The
mobile phase was an aqueous solution of 25 mM ammonium formate, pH of 2.0. The
flowrate through the column was 0.5 mL min'- . Levulinic acid, 4-hydroxyvalerate, and
3-hydroxyvalerate were used as HPLC standards and had respective retention times of
7.4, 7.0, and 8.0 minutes.
Mass spectrometry (MS) analysis was performed using an Agilent 6120 Quadrupole
LC/MS unit operated in positive ion electrospray mode. The unit was operated
downstream of the liquid chromatography column described above under the same
chromatography conditions. Samples were vaporized at 150 0C and nitrogen at 3000 C, 60
psig, and 5.0 L min' was used as the carrier gas for MS analysis.
Chapter 4: Valerolactone Production in P. putida
This work is in press in Appl. Environ. Microbiol. as of the writing of this thesis.
Enzymes are powerful biocatalysts capable of performing specific chemical
transformations under mild conditions. Yet as catalysts they remain subject to the laws
of thermodynamics, namely that they cannot catalyze chemical reactions beyond
equilibrium. In this chapter, the phenomenon and application of using extracytosolic
enzymes and medium conditions such as pH to catalyze metabolic pathways beyond their
intracellular catalytic limitations is described. This methodology, termed "integrated
bioprocessing" because it integrates intracellular and extracytosolic catalysis, was applied
to a lactonization reaction in Pseudomonas putida for the economical and high-titer
biosynthesis of 4-valerolactone from the inexpensive and renewable source levulinic
acid. Specifically, mutant paraoxonase I (PON1) was expressed in P. putida, shown to
export from the cytosol in Escherichia coli and P. putida using an N-terminal sequence,
and demonstrated to catalyze the extracytosolic and pH-dependent lactonization of 4-
hydroxyvalerate to 4-valerolactone. With this production system, the titer of 4-
valerolactone was enhanced substantially in reduced-pH media using extracytosolically-
expressed lactonase vs. an intracellular lactonase: from <0.2 g L'~ to 2.1 + 0.4 g L-' at the
shake flask scale. Based on these results, production of 4-hydroxyvalerate and 4-
valerolactone was scaled up to a 2 L bioreactor and titers of 27.1 g L and 8.2 g L-1 for
the two respective compounds were achieved. These results illustrate the utility of
integrated bioprocessing as a strategy for enabling lactone production from novel
metabolic pathways and enhancing product titers.
Background
In nature, metabolism is not restricted to the cytosol. Metabolic activity can occur in the
periplasm, on cell surfaces, or even extracellularly in the environment. When
extracytosolic enzyme expression occurs, it is often to convey an advantage to the cell
that is not possible with the enzyme in the cytosol. For instance, E. coli alkaline
phosphatase is expressed in the periplasm to detoxify compounds before they can enter
the cell and to allow the enzyme better access to the extracellular environment for
scavenging phosphate (Derman and Beckwith, 1991). Penicillium decumbens secretes
cellulases presumably to break down extracellular substrates into a form amenable to
uptake by the cell for further metabolism (Sun et al., 2008). Each of these enzymes exists
as a component of larger metabolic pathways (phosphate and cellulosic material
metabolism) and each has evolved for non-cytosolic expression to facilitate the
physiological goals of their respective pathways.
In microbial biotechnology, the objective is typically not physiological but commercial in
nature: to increase the titer of a small-molecule metabolic product. Though the goal has
changed, the lessons we can learn from natural systems remain. The cytoplasm is not
always the best choice for enzyme expression because cytoplasmic conditions are not
necessarily optimal for enzyme productivity. One such system is the intramolecular
lactonization of hydroxyacids such as 4-hydroxyvalerate (4HV) to lactones such as 4-
valerolactone (4VL). This reaction, catalyzed in this work by the G3C9 variant of
paraoxonase I (PON1; Aharoni et al., 2004), is known to be highly pH-dependent.
Because lactonization is acid-catalyzed and because hydroxyacids and lactones exist in
pH-dependent equilibrium with each other, control of the pH at which lactonization
occurs is critical to achieving high titers of lactones (Teiber et al., 2003). The
cytoplasmic pH, typically about 7.5, is too high to achieve good titers of lactones at
equilibrium (Wilks and Slonczewski, 2007). This limitation in lactone titer is
thermodynamic in nature, meaning that overexpressing the lactonase or other traditional
metabolic engineering techniques would be ineffective at improving lactone production.
However, having the lactonase perform catalysis outside the cytosol, where the pH can be
lowered, would alter the equilibrium in favor of lactone production, thereby increasing
product titer.
To implement such a system, we used extracytosolically-expressed PON1 to catalyze the
lactonization reaction in reduced pH-media (pH - 6). In Chapter 3, it was found that
Pseudomonas putida was capable of producing high titers of 4HV from the renewable
carbon source levulinic acid (Martin and Prather, 2009). This process is achieved
through coenzyme-A carriers and the secretion of 4HV into the extracellular medium
was enhanced by the expression of an intracellular thioesterase. Thus, P. putida can
serve as an intracellular source of 4HV. This 4HV can then be lactonized by
extracytosolically-expressed PON1 in reduced-pH media to yield 4VL (Figure 4.1).
This general strategy is termed "integrated bioprocessing" for its integration of cytosolic
and extracytosolic biocatalysis to enhance production.
Reduced-pH Medium 0 W V / OH
4-Valerolactone (4VL) , ,
OH
Figure 4.1: Integrated bioprocessing system for the production of 4VL from levulinate. Production of
4HV from levulinate occurs intracellularly, while the lactonization reaction takes place extracytosolically
in reduced-pH media. The enzyme(s) responsible reaction step(s) from levulinate to 4-hydroxyvaleryl-
CoA occur in P. putida and are currently not known.
There is conflicting evidence as to whether the G3C9 variant of PON1 expressed in
microbes would be cytosolic (Aharoni et al., 2004) or whether G3C9 PON1 would be
associated with the membrane as native PON1 is (Deakin et al., 2002). In particular it
was noted that G3C9 PON1 had a significantly altered N-terminal primary sequence
relative to native PON1 (Figure 4.2), and that the altered sequence looked similar to that
of alkaline phosphatase (PhoA), a protein known to be membrane-associated in E. coli.
Thus in this work, it was first demonstrate that the G3C9 variant of PONI (referred to as
simply PON1 throughout the rest of this report) is expressed outside of the cytosol in
both E. coli and P. putida and consequently that it responds strongly to changes in the
medium pH. Then, intracellular 4HV production was combined with extracytosolic
_ __
lactonization to enable the high-titer biochemical production of 4VL. This work
represents the first report of 4VL synthesis in a biological system.
Native PON1 (H. Sapien)
G3C9 PON1 Variant
PhoA (E. coIi)
MAKLIALTLLGMGLALFRNHQSSYQ
MAKLTALTLLGLGLL FDGQS SFQ
MKQSTIALAL LPLLFTPVTKARTPE
Figure 4.2: Comparison of the first 25 N-terminal residues of native human PON1, the G3C9 variant of
PON1 created by Aharoni and coworkers (2004), and E. coli PhoA (a protein known to export into the
periplasm). Aliphatic residues (which bury within the membrane) are shown in green while cationic
residues (presumed to bind to the negatively-charged heads of phospholipids) are underlined in red. In this
work it is hypothesized that the G3C9 variant of PON1 possesses an N-terminal signal sequence similar
enough to bacterial signal sequences to allow PON1 export from the cytosol in both E. coli and P. putida.
4VL has been reported to be an ideal compound for use as a fuel and in the production of
carbon-based chemicals (Horvith et al., 2008). It has also seen extensive use as a
component of block-copolymers for drug delivery (Atwood et al., 2007; Chang and Chu,
2008), as a precursor for acrylic compounds (Manzer, 2004), and can be used as a
precursor for the production of "bio-nylon" polymers (Lange et al., 2007). Current
synthetic methods for 4VL also utilize levulinate as the starting material but require
supercritical solvents (Manzer and Hutchenson, 2005) or carbon dioxide (Bourne et al.,
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2007) with hydrogen gas under harsh conditions (-10-40 MPa and -200'C) and
ruthenium-based catalysts. In contrast, our biological method of production is done
under mild conditions without the need for harsh solvents, hydrogen, rare metal
catalysts, or supercritical fluids. This integrated bioprocessing system to produce 4VL
from levulinate (Figure 4.1) was compared to an entirely intracellular 4VL production
pathway using cytosolically-expressed PON1 to demonstrate the effectiveness of
integrated bioprocessing to improve product titers at different pH values. The system
was scaled up to a 2.0 L bioreactor to further increase product titers as well as take
advantage of automated pH control.
Results
Confirmation of Extracytosolic PON1 Expression
To demonstrate the integrated bioprocessing system for the production of 4VL, it was
first necessary to establish the localization of the PON1 lactonase. It was suspected that
the G3C9 PON1 variant (Aharoni et al., 2004) might export from the cytosol using an N-
terminal sequence (Figure 4.2). In particular, key similarities were identified between the
first 23 amino acids of G3C9 PON1 and E. coli alkaline phosphatase, a protein known to
export from the cytoplasm. First, the spacing between the two lysines in the N-termini of
these two proteins was identical. These lysines are cationic at physiological pH and can
associate with negatively-charged phospholipid heads in a cell membrane. Second, both
N-termini have several hydrophobic residues between these two lysines, which would
help anchor that part of the protein inside a cell membrane. Comparing the N-termini of
native human PON1 with G3C9 PONI shows that the spacing between the two cationic
residues differs substantially between the two proteins. It was suspected that this
difference would allow G3C9 to export from the cytosol. Considering that G3C9 PON1
was evolved from human PON1 with the goal of functional expression in E. coli
(Aharoni et al., 2004), this key difference in the N-terminal signal sequences of the two
lactonases may be what allows G3C9 to be functionally expressed in E. coli.
To test G3C9 PONi (hereinto referred to as PON1) for any ability to export from the
cytosol, fusions of PON1 with E. coli alkaline phosphatase (PhoA), an enzyme only
active in the periplasm (Derman and Beckwith, 1991), were constructed. PONI fusions
that successfully export from the cytoplasm enable PhoA activity. To construct the
protein fusions, PON1 and a truncated version of PON1 with residues 2-23 removed,
tPON1, were fused to a truncated version of phoA (tPhoA) with residues 1-23 removed.
The fusions were constructed as N-PON1-tPhoA-C and N-tPON1-tPhoA-C, with an XbaI
restriction site used as the linker between PON1 or tPON1 and tPhoA. The stop codon of
PON1 and tPON1 was removed to allow translation of the entire fusion. Additionally,
PhoA and tPhoA were tested as controls. Cells to be tested were streaked on LB plates
supplemented with phosphate (to suppress endogenous phophatase expression), IPTG and
the indicator bromo-4-chloro-3-indolyl phosphate (XP). Colony color was detected by
eye: blue or bluish colonies indicated active, periplasmic PhoA, while completely white
colonies indicated that the PhoA construct was inactive. The qualitative results of this
assay are shown in Table 4.1 for constructs in E. coli and P. putida, along with data from
a quantitative PNP-based PhoA assay of E. coli construct lysates. These data show that
in both organisms, PON1-tPhoA is exported from the cytosol while tPON1-tPhoA is not,
indicating that PONI is capable of export from the cytosol and that the first 23 N-
terminal residues of PON1 are essential for this process.
Table 4.1: PhoA assay results for PON1-PhoA protein fusions. Qualitative results of a XP plate-based
assay for phoA activity for various protein constructs in E. coli and P. putida are listed along with
quantitative data from a PNP-based PhoA assay of E. coli construct lysates. Protein fusions are written
from N- to C-terminus (e.g. N-PON1-tPhoA-C). A "t" in front of a protein name indicates that the protein
has had its N-terminal signal sequence removed. PNP assay data given as the averages and standard
deviations of three independent experiments.
E. coli Colony Color P. putida Colony Color PNP PhoA Activity in
Construct on XP Plates on XP Plates E. coli (U/mg)
PhoA Blue Blue 1.79 ± 0.06
tPhoA White White 0.25 + 0.05
PON1-tPhoA Blue Blue 3.88 + 0.13
tPON1-tPhoA White White 0.26 ± 0.05
To provide additional verification of extracytosolic PON1 expression, whole-cells and
lysates of E. coli expressing PON1 and tPON1 were assayed for lactonase activity at low
pH (6.2) and high pH (7.2) (Figure 4.3). Based on the results of the PhoA fusion studies
in the previous section, PON1 should be an extracytosolic lactonase while tPON1 should
be a cytosolic lactonase. Thus in whole-cells, PON1 should be exposed to the
extracellular pH while tPON1 should be exposed to only the intracellular pH of
approximately 7.5. In lysates, however, both PON1 and tPON1 should be exposed to the
medium pH, as there is no cytosolic membrane to shield them. As the degree of PON1-
catalyzed lactonization is known to be pH-dependent (Teiber et al., 2003), PON1 exposed
to lower pH values produces more 4VL from 4HV. Thus lactone production can be used
to estimate the pH that PON1 is exposed to and consequently to identify whether PON1
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is localized intracellularly or extracytosolically. At an extracellular pH of 6.2, both
whole-cells and lysates containing PON1 are highly active, while only the lysate from
tPON1 cells is highly active at this pH (Figure 3a). Whole-cells expressing tPON1 are
only minimally active, achieving only 1.5-2.0% conversion of 4HV into 4VL. At an
extracellular pH of 7.2, the results are essentially the same (Figure 4.3b), the only
difference being that the more active samples are limited to 4% conversion by the higher
pH. The tPON1 sample here again achieves approximately 1.5-2.0% conversion,
presumably because the tPON1 in whole-cells is exposed to the same higher intracellular
pH (7.5) irrespective of the medium pH value.
(A)
30%
25%
S20%
00O 15%
0 10%
5% -6
0%
0 10 20 30 40 50 60 70 80 90 100
Time (Hrs)
(B)
5.0%
4.5%
4.0%
o 3.5%
3.0%
. 2.5%
r 2.0%
0
o 1.5% -
1.0%
0.5%
0.0% .
0 10 20 30 40 50 60 70 80 90 100
Time (Hrs)
Figure 4.3: Conversion of 4HV to 4VL by E. coli whole-cells and lysates with expressed PONI or tPON1
versus time at a pH of 6.2 (A) and 7.2 (B). Solid squares and triangles represent whole-cell data while
empty squares and triangles represent lysate data. Squares are data obtained using PON1 while triangles
are data obtained using tPON1. The data points shown are the averages and standard deviations of three
independent experiments.
Effect of Medium pH on 4VL Production
To better understand how medium pH affects lactone production, we assayed whole E.
coli cells expressing PON1 for their ability to convert 75 mM 4HV into 4VL at pH values
of 5.9, 6.2, 6.4, 6.7 and 7.2. E. coli cells expressing tPON1 and no PON 1 (empty plasmid
control) were also tested at a pH of 6.2, and the conversion of 4HV into 4VL was
monitored over time. Both the rate and amount of conversion were strongly dependent
on the pH, with lower pH's allowing for the highest conversions but at lower production
rates (Figure 4.4). Higher pH values allowed for more rapid conversion but the
conversion leveled out at a much lower level. This behavior is consistent with a pH-
dependent equilibrium being established between 4HV and 4VL, a phenomenon that has
previously been observed (Teiber et al., 2003). The pH effect on lactone production is
significant - a decrease of a single pH unit (from 7.2 to 6.2) creates a 7-fold improvement
in lactone production (Figure 4.4). The extracytosolic version of PON1 produced 11-fold
more 4VL than tPON1 at a medium pH of 6.2.
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Figure 4.4: Conversion of 4HV to 4VL at various pH values by whole-cell E. coli expressing PONI or
tPON1. The solid squares, gray-filled squares, empty squares, solid triangles, and empty triangles represent
samples with pH values of 5.9, 6.2, 6.4, 6.7 and 7.2 respectively for cells expressing PON1. The filled and
empty circles represent lactonization by tPON1 and a no PON1 control, respectively, both at a pH value of
6.2. The data points shown are the averages and standard deviations of three independent experiments.
Production of 4VL in Shake Flasks
The above observations of PON1 localization outside of the cytosol and the lactonization
reaction being strongly pH dependent were combined to create an integrated
bioprocessing approach to producing 4VL (Figure 4.1). In Chapter 3, it was found that P.
putida is capable of producing high concentrations of 4HV from levulinate when E. coli
thioesterase II (tesB) is expressed (Martin and Prather, 2009). Thus by supplying
levulinate to recombinant P. putida expressing tesB and PON1, first 4HV and then 4VL
is produced. Because low pH values can inhibit P. putida growth, 4VL production from
levulinate was done in two phases. In the first phase, recombinant P. putida cells
expressing tesB and either PON1 or tPON1 were grown in LB medium supplemented
with levulinate and the pH was unregulated. During this time 10.9 ± 1.3 g L-1 and 12.0 ±
0.9 g L-1 of 4HV were produced in the PON1 and tPON1 cultures respectively, and the
pH of the cultures rose to approximately 8.0-8.5 (data not shown). No 4VL was detected
during the first phase. After 96 hours, the cultures were split into two halves and the pH
of the medium in each half was adjusted downward to either 6.3 or 7.3. During this
second phase, lactone production was monitored for an additional 96 hours. While all
cultures had similarly high concentrations of 4HV at the beginning of the second phase,
the 4VL titer was significantly enhanced only by extracytosolic PON1 at pH 6.3 (Figure
4.5). The enhancement of 4VL titer was 11-fold for PONi at pH 6.3 vs. 7.3 (2.1 ± 0.4 g
LU' 4VL vs. 0.19 ± 0.02 g L') and 13-fold for PONI vs. tPON1 at pH 6.3 (2.1 ± 0.4 g L
4VL vs. 0.15 ± 0.02 g L).
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Figure 4.5: Production of 4VL from levulinate by recombinant P. putida expressing tesB and either PONI
(filled symbols) or tPON1 (open symbols) grown in shake flasks. Cultures were grown in LB medium
supplemented with glucose and levulinate for 96 hours prior to t = 0, during which time the pH was
unregulated. 10.9 + 1.3 g L-' and 12.0 + 0.9 g L-' of 4HV was produced in the PON1 and tPON1 cultures,
respectively. At t = 0 hours the pH of the medium was adjusted to either 6.3 (red squares) or 7.3 (blue
circles). The data points shown are the averages and standard deviations of three independent experiments.
Bioreactor-Scale Production of 4VL
Production of 4VL was scaled to a 2.0 L fed-batch reactor to take advantage of automated
pH control as well as to further improve 4VL titer. 1.0 L of TB medium was inoculated
with P. putida KT2440 expressing tesB and PON1 and the production of 4HV and 4VL
was monitored over time (Figure 4.6). Levulinate feeding to the reactor did not begin
until the cells were in stationary phase (22 hours after inoculation). Levulinate
concentrations were maintained between 2 and 20 g L' throughout the experiment to
allow for 4HV production without inhibiting cellular metabolism with excessive
levulinate. Having some excess levulinate was found to inhibit the metabolism of the
4HV product (data not shown). The pH was maintained at 7.0 during the 4HV
accumulation phase. After 67 hours of cultivation the pH was shifted to 6.0 to allow for
4VL production and levulinate feeding was stopped.
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Figure 4.6: Production of 4HV (gray-filled squares) and 4VL (black squares) from levulinate (empty
squares) by recombinant P. putida expressing tesB and PON1 grown in a 2.0 L bioreactor. Cell density is
indicated by cross-shaped symbols. Levulinate feeding began after 23 hours (first dashed line), and at t =
67 hours the pH of the medium was set to 6.0 to allow for 4VL accumulation (second dashed line). Cell
density is indicated by crosses.
During the 4HV accumulation phase, the 4HV titer reached 27.1 g L-1 (Figure 4.6), which
corresponded to a 26.2% yield from levulinate. The 4HV productivity of the reactor
during this phase was 0.81 g L' hr'- . Prior to the pH shift, the titer of 4VL reached 1.6 g
L-', corresponding to 6.5% lactonization of the 4HV produced. Significant 4VL
accumulation did not occur until after the pH was shifted downward from 7.0 to 6.0.
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After the pH shift, the titer of 4VL improved 5-fold to 8.2 g L-' and the fraction of 4HV
converted to 4VL increased to 33.1%.
Discussion
Identification of G3C9 PON1 as an Extracytosolic Lactonase
To establish the 4VL integrated bioprocessing system as a tool for product titer
enhancement, it was first necessary to verify the functionality of the individual
components. One of the central components of integrated bioprocessing is the utilization
of extracytosolic space to carry out biochemical conversions under conditions more
favorable than those in the cytosol. Thus it is critical to establish the extracytosolic
expression of a component in the pathway of interest. Here, that component is the PON 1
lactonase.
Because of differing evidence as to whether PON1 would export from the cytosol
(Aharoni et al., 2004; Deakin et al., 2002), several experiments to test for protein export
were performed. First, qualitative screening of protein fusions of PON1 with truncated
PhoA (tPhoA) was performed in E. coli and P. putida by streaking these cells on plates
containing the chromogenic PhoA substrate XP. Only PON1 protein fusions with an
intact N-terminal signal sequence were found to have PhoA activity, and PON1 fusions
without this sequence lacked PhoA activity (Table 4.1). These qualitative results were
corroborated quantitatively through a p-nitrophenolphosphate-based assay for PhoA
activity.
Additionally, lactonase assays were done with recombinant E. coli cells expressing PON1
and tPON1 to corroborate PON1 export. Lactone production is known to be highly pH-
dependent, as lactones establish pH-dependent equilibria with their hydrolyzed forms
(Figure 4.4; Teiber et al., 2003). Furthermore, it is known that the cytosolic pH remains
constant for intact cells over a wide range of medium pH values (Wilks and Slonczewski,
2007). Thus by assaying lactonase activity at different pH values in cells expressing
exported lactonase (PON1) versus intracellular lactonase (tPON1), one can determine if
these lactonases are indeed exported or retained in the cytosol. The results of this
experiment showed that PON1 exposed the medium pH (whether by protein export across
the cytoplasmic membrane or in the case of lysates removal of the membrane altogether)
had enhanced lactone production (Figures 4.3a and 4.3b) and that the degree of
enhancement depended strongly on how much lower the medium pH is from the
cytosolic pH.
These results, taken together, strongly support the hypothesis that the G3C9 PON1
variant is capable of export from the cytosol and that it uses an N-terminal signal
sequence to accomplish the exportation. The primary N-terminal sequence of G3C9
PON1 contains a stretch of hydrophobic residues bracketed by appropriately-positioned
lysine residues that presumably insert PONi into the cellular membrane (Figure 4.2).
This is characteristic of Sec-dependent protein transport (Manting and Drissen, 2000),
though additional studies would be needed to verify this. Furthermore, it is unclear
whether PON1 is periplasmic or is displayed on the outer membrane. It is clear however
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that PON 1 is not secreted into the medium, as we never detected lactonase activity in the
supernatants of any of the cultures examined in this work (data not shown).
pH Effect on Lactone Production: Cytosolic versus Extracytosolic PON1
Next, there needs to be a benefit to carrying out the extracytosolic reaction outside of the
cytoplasm, namely an increase in product titer, in order to justify the use of an integrated
bioprocess system. Lactone production using PON1 is highly pH-dependent (Teiber et
al., 2003), however the intracellular pH is maintained at a relatively high and unfavorable
level for lactone production - approximately 7.5 for E. coli for example (Wilks and
Slonczewski, 2007). However by employing extracytosolic PON1 in media with lower
pH values (relative to the cytosolic pH), the titers of lactone produced can be increased.
To test this, whole-cells of recombinant E. coli expressing PONI were suspended in
buffered media at different pH values and supplied with 4HV to lactonize. The pH effect
on lactonization was found to be quite potent: a decrease in a single pH unit increased the
equilibrium amount of lactone seven-fold (23.6% conversion at pH 6.2 versus 3.3%
conversion at pH 7.2; Figure 4.4). Expressing PON1 extracytosolically conveyed a full
order of magnitude difference in lactone titer (23.6% conversion at a pH of 6.2 versus
2.1% for the tPON1 sample at a pH of 6.2).
Production of 4VL using Integrated Bioprocessing
To complete the integrated bioprocessing lactone production system, the 4HV should be
produced by the cell rather than supplied directly to the medium. This establishes that the
increase in 4VL production by using an extracytosolic lactonase is due to the integrated
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bioprocessing effect rather than an artifact of substrate transport across the cytosolic
membrane. In Chapter 3, it was found that recombinant P. putida expressing thioesterase
II (tesB) from E. coli was capable of producing high titers of 4HV from levulinate
(Martin and Prather, 2009). Thus the full integrated bioprocessing system, one which
combines both cytosolic hydroxyacid production with extracytosolic lactonization
(Figure 4.1), can be tested in recombinant P. putida expressing both tesB and PON1.
Integrated bioprocessing was applied to the production of 4-valerolactone from levulinate
in P. putida, and it was found that this approach was necessary to realize significant
production from this novel pathway. A 13-fold improvement in lactone titer was realized
by employing an extracytosolic lactonase for the lactonization reaction versus an
intracellular lactonase control (Figure 4.5). Placing the lactonase enzyme outside of the
cytosol, where its environment can be controlled by manipulating medium conditions,
was key in realizing improved 4VL titers, as the benefits of using an extracytosolic
lactonase over an intracellular one in this system disappear when the medium pH
approaches that of the cytosol (0.19 + 0.02 g L-1 4VL with PON1 at pH 7.3 versus 0.15 +-
0.02 g L' for tPON1). To further increase 4VL titer and allow for automated pH control,
the 4VL integrated bioprocessing system was tested at the bioreactor scale, and 8.2 g L-1
of 4VL was produced (Figure 4.6). As expected, 4VL production in the bioreactor was
highly dependent on medium pH, and a 5-fold improvement in equilibrium 4VL titer was
observed when the pH of the medium was decreased to 6.0 from 7.0
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Applications and Implications of Integrated Bioprocessing
Integrated bioprocessing is a viable strategy for enabling and improving product
production in a broad array of biological systems. In general, integrated bioprocessing is
applicable to any enzyme that performs sub-optimally under cytosolic conditions. Such
enzymes would exhibit poor activity and consequently may become bottlenecks in
production from desired metabolic pathways. By placing these enzymes outside of the
cytosol, the conditions under which the enzymes operate can be easily manipulated by
altering the properties of the culture medium.
The integrated bioprocessing approach employed here can be generalized to other
enzymes who better function at lower or higher pH values than those found in the
cytosol. Examples of such enzymes are E. coli glutamate decarboxylase, which has a pH
optimum of about 4.5 (Capitani et al., 2003), and Pseudomonas pseudoalcaligenes
alkaline lipase, which has a pH optimum of 8-10 (Lin et al., 1996). By localizing such
enzymes outside of the cytosol and manipulating the medium pH, the activity from these
enzymes can be improved. Yet another opportunity to use integrated bioprocessing is to
overcome substrate transport issues with the cell membrane. A classic example of this
strategy is the use of extracellular cellulases in both natural (Sun et al., 2008) and
engineered (Shin and Chen, 2008) systems to degrade cellulosic matter for cellular
uptake and metabolism. This concept can be expanded, for instance, to include
extracytosolic expression of oxygen-requiring enzymes (such as oxygenases) in a
metabolic pathway to give them better access to molecular oxygen. By placing enzymes
outside of the cytosolic membrane, where significant oxygen consumption takes place
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due to oxidative phosphorylation, these enzymes would be exposed to higher
concentrations of oxygen.
However, integrated bioprocessing has several limitations, chief among them is the
inability to use enzymes that require expensive cofactors. Cofactors such as NAD(H),
NADP(H), and ATP are cytosolic; enzymes requiring these molecules cannot function
extracytosolically and therefore do not readily lend themselves to integrated
bioprocessing. Also while integrated bioprocessing allows one to manipulate the reaction
conditions for a given enzyme, one still cannot use conditions that would kill the cell
expressing the enzyme or denature the enzyme itself. For instance in this work, we could
not obtain even larger amounts of 4VL by performing integrated bioprocessing with P.
putida cells in pH 2 medium because neither the cells nor the enzyme would tolerate a pH
value that low. While integrated bioprocessing allows one to "bend" the conditions under
which biocatalysis occurs, one still cannot "break" the enzyme or its host cell.
Despite these exceptions, integrated bioprocessing remains a valuable option for
enhancing the activity of enzymes that underperform in the cytosol. This methodology
has been successfully applied to lactonization, a reaction that is difficult to perform in
aqueous and cellular systems due to the significant rate of lactone hydrolysis that occurs
at neutral pH. Through the use of integrated bioprocessing in this work, lactone titer
increased by over an order of magnitude. Though in this work a pH difference across the
cytosolic membrane was exploited to enhance product titer, other differences across this
membrane such as oxygen concentration or redox state can be exploited for integrated
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bioprocessing. All one needs is a suboptimal cytosolic enzyme, an N-terminal signal
sequence to export the enzyme, and a parameter (pH, dissolved oxygen, etc.) that can be
manipulated in the medium to enhance the exported enzyme's activity.
Materials and Methods
Chemicals
All chemicals were purchased at the highest grade or purity available unless otherwise
indicated. LB broth, glucose, isopropyl 3-D-l-thiogalactopyranoside (IPTG), and
antibiotics were purchased from Becton Dickinson and Company (Sparks, MD),
Mallinckrodt (Hazelwood, MO), Teknova (Hollister, CA), and Calbiochem (San Diego,
CA), respectively. The sources for other chemicals are described in the relevant methods
below.
Strains and Plasmids
Escherichia coli DH10OB was used for all E. coli studies and molecular cloning in this
work and was purchased from Invitrogen (Carlsbad, CA). Pseudomonas putida KT2440
was obtained from the American Type Culture Collection (ATCC #47054). pRK415
(TetR) was used to express the thioesterase II (tesB) gene from E. coli MG 1655, while a
gentamycin-resistant variant of the plasmid pMMB206, called pMMB206G, was used for
the expression of PON1. pRK415 was a generous gift from Prof. Keith Poole while
pMMB206 was obtained from ATCC (ATCC # 37808). pMMB206G was produced
from pMMB206 by the introduction of a gentamycin resistance cassette excised with
XmnI from the plasmid pBSL141 (ATCC #87146) at an XmnI restriction site in
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pMMB206. All molecular biology manipulations were performed using standard cloning
protocols (Sambrook and Russell, 2001).
The tesB gene was cloned by PCR into pRK415. Primers used were purchased from
Sigma-Genosys (St. Louis, MO, USA) and were as follows (restriction sites used for
cloning are underlined): EcoRI-tesB-FP (5'-
GAATTCTACTGGAGAGTTATATGAGTCAGG-3') and SalI-tesB-RP (5'-
GTCGACTTAATTGTGATTACGCATC-3'). HotStar HiFidelity DNA polymerase was
purchased from Qiagen (Valencia, CA, USA) and used according to the manufacturer's
instructions. The PON1 gene was similarly cloned by PCR into pMMB206G using the
primers PstI-PON1-FP (5'-GACACTGCAGATGGCTAAACTGACAGCG-3') and
XbaI-PON 1-RP (5'-CATATCTAGATTACAGCTCACAGTAAAGAGCTTTG-3').
Truncated PON1 (tPON1) was made by eliminating the second through the 2 3 rd amino
acids from the N-terminus of PON1. tPON1 was amplified from pMMB206G-PON1 by
PCR using PstI-tPON1-FP (5'-GACACTGCAGATGTCTTCTTTCCAAACACGAT-3')
and XbaI-PON 1-RP and inserted into pMMB206G to make pMMB206G-tPON1.
Alkaline phosphatase (PhoA) protein fusion vectors were constructed by first cloning
phoA by PCR from DH 10B E. coli genomic DNA into pRK415 using the primers XbaI-
phoA-FP (5'-GACATCTAGAATGAAACAAAGCACTATTGCAC-3') and KpnI-phoA-
RP (5'-GACAGGTACCTTATTTCAGCCCCAGAGC-3') to make pRK415-phoA.
Truncated phoA (tPhoA) was cloned in a similar manner into pRK415 using the primers
XbaI-tphoA-FP (5'-GACATCTAGACGGACACCAGAAATGCCT-3') and KpnI-phoA-
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RP). pRK415-PONl-tphoA and pRK415-tPON1-tphoA vectors were made by digesting
pMMB206G-PON1 and pMMB206G-tPON1 with PstI and XbaI and ligating into a
similarly digested pRK415-tphoA.
Culture Conditions
For shake-flask scale 4VL production experiments, recombinant P. putida harboring the
plasmids pRK415-tesB and pMMB206G-PON1 or pMMB206G-tPON1 was cultured in
50 mL LB in a 250 mL shake flask at 320C. Gentamycin (20 mg L') and tetracycline (10
mg L') were added to provide selective pressure for plasmid maintenance. Cultures were
inoculated to an initial optical density at 600 nm (OD 60oo) of 0.05, and 50 L of 1 M IPTG
was added at the beginning of the culture for induction of gene expression. 200 [L of a 5
mg L-' aqueous solution of bromothymol blue was added to the cultures as an indicator of
culture pH. 1 mL of 20% glucose was added at approximately t = 0, 24, 48, and 72
hours. Similarly 2.0 M levulinate was supplied to the cultures as follows: 0.875 mL at t =
0 hours, 2.5 mL at t = 24 hours, and 3.75 mL at t = 48 and 72 hours. At t = 96 hours, the
pH of the cultures was adjusted to the desired value using 6 N HC1. Additional 6 N HCI
was added as needed to maintain the desired pH values. Cultures were then incubated at
32oC at the desired pH for an additional 96 hours to allow for 4VL production.
Bioreactor experiments were performed in a 2.0 L Biostat B bioreactor from Sartorius
AG (Goettingen, Germany) equipped with two six-blade disk impellers. The bioreactor
was inoculated with 50 mL of LB containing late-exponential phase recombinant P.
putida harboring the plasmids pRK415-tesB and pMMB206G-PON1. The working
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volume of the bioreactor was 1.0 L, and it was operated at 320 C. Air (0.5-1.0 vvm) was
sparged into the bioreactor and the stirrer speed was varied between 300 and 850 rpm to
maintain dissolved 02 levels between 10% and 40% of air saturation. The pH of the
reactor was set to 7.0 and was controlled with the automatic addition of 28% ammonium
hydroxide and 4.0 M phosphoric acid. The medium in the reactor consisted of terrific
broth (12 g L' tryptone, 24 g L' yeast extract, 9.4 g L potassium hydrogen phosphate
and 2.2 g L' potassium dihydrogen phosphate) with 1.0 mM IPTG, 2.0% glucose, 20 mg
L-' gentamycin, 10 mg L tetracycline, 4 mM magnesium sulfate, 0.2 mM calcium
chloride, and 0.1 mg/L ferric ammonium citrate. After 22 hours of initial growth,
levulinic acid was continuously fed to the reactor from a 400 g L-1 feedstock to maintain
the concentration of levulinate between 2 and 20 g L-'. The concentrations of levulinate,
4HV, and 4VL in the bioreactor were monitored by HPLC, while cell density was
monitored by measuring optical density at OD 600 and converted into g DCW L-1 using a
conversion factor of 0.42 g DCW OD600oo' L-1 (15). After 67 hours, the pH of the culture
was adjusted to 6.0 and levulinate feeding was discontinued. The culture was continued
at 320 C for an additional 50 hours to allow for 4VL production.
Lactonase Assays
Whole-cell and lysate samples were tested for lactonase activity in IX M9 salts
(Sambrook and Russell, 2001) with the nitrogen source (ammonium chloride) removed
and exchanged for an equal molarity of sodium chloride to prevent the growth of whole-
cell samples. Unless otherwise noted, this medium was supplemented with 0.1 M CaC12
to supply a divalent ion to PON (Teiber et al., 2003), 50 mM 4-hydroxyvalerate and 40
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mM 2-(N-morpholino)ethanesulfonic acid (MES) buffer. The pH of this medium was
adjusted with 10 N NaOH or 6 N HCI to a desired value in the range of 5.0-7.0. When
testing whole-cells, cells were centrifuged at 2,500 x g for 5 minutes, their original
medium removed, and the cells were resuspended in 0.9% (w/v) sterile sodium chloride
to an OD600 of 25. This suspension was then used to supply cells to whole-cell lactonase
assay experiments to an OD 600 of 0.5. For the analysis of cell lysates (prepared by
repeateded freezing and thawing of lysozyme-treated cells), 1 mg of total protein (bovine
serum albumin equivalent as assayed by the Bradford method (Bradford, 1976)) was
added to the lactonase assay mixture. All samples were then incubated with shaking at
37oC and samples were periodically withdrawn for HPLC analysis to determine the
amount of 4VL produced.
Alkaline Phosphatase Assays
Alkaline phosphatase (PhoA) activity was qualitatively assessed on agar plates using
bromo-4-chloro-3-indolyl phosphate (XP) purchased from Amresco (Solon, OH) as an
indicator. Recombinant E. coli or P. putida to be tested for PhoA activity were streaked
onto LB plates supplemented with 10 mg L-' tetracycline, 1 mM IPTG, 100 mg L-1 XP,
and 75 mM phosphate (to suppress endogenous phosphatase expression). These plates
were incubated at 37C (E. colh) or 300C (P. putida) for 24-48 hours and their color was
assessed by eye. Blue colonies indicated active, periplasmic PhoA, while white colonies
indicated that the PhoA construct was inactive.
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PhoA activity was quantitatively assessed in cell lysates using p-nitrophenyl phosphate
(PNP) purchased from Amresco (Solon, OH). The assay mixture consisted of 15 mM
PNP and 2.0 mM MgSO 4 in 1.0 M Tris-HC1, pH 8.0. To this mixture crude protein lysate
(30 [tg of total protein bovine serum albumin equivalent as assayed by the Bradford
method (Bradford, 1976)) was added and the solution was briefly vortexed to mix. The
liberation of p-nitrophenol was monitored by measuring the absorbance of the mixture at
405 nm at room temperature. One unit of PhoA activity is defined as 1 [tmol of p-
nitrophenol liberated per minute at room temperature.
HPLC Analysis
All HPLC samples were prepared by taking 1 mL of culture broth, centrifuging for 5
minutes at 16,000 x g to pellet cells, and taking the supernatant for analysis. HPLC
analysis was performed on an Agilent 1100 Series instrument equipped with a Zorbax
SB-Aq column (0.46 cm x 15 cm, 3.5 gm) purchased from Agilent Technologies (Santa
Clara, CA). The column temperature was maintained at 650C. Levulinic acid, 4HV, and
4VL were detected on a refractive index detector and had retention times of
approximately 3.43, 3.28 and 5.11 minutes respectively. The mobile phase was 25 mM
ammonium formate in water (pH 2.0) and the flow rate through the column was 1.0 mL
min'. Levulinic acid and 4VL purchased from Alfa Aesar (Ward Hill, MA) were used as
standards, while the 4HV standard was prepared by saponification of 4VL with 10 N
sodium hydroxide at 40C.
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Chapter 5: 3-Hydroxybutyrate Production in E. coli
This work was published in Tseng et al., 2009 and much of the data in this chapter was obtained
in collaboration with Hsien-Chung Tseng.
In this chapter, synthetic metabolic pathways constructed for the production of
enantiopure (R)- and (S)-3-hydroxybutyrate (3HB) from glucose in recombinant
Escherichia coli are described. To promote maximal metabolic flux towards 3HB, three
thiolase homologs (BktB, Thil, and PhaA) and two CoA-removal mechanisms (Ptb-Buk
and TesB) were profiled. Two enantioselective 3-hydroxybutyryl-CoA dehydrogenases
(PhaB, producing the (R)-enantiomer and Hbd, producing the (S)-enantiomer) were
utilized to control the 3HB chirality across two E. coli backgrounds, BL21 Star(DE3) and
MG1655(DE3), representing E. coli B and E. coli K-12 derived strains, respectively.
MG1655(DE3) was found to be superior for the production of each 3HB stereoisomer
although the recombinant enzymes exhibited lower in vitro specific activities compared
to BL21Star(DE3). Hbd in vitro activity was significantly higher than PhaB in both
strains. The engineered strains achieved titers of enantiopure (R)-3HB and (S)-3HB as
high as 2.92 g L'1 and 2.08 g L-1, respectively, in shake flask cultures within two days.
The NADPH/NADP + ratio was found to be two- to three-fold higher than the
NADH/NAD + ratio under the culture conditions examined, presumably affecting in vivo
activities of PhaB and Hbd and resulting in greater production of (R)-3HB than (S)-3HB.
Introduction
The synthesis of chiral molecules is of significant interest in the pharmaceutical industry
because frequently one stereoisomer of a drug has efficacy while the other has either
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substantially reduced or no activity, or may even have adverse effects (Patel, 2006;
Pollard and Woodley, 2007). Additionally, chiral molecules serve as building blocks for
many pharmaceuticals and high value compounds. Thus, the ability to prepare chiral
molecules with high optical purity is important. Stereoselective chemical processes
generally employ expensive chiral catalysts, require harsh physical conditions and
solvents, and suffer from extensive byproduct formation. In contrast, enzyme-catalyzed
reactions are highly stereoselective and can be performed in aqueous solutions under
mild conditions (Patel, 2006). As a result, the use of biological processes for chiral
molecule production has been extensively investigated (Chen and Wu, 2005; Shiraki et
al., 2006; Tokiwa and Calabia, 2008; Zhao et al., 2003). One example of such a process
is the biosynthesis of 3-hydroxybutyric acid (3HB), a versatile chiral molecule
containing one hydroxyl group and one carboxyl group, used as a building block for the
synthesis of optically-active fine chemicals, such as vitamins, antibiotics, pheromones,
and flavor compounds (Chiba and Nakai, 1985; Chiba and Nakai, 1987; Mori, 1981;
Seebach et al., 1986).
The biosynthesis of 3HB has typically been achieved using two different mechanisms:
depolymerization (in vitro or in vivo) of microbially synthesized poly-(R)-3-
hydroxybutyric acid (PHB) (De Roo et al., 2002; Lee and Lee, 2003), or direct synthesis
of 3HB without a PHB intermediate (Gao et al., 2002; Lee et al., 2008; Liu et al., 2007).
However, due to the stereospecific constraints of PHB synthesis, in which polymers are
composed exclusively of (R)-3HB monomer units, the synthesis of (S)-3HB from PHB is
effectively impossible. In contrast, direct synthesis of both enantiopure (R)-3HB and
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(S)-3HB is possible. Pathways facilitating (R)-3HB synthesis have been constructed in
Escherichia coli by simultaneous expression of phaA (encoding acetoacetyl-CoA
thiolase) and phaB (encoding (R)-3-hydroxybutyryl-CoA dyhydrogenase) from
Ralstonia eutropha H16, and ptb (encoding phosphotransbutyrylase) and buk (encoding
butyrate kinase) from Clostridium acetobutylicum ATCC 824 (Gao et al., 2002). In
addition to the use of ptb and buk to catalyze the conversion of (R)-3HB-CoA to (R)-
3HB, tesB (encoding thioesterase II from E. colh) has also been used for the direct
hydrolysis of (R)-3HB-CoA to yield (R)-3HB (Liu et al., 2007). The production of (S)-
3HB in E. coli has recently been reported using a biosynthetic pathway consisting of
phaA from R. eutropha H16, hbd (encoding (S)-3-hydroxybutyryl-CoA dehydrogenase)
from C. acetobutylicum ATCC 824, and bch (encoding 3-hydroxyisobutyryl-CoA
hydrolase) from Bacillus cereus ATCC 14579 (Lee et al., 2008).
In E. coli, the synthesis of both enantiomers of 3HB begins with the condensation of two
molecules of acetyl-CoA, catalyzed by a thiolase, to give acetoacetyl-CoA (Figure 5.1).
The acetoacetyl-CoA is then reduced either to (R)-3-hydroxybutyryl-CoA ((R)-3HB-
CoA) via ketone reduction mediated by an NADPH-dependent (R)-3-hydroxybutyryl-
CoA dehydrogenase (PhaB), or to (S)-3-hydroxybutyryl-CoA ((S)-3HB-CoA) via an
NADH-dependent (S)-3-hydroxybutyryl-CoA dehydrogenase (Hbd). (R)-3HB-CoA and
(S)-3HB-CoA can each be further modified via a suitable CoA-removal reaction to form
(R)-3HB and (S)-3HB, respectively. In an effort to increase chiral 3HB production, it is
essential to identify a thiolase capable of efficiently catalyzing the first reaction in the
3HB biosynthetic pathways, to draw acetyl-CoA from competing endogenous pathways.
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Thus, three different thiolases, BktB and PhaA from R. eutropha H16, and Thil from C.
acetobutylicum ATCC 824, were examined to determine which is most proficient for
3HB synthesis. (R)-3HB-CoA and (S)-3HB-CoA synthesized via the reduction reaction
catalyzed by PhaB and Hbd, respectively, must be converted to their respective free acid
forms before transport or diffusion out of the cell. Two sets of CoA-removing enzyme
mechanisms have been compared in this work, including the phosphotransbutyrylase
(Ptb) and butyrate kinase (Buk) system encoded by the ptb-buk operon from C.
acetobutylicum ATCC 824, and acyl-CoA thioesterase II (TesB) from E. coli MG1655.
Moreover, it has long been argued whether B strains or K-12 strains of E. coli would
serve as better hosts for the biosynthesis of small molecules. Microarrays and Northern
blot analyses have suggested that several metabolic pathways, including the TCA cycle,
glyoxylate shunt, glycolysis, and fatty acid degradation are different between these two
strains (Phue et al., 2005; Schneider et al., 2002; Walle and Shiloach, 1998; Xia et al.,
2008), implying that they may differ significantly in their ability to supply significant
levels of acetyl-CoA as the precursor for 3HB synthesis. Thus, we have also compared
3HB synthesis across two representative E. coli strains: E. coli BL21 Star(DE3) (B strain)
and E coli MG1655(DE3) (K-12 strain). 3HB chirality was examined and verified by
high performance liquid chromatography (HPLC) analysis using a chiral stationary phase
to provide separation.
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Glucose
(S)-3HB (R)-3HB
Figure 5.1: Schematic representation of (S)-3HB or (R)-3HB synthesis from glucose in engineered E. coli.
BktB, acetoacetyl-CoA thiolase from R. eutropha H16; Thil, acetoacetyl-CoA thiolase from C.
acetobutylicum ATCC 824; PhaA, acetoacetyl-CoA thiolase from R. eutropha H16; Hbd, (S)-3-
hydroxybutyryl-CoA dehydrogenase from C. acetobutylicum ATCC 824; PhaB, (R)-3-hydroxybutyryl-CoA
dehydrogenase from R. eutropha H16; Ptb, phosphotransbutyrylase from C. acetobutylicum ATCC 824;
Buk, butyrate kinase from C. acetobutylicum ATCC 824; TesB, acyl-CoA thioesterase II from E. coli
MG1655.
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Results
Production of Chiral 3HB in BL21Star(DE3)
The chiral 3HB pathways were first constructed in BL21 Star(DE3), an E. coli B strain,
by co-transforming one pETDuet-1 derivative (pET-H-B, pET-H-T, pET-H-P, pET-P-B,
pET-P-T, or pET-P-P) and one pCDFDuet-1 derivative (pCDF-T or pCDF-PB) (Table 1).
All strains were cultured at 300 C for 48 h in LB medium supplemented with 20 g L-1
glucose, and accumulation of chiral 3HB in the culture medium was measured. The
capabilities of two sets of CoA-removing enzymes, Ptb-Buk and TesB, were then
compared for (R)-3HB or (S)-3HB production. TesB successfully removed the CoA
moiety from both (R)-3HB-CoA and (S)-3HB-CoA to release the free acids (Table 5.1).
In comparison, Ptb-Buk could also convert (R)-3HB-CoA but was essentially inactive on
(S)-3HB-CoA. Titers as high as 1.58 g L' and 2.41 g L-' of (S)-3HB and (R)-3HB,
respectively, could be achieved when TesB was used to remove CoA. In the case of Ptb-
Buk, only trace amount of (S)-3HB (less than 0.10 g L-') was produced, and 1.26 g L-' of
(R)-3HB was observed. It was also noted that less acetate, 1.02 g L-' on average, was
produced with the TesB system compared to that with the Ptb-Buk system, which was
1.55 g L'1 on average.
The efficacies of three different thiolases on chiral 3HB production were then compared.
Both BktB and PhaA were found to yield similar titers of (R)-3HB when co-expressed
with PhaB and Ptb-Buk (-1.25 g L') or PhaB and TesB (-2.39 g L-1). However, Thil
gave approximately 20% lower titers of (R)-3HB and increased acetate production
compared to BktB and PhaA. This phenomena was not observed in (S)-3HB production,
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where each of the thiolases resulted in similar titers of (S)-3HB, with an average of 1.52 g
L-1 . In general, TesB could outperform Ptb-Buk for CoA removal, resulting in
significantly higher titers of both (R)-3HB and (S)-3HB (Table 5.1).
Table 5.1: Extracellular production of chiral 3HB by E.
shake flasksa, b
3HB Synthesis Pathways Acetate 3HB
Step 1 Step 2 Step 3 (g L 1) (g L -')
BktB 1.53 ± 0.13 <0.1
" Thil Hbd 1.79 ± 0.03 <0.1
Ptb-PhaA 1.55 ± 0.14 <0.1Buk
BktB 1.33 ± 0.02 1.23 ± 0.06
Thil PhaB 1.66 ± 0.08 1.03 ± 0.02
PhaA 1.41 ± 0.11 1.26 ± 0.06
BktB 0.89 ± 0.07 1.55 ± 0.05
S Thil Hbd 1.09 ± 0.12 1.58 ± 0.07
PhaA 1.01 ± 0.03 1.44 ± 0.04TesBM BktB 0.88 ± 0.03 2.41 ± 0.04
I? Thil PhaB 1.20 ± 0.03 1.90 ± 0.06
PhaA 1.05 ± 0.09 2.36 ± 0.08
coli BL21 Star(DE3) grown in
3HB specific
content
(g g-DCW-)
NAc
NA
NA
1.19 + 0.05
0.69 ± 0.01
1.19 ± 0.15
3HB yield
(g g-Glucose -)
NA
NA
NA
0.18 ± 0.01
0.15 ± 0.01
0.20 ± 0.03
1.50 + 0.09 0.27 + 0.01
1.22 ± 0.06 0.24 ± 0.01
1.43 ± 0.04 0.26 ± 0.02
2.24 ± 0.04 0.30 ± 0.00
1.52 ± 0.03 0.26 ± 0.01
2.06 ± 0.17 0.30 ± 0.02
a Cells were grown aerobically in LB media with the addition of 2% glucose at 300C for 48 h. 1 mM IPTG
was added when OD 6 00 reached 0.4-0.8.
b Data are presented as the average value and standard deviation of measurements from three independent
cultures.
SNA: not applicable
Production of Chiral 3HB in MG1655(DE3)
Since TesB was identified as the most effective enzyme among those tested for CoA
removal in BL21Star(DE3), further investigation of MG1655(DE3), an E. coli K-12
strain, exclusively employed 3HB pathways using TesB. In all cases, (R)-3HB or (5)-
3HB production was substantially higher with MG1655(DE3) than with BL21Star(DE3)
under the same culture conditions (Figure 5.2). MG1655(DE3) produced up to 2.08 g L1
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of (S)-3HB and 2.92 g L 1 of (R)-3HB, -30% and -20% higher titers, respectively, than
those produced by BL21Star(DE3). It is also interesting to note that generally less
acetate was produced in MG1655(DE3) than in BL21Star(DE3), suggesting that more
acetyl-CoA carbon flux was directed towards 3HB biosynthesis in MG1655(DE3) than
towards acetate production. These two production systems were also compared in terms
of 3HB specific content (g g-DCW-') and 3HB yield (g g-Glucose%-). 3HB specific
contents in MG1655(DE3) strains were -50-120% greater than their respective
BL21Star(DE3) counterparts as a result of increased 3HB production and reduced
biomass accumulation (Figure 5.2). The comparison of 3HB yield on glucose shows that
the efficiency of 3HB production from glucose in MG1655(DE3) was higher than in
BL21Star(DE3). Generally, MG1655(DE3) was able to produce more chiral 3HB and
less acetate, while also accumulating less biomass than BL21Star(DE3).
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Thfolases BktB Thil PhaA BktB Thil PhaA
3HBp.c 1.50 2.31 1.22 2.62 1.43 2.42 2.24 3.41 1.52 3.41 2.06 3.63
g.4lucoe) 0.27 034 0.24 031 0.26 0.27 0.30 0.43 0.26 038 0.30 0.41
(S)-3MB Biosynthesis Pathways (Hbd/TesB) (R)-3HB Biosynthesis Pathways (PhaB/TesB)
Figure 5-2: Extracellular production of chiral 3HB by E. coliBL21Star(DE3) and MG1655(DE3) grown in
shake flasks. (S)-3HB was produced when Hbd was employed (left), while (R)-3HB was produced when
PhaB was employed (right). In all cases, TesB was used to mediate CoA removal.
Confirmation of 3HB Stereochemistry
E. coli BL21Star(DE3) harboring bktB, tesB, and either phaB or hbd was grown at 300C
in 50 mL LB supplemented with 20 g L-' glucose for 48 hours. The stereochemistry of
the resulting 3HB in the media from these cultures was determined by methyl
esterification of the 3HB present followed by chiral HPLC analysis as described in the
Materials and Methods section at the end of this Chapter. The results confirm previous
reports that cells harboring a thiolase and CoA-removal enzyme produce (R)-3HB if the
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cells are concomitantly expressing phaB and synthesize (S)-3HB if they are expressing
hbd (Figure 5.3; Lee et al., 2008; Liu et al., 2007)
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Figure 5.3: HPLC spectra of (A) methyl-(R)-3HB and methyl-(S)-3HB standards, (B) culture medium from
E. coli BL21 Star(DE3) expressing bktB, phaB and tesB after boiling in methanol, (C) culture medium from
E. coli BL21 Star(DE3) expressing bktB, hbd and tesB after boiling in methanol, and (D) culture medium
from E. coli BL21 Star(DE3) after boiling in methanol as a control.
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Measurement of Specific Activities of 3HB Synthesis Enzymes Expressed in E. coli
To better understand the differences in 3HB titers between the different 3HB pathways in
E. coli BL21Star(DE3) and MG1655(DE3), a correlation between in vivo chiral 3HB
production and in vitro enzyme activities was sought. The activities of BktB, Thil, PhaA,
Hbd and PhaB were measured in recombinant E. coli BL21Star(DE3) and
MG1655(DE3). The background acetoacetyl-CoA thiolase activities in E. coli
BL21Star(DE3) and MG1655(DE3) were very weak (<0.04 U mg protein-'), and there
were undetectable 3-hydroxybuytyryl-CoA dehydrogenase activities (Table 5.2).
Plasmid-based expression of BktB, Thil, PhaA, Hbd and PhaB was able to give
functional enzymes in both E. coli strains (Table 5.2). It is interesting to note that all
enzymes analyzed had greater specific activities in BL21Star(DE3) than in
MG1655(DE3), showing approximately 130% to 360% higher thiolase activity and 24%
to 44% higher 3-hydroxybuytyryl-CoA dehydrogenase activity, although 3HB production
was lower. For comparison of alternative acetoacetyl-CoA thiolases, Thil had
approximately 6-fold higher specific activity than BktB and PhaA in BL21 Star(DE3), and
6-fold and 3-fold higher specific activity than BktB and PhaA, respectively, in
MG1655(DE3). For 3-hydroxybuytyryl-CoA dehydrogenase activities of PhaB and Hbd,
results show that the activities of Hbd (NADH-dependent) were approximately 140-fold
and 120-fold higher than those of PhaB (NADPH-dependent) in BL21Star(DE3) and
MG1655(DE3), respectively.
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Table 5.2: Enzyme specific activities (U mgl)a of crude extracts of E. coli
BL21Star(DE3) and MG1655(DE3)
E. coli StrainsbEnzymes BL21 Star(DE3) MG1655(DE3)
Control 0.04 ± 0.01 0.03 ± 0.00
BktB 5.05 ± 0.69 1.10 + 0.24
Acetoacetyl-CoA Thiolase
Thil 29.66 + 3.87 6.85 + 0.97
PhaA 5.90 + 0.87 2.56 ± 0.36
Control NDC ND
3-Hydroxybutyryl-CoA Hbd 58.78 + 7.76 40.76 + 8.08
Dehydrogenase PhaB 0.41 -0.18 0.33 - 0.05
a One unit was defined as the conversion of 1 tmol of substrate to product per min at 250C.
bData are presented as the average value and standard deviation of measurements from three
independent cultures.
C ND: not detected
Measurement of Cofactor Levels in Engineered MG1655(DE3) Strains
Although Hbd consistently showed higher in vitro activity than PhaB, the accumulated
titers of (S)-3HB were lower than for (R)-3HB. Since these two enzymes have different
pyridine nucleotide cofactor (NADPH/NADH) specificities, the intracellular levels of the
reduced and oxidized cofactors were measured to gain additional insight into 3HB
pathway performance (Table 5.3). At the late exponential phase (4 h post-induction), the
specific contents of NADH and NADPH in all tested recombinant strains were found to
be significantly lower than those of their respective oxidized forms (NAD+ and NADP+),
with the ratios of NADH/NAD+ and NADPH/NADP + ranging from 0.08-0.16 and 0.26-
0.31, respectively. At the stationary phase (24 h post-induction), reduced cofactor
increased concomitantly with the decrease of oxidized cofactor, resulting in higher ratios
of NADH/NAD+ and NADPH/NADP + ranging from 0.20-0.44 and 0.79-0.99,
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respectively. Consistent with previously published reports (Brumaghim et al., 2003; Lee
et al., 1996), in general NADH was found to be the predominant reducing equivalent in
our E. coli strains while the NADPH/NADP + ratio was considerably higher than the
NADH/NAD + ratio under the culture conditions examined.
Table 5.3: Levels and ratios of NAD , NADH, NADP +, and NADPH cofactors in engineered
MG1655(DE3) strains
pET-H-P pET-P-P pETDuetpCDF-T pCDF-T pCDFDuet
Post-induction time (hr) 4 24 4 24 4 24
NAD +  6.15 ± 0.75 3.95 ± 0.29 7.11 ± 0.08 4.94 + 0.13 8.05 ± 1.09 4.79 ± 0.44
Cofactor levelsa NADH 0.97 ± 0.11 1.75 ± 0.02 0.59 ± 0.07 1.49 ± 0.21 0.85 ± 0.08 0.96 ± 0.06
(nmol/mg-DCW) NADP +  1.58 ± 0.16 0.96 ± 0.08 1.89 ± 0.18 1.22 ± 0.05 2.12 ± 0.04 1.12 ± 0.12
NADPH 0.50 ± 0.08 0.94 ± 0.09 0.49 ± 0.03 0.97 ± 0.23 0.59 ± 0.02 0.97 ± 0.09
NADH/NAD +  0.16 ± 0.00 0.44 ± 0.03 0.08 ± 0.01 0.30 ± 0.03 0.11 ± 0.00 0.20 ± 0.01Cofactor ratios
NADPH/NADP 0.31 ± 0.02 0.99 ± 0.18 0.26 ± 0.01 0.79 ± 0.16 0.28 ± 0.02 0.87 ± 0.01
aData are presented as the average and standard deviation of measurements from two independent cultures.
Discussion
The underlying objective of this study was to explore the high level production of both
(R)- and (S)-3HB in recombinant E. coli by investigating different host strains, thiolase
homologs, and CoA-removal mechanisms. Shake flask-scale production of
enantiomerically pure (R)-3HB and (S)-3HB to concentrations of up to 2.92 g L' and
2.08 g L', respectively, were achieved. Biosyntheis of enantiopure (S)-3HB was
reported at titers of 0.61 g L' (Lee et al., 2008), which was the highest reported
concentration prior to this study.
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E. coli B versus E. coli K-12 in Chiral 3HB Production
As previously described (Phue et al., 2005), there exist several intrinsic differences in
metabolic pathways between E. coli B and K-12 strains, suggesting that the availability
of metabolic intermediates as precursors for engineered biosynthetic pathways may also
differ between these two strains. In addition, it has been generally concluded that the E.
coli B strains are capable of producing greater amounts of proteins than the E. coli K-12
strains, making E. coli B strains better for protein production (Terpe, 2006). However, in
terms of their role as microbial chemical factories, higher expression levels of
recombinant proteins may not necessarily result in higher product titers, especially when
substrate availability rather than enzymatic activity is rate limiting in the pathway. The
results presented here support the hypothesis that host strain selection can critically
influence the activity of recombinant enzymes as well as the productivity of a non-natural
pathway. Although strains constructed in BL21Star(DE3) showed much higher
acetoacetyl-CoA thiolase and 3-hydroxybuytyryl-CoA dehydrogenase activities than
those constructed in MG1655(DE3), the chiral 3HB titers from recombinant
BL21Star(DE3) were roughly 20% to 30% lower than those from MG1655(DE3). Such
discrepancy between product titers and enzyme activities in those strains suggests that
distribution of precursors, i.e., acetyl-CoA, and not enzyme expression levels was the
limiting factor for chiral 3HB production. It further implies that metabolic networks play
an important role in chiral 3HB synthesis (Stelling et al., 2002). This hypothesis is
supported by the observation that significantly more cell mass (data not shown) and
acetate were accumulated in BL21Star(DE3) probably due to a large fraction of carbon
flux drawn into the TCA cycle and acetate production pathway at the acetyl-CoA node
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(Figure 5.1 and 5.2). This flux distribution resulted in less acetyl-CoA directed into
engineered chiral 3HB pathways in BL21Star(DE3). In contrast, MG1655(DE3), likely
with a different distribution within its metabolic network, achieved high-level production
of chiral 3HB while accumulating less cell mass and acetate despite its relatively lower
enzyme activities. Since excess accumulation of cell mass and byproduct formation
represent an inefficient use of carbon resources that will reduce the yield of desired
products, MG1655(DE3) served as the superior production strain by better balancing its
growth while maintaining efficient production of chiral 3HB.
Effect of Alternative Acetoacetyl-CoA Thiolases on Chiral 3HB Production
It was originally anticipated that the three different acetoacetyl-CoA thiolases (Step 1 of
Figure 5.1) examined in this work would differ in terms of chiral 3HB production by
directing different amounts of carbon flux (in the form of acetyl-CoA) into the
engineered 3HB pathways. With the exception of Thil for (R)-3HB synthesis in
BL21Star(DE3), the choice of thiolase had little effect on chiral 3HB titers even though
the enzymes were found to display different specific activities in vitro in both
recombinant strains (Table 5.2). Thil showed the highest in vitro specific activity in both
strains, but recombinant BL21Star(DE3) with either Thil/PhaB/TesB or Thil/PhaB/Ptb-
Buk yielded reduced (R)-3HB titers compared to other BL21Star(DE3) counterparts. To
explain this contradiction, it should be noted that in vitro thiolase activity was assayed in
the thiolytic direction, where two acetyl-CoA molecules were synthesized from one
acetoacetyl-CoA and one CoA molecule. Thus, as a result of the combined effect of a
hundred-fold lower PhaB activity compared to Hbd and a higher Thil activity compared
125
to BktB and PhaA in BL21Star(DE3), the acetoacetyl-CoA synthesized by Thil could
accumulate in the cell. Since the thiolytic reaction is highly exergonic, thiolysis of
acetoacetyl-CoA by thiolase is thermodynamically favored (Masamune et al., 1989). The
accumulated acetoacetyl-CoA would then be cleaved into two acetyl-CoA molecules in
the thiolytic direction, thereby supplying more acetyl-CoA to cell mass and acetate
accumulation. In contrast, this did not occur in MG1655(DE3) probably due to the less
active competing pathways towards cell mass and acetate accumulation and a negligible
thiolytic reaction as a result of lower enzyme activities compared to BL21 Star(DE3).
TesB versus Ptb-Buk as a CoA Removal System
It has been suggested that the efficient removal of CoA from (R)-3HB-CoA can lead to
enhanced (R)-3HB production (Gao et al., 2002), which could also be true for (S)-3HB
production. To test this concept, two CoA-removal systems were assessed. The first is
Ptb-Buk, encoded by an operon from C. acetobutylicum, which has been used for direct
synthesis of polyhydroxyalkanoate (PHA) together with a PHA synthase utilizing the
reverse reaction (i.e., the formation of the CoA thioester) (Liu and Steinbiichel, 2000b).
The second is TesB from E. coli, which is reported to possess a broad substrate
specificity but unknown physiological function in E. coli (Zheng et al., 2004). While
Ptb-Buk uses a two-step CoA-removal scheme through a phosphorylated intermediate,
TesB catalyzes one-step CoA-removal by direct hydrolysis (Figure 5.1). More chiral
3HB was likely produced in the TesB system than in the Ptb-Buk system due to the
essentially irreversible hydrolysis by TesB. In addition, it was noted that pathways
incorporating the Ptb-Buk system do not yield (S)-3HB (Table 5.1), which is consistent
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with a previous report (Lee et al., 2008). The low level production (<0.10 g L- ) of (S)-
3HB produced by strains containing the Ptb-Buk system may have been due to the
endogenous TesB activity in E. coli. In fact, in recombinant strains of E. coli
BL21Star(DE3) in which phaA and hbd were solely expressed (i.e., no over-expression of
tesB or ptb-buk), similarly low levels of (S)-3HB were also produced (data not shown).
Discrepancies between Enzyme Activities of Hbd and PhaB and 3HB Titers
Although Hbd demonstrated much higher in vitro specific activities than PhaB,
significantly lower titers of (S)-3HB than (R)-3HB were achieved in all strains expressing
Hbd (Tables 5.1 and 5.2). This contradictory behavior may have been influenced by the
following three factors in vivo: (1) the cofactor balance between NADH and NADPH and
their respective oxidized counterparts; (2) the substrate preference of TesB for (R)-3HB-
CoA over (S)-3HB-CoA; and (3) the competing pathway of fatty acid P-oxidation where
(S)-3HB-CoA is an intermediate.
Given that Hbd and PhaB are NADH- and NADPH-dependent dehydrogenases,
respectively, the physiological levels of NADH and NADPH and their redox ratios in E.
coli most likely influences the in vivo catalytic activities of Hbd and PhaB, affecting
chiral 3HB titers accordingly. Since NADH is the predominant reducing equivalent
found in E. coli under normal conditions (Brumaghim et al., 2003) as well as conditions
examined here (Table 5.3), these results indicate that Hbd should theoretically show
higher in vivo activity than PhaB resulting in greater (S)-3HB than (R)-3HB production.
The opposite, however, was observed in this study, suggesting that the physiological
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NADH/NADPH ratio alone can not resolve the contradiction. It may instead be
explained by differences in the physiological ratios of NADH/NAD +  and
NADPH/NADP +. It was shown in this study that the ratio of NADPH/NADP + is
substantially higher than that of NADH/NAD + in E. coli MG1655(DE3) under the culture
conditions used in this work (Table 5.3). These results, together with previous findings
that the PHB synthesis is likely affected by the intracellular NADPH/NADP + ratio (Lee
et al., 1996), suggest that in the case of chiral 3HB synthesis, a higher NADPH/NADP +
ratio may result in more favorable reduction by PhaB while reduction by Hbd may be
limited by the lower NADH/NAD + ratio. Overall, these observations are consistent with
correspondingly higher yields of (R)-3HB than (S)-3HB in the present study.
In a similar manner to the substrate preference of Ptb-Buk for (R)-3HB-CoA, TesB might
cleave (R)-3HB-CoA more efficiently than (S)-3HB-CoA. To verify this possibility, it
will be informative to perform in vitro enzyme assays using (S)-3HB-CoA and (R)-3HB-
CoA as substrates. Unfortunately, these chemicals are not commercially available,
preventing the pursuit of this experiment.
The third hypothesis was tested using an E. coli mutant with an impaired fatty acid 1-
oxidation pathway. The E. coli MG1655(DE3) mutant was created using the method of
Datsenko and Wanner (2000) by insertional inactivation of fadB, encoding 3-
hydroxyacyl-CoA dehydrogenase. This fadB mutation should presumably attenuate or
block the fatty acid P-oxidation cycle, thereby reducing the degradation of (S)-3HB-CoA.
However, this mutant failed to achieve higher titers of (S)-3HB compared to its native
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counterpart (data not shown). It is possible that other FadB homologs were involved in
the degradation of (S)-3HB-CoA. For example, fad] (previously called yfcX), encodes a
subunit of enoyl-CoA hydratase that has been shown to possess the same catalytic
function as FadB (Si Jae Park, 2004; Snell et al., 2002).
Conclusions
The findings of this study suggest that the distribution of acetyl-CoA is likely the key
factor affecting the production of chiral 3HB between E. coli BL21Star(DE3) and
MG1655(DE3). Thus, in order to alter the distribution, further research should focus on
blocking competing pathways for acetyl-CoA, for example, by deletion of acetate
synthesis pathways comprised of acetate kinase and phosphotransacetylase (encoded by
ackA-pta) or pyruvate oxidase (encoded by poxB) (Lin et al., 2005). Also, we can not
entirely rule out the possibility that the overall higher titers of chiral 3HB in recombinant
MG1655(DE3) might have been due to their higher TesB specific activities compared to
BL21 Star(DE3) counterparts in the case where CoA-removal is rate-limiting. Therefore,
in vitro enzyme assays of both TesB and Ptb-Buk should be able to further elucidate the
cause of superior titers of chiral 3HB in MG1655(DE3) than in BL21Star(DE3). Overall,
production of -3 g L-1 (R)-3HB and -2 g L-1 (S)-3HB were achieved in shake flask
cultures within two days. Further strain engineering should lead to more economical
production of chiral 3HB. The high productivity of this 3HB pathway and the
availablilty of several homologous pathway enzymes makes this pathway an attractive
candidate for the biosynthesis of a broader range of 3-hydroxyalkanoic acids, including
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3,4-dihydroxybutyric acid (DHBA). The substrate range of the 3HB pathway is explored
in great detail in Chapter 6.
Materials and Methods
Microorganisms
The bacterial strains used in this work are listed in Table 5.4. C. acetobutylicum ATCC
824 was purchased from the American Type Culture Collection (ATCC, Manassas, VA).
R. eutropha H16 was provided by Professor Anthony Sinskey of the Department of
Biology at the Massachusetts Institute of Technology, USA. E. coli DH10OB (Invitrogen,
Carlsbad, CA) and ElectroTen-Blue (Stratagene, La Jolla, CA) were used for
transformation of cloning reactions and propagation of all plasmids. BL21Star(DE3)
(Invitrogen, Carlsbad, CA) and MG1655(DE3) were used as host strains for the
biosynthesis of chiral 3HB, where MG1655(DE3) was constructed using a XDE3
Lysogenization Kit (Novagen, Darmstadt, Germany) for site-specific integration of XDE3
prophage into E. coli MG1655 (kindly donated by Professor Gregory Stephanopoulos of
the Department of Chemical Engineering at the Massachusetts Institute of Technology,
USA).
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Table 5.4: E. coli strains, plasmids and oligonucleotides used
Name Relevant Genotype Reference
Strains
DH10B
ElectroTen-Blue
MG1655
BL21 Star(DE3)
MG1655(DE3)
Plasmids
pGEM-T easy
pETDuet- 1
pCDFDuet-1
pET-H
pET-H-B a
pET-H-T a
pET-H-P a
pET-P
pET-P-B a
pET-P-T a
pET-P-P a
pCDF-T
pCDF-PB
Primersb
bktB US EcoRI
bktB DS XhoI
thil US EcoRI
thil DS XhoI
phaA_US_EcoRI
phaA_DS_XhoI
hbd US EcoRI
hbd DS NotI
phaBUS_EcoRI
phaB_DS_NotI
tesB US EcoRI
tesB DS SalI
F- mcrA A(mrr-hsdRMS-mcrBC) (p801acZAM15 AlacX74
recAl endAl araD139A(ara, leu)7697 galUgalK -rpsL nupG
A(mcrA) 183 A (mcrCB-hsdSMR-mrr) 173 endAl supE44 thi-1
recAl gyrA96 relAl lac Kanr [F' proAB lacPZAM 15 Tnl
(Tetr)]
F X- ilvG- rib-50 rph-1
F- ompThsdSB (rB" mB-) gal dcm rnel31 (DE3)
F V ilvG- rfb-50 rph-l (DE3)
PCR cloning vector; Fl ori, Ampr
ColEl(pBR322) ori, lacId, T71ac, Ampr
CloDF13 ori, lad, T7ac, Strr
pETDuet-1 harboring hbd from C. acetobutylicum ATCC 824
pETDuet- 1 harboring bktB from R. eutropha H 16, and hbd from
C. acetobutylicum ATCC 824
pETDuet-1 harboring thil and hbd from C. acetobutylicum
ATCC824
pETDuet-1 harboring phaA from R. eutropha H 16, and hbd
from C. acetobutylicum ATCC 824
pETDuet-1 harboring phaB from R. eutropha H 16
pETDuet- 1 harboring bktB and phaB from R. eutropha H 16
pETDuet-1 harboring thil from C. acetobutylicum ATCC 824,
and phaB from R. eutropha H 16
pETDuet- 1 harboring phaA and phaB from R. eutropha H 16
pCDFDuet-1 harboring tesB from E. coli MG165 5
pCDFDuet-1 harboring ptb-buk operon from C. acetobutylicum
ATCC 824
Sequence 5'--3 '"
GAA TTCATGACGCGTGAAGTGGTAGTG
CTCGAGCGCAAGGCTAACCTCAGAT
ATAGAA TTCCATGAGAGATGTAGTAATAGTAAGTG
TATTGAACCTC CTCGA GAACTTAGTTATAT
GAA TTCGACTACACAATGACTGACGTTGTC
CTCGAGAAAACCCCTTCCTTATTTGC
GAA TTCGGGAGGTCTGTTTAATGAAAA
GCGGCCGCTGTAAACTTATTTTG
GAA TTCAACGAAGCCAATCAAGGAG
GCGGCCGCGCAGGTCAGCCCATATG
GAA TTCTACTGGAGAGTTATATGAGTCAGG
GTCGACTTAATTGTGATTACGCATC
Invitrogen
Stratagene
ATCC 700926
Invitrogen
This study
Promega
Novagen
Novagen
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
Sigma-Genosys
Sigma-Genosys
Sigma-Genosys
Sigma-Genosys
Sigma-Genosys
Sigma-Genosys
Sigma-Genosys
Sigma-Genosys
Sigma-Genosys
Sigma-Genosys
Sigma-Genosys
Sigma-Genosys
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a Each gene is under the control of the T71ac promoter with a ribosome binding site.
b Primers were synthesized at Sigma-Genosys, St. Louis, MO.
C Restriction enzyme sites used in the cloning are shown in underlined italics.
Plasmid Construction
Genes derived from C. acetobutylicum ATCC 824 (thil, hbd, and ptb-buk operon), R.
eutropha H16 (phaA, bktB, and phaB), and E. coli K-12 (tesB) were obtained by
polymerase chain reaction (PCR) using genomic DNA (gDNA) templates. All gDNAs
were prepared using the Wizard Genomic DNA Purification Kit (Promega, Madison,
WI). Custom oligonucleotides (primers) were purchased for all PCR amplifications
(Sigma-Genosys, St. Louis, MO) as shown in Table 5.4. In all cases, HotStar HiFidelity
Polymerase (Qiagen, Valencia, CA) was used for DNA amplification. Restriction
enzymes and T4 DNA ligase were purchased from New England Biolabs (Ipswich, MA).
Recombination DNA techniques were performed according to standard procedures
(Sambrook and Russell, 2001).
Two co-replicable vectors, pETDuet-1 and pCDFDuet-1 (Novagen, Darmstadt,
Germany), were used for construction of chiral 3HB biosynthetic pathways (Tolia and
Joshua-Tor, 2006). Both Duet vectors contain two multiple cloning sites (MCS), each of
which is preceded by a T71ac promoter and a ribosome binding site (RBS), affording
high-level expression of each individual gene.
For cloning genes, PCR products incorporated with desired restriction sites within the 5'
and 3' primers were first cloned into pGEM-T Easy vector (Promega, Madison, WI) using
TA cloning. The resulting plasmids were then digested and the genes were subcloned
into pETDuet-1 or pCDFDuet-1. The hbd gene was inserted in between the EcoRI and
NotI sites (MCS I) of pETDuet-1 to create pET-H. The phaB gene was inserted between
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the NcoI and NotI sites (MCS I) of pETDuet-1 to create pET-P. Plasmids of pET-H-B,
pET-H-T, and pET-H-P were constructed by inserting bktB, thil, and phaA, respectively,
between the MfeI and XhoI sites (MCS II) of pET-H. In a similar manner, plasmids pET-
P-B, pET-P-T, and pET-P-P were constructed by inserting bktB, thil, and phaA,
respectively, between the MfeI and XhoI sites (MCS II) of pET-P. Plasmid pCDF-PB
was created by inserting the ptb-buk operon between the EcoRI and Sall sites of
pCDFDuet-1. Cloning the tesB gene between the EcoRI and Sall sites of pCDFDuet-1
resulted in plasmid pCDF-T. All constructs were confirmed to be correct by restriction
enzyme digestion and nucleotide sequencing. Plasmids constructed in the present work
are listed in Table 5.4.
Culture Conditions
Seed cultures of the recombinant strains were grown in LB medium at 300 C overnight on
a rotary shaker at 250 rpm. For the biosynthesis of chiral 3HB, the seed cultures were
used to inoculate 50 mL LB medium in 250 mL flasks supplemented with 20 g L-1
glucose at an inoculation volume of 5%. Cultures were incubated at 300 C on a rotary
shaker until OD 600 reached 0.4-0.8. At this point, 1 mM IPTG was added to the cultures
to induce recombinant protein expression. In all cases, LB medium was supplemented
with 50 mg L'1 ampicillin and 25 mg L-1 streptomycin, and cultures were incubated
aerobically. Culture broth was sampled at 4 h post-induction for enzyme assays, and at
48 h post-induction for HPLC analysis.
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Metabolite Analysis and Dry Cell Weight Determination
Samples were centrifuged to pellet cells while the aqueous supernatant was collected for
HPLC analysis. Concentrations of 3HB, glucose, and acetate were analyzed via HPLC
using an Agilent 1100 series instrument equipped with a refractive index detector (RID).
Analyte separation was achieved using an Aminex® HPX-87H anion exchange column
(Bio-Rad Laboratories, Hercules, CA) according to the method of Buday et al. (1990)
using 5 mM H2SO 4 as the mobile phase.
The dry cell weight (DCW) was determined in triplicates by filtering culture broth (25
mL) through a pre-weighed filter paper (0.45-pm cellulose acetate filters, Whatman,
Maidstone, UK), followed by washing with deionized water (25 mL). The filter paper
was then dried for two days in a 70 0 C oven and weighed for DCW determination. One
OD 600 unit was equivalent to 0.42 g-DCW L for BL21Star(DE3) and 0.39 g-DCW L-1
for MG1655(DE3).
Methyl Esterification of 3HB
50 mL of 3HB-containing LB microbial culture was centrifuged at 6000 x g for 10 min
and the supernatant was transferred to an evaporation dish for evaporating overnight in a
500C oven, resulting in a brown residue. To this residue, 2 mL of acidic methanol (4:1
methanol:concentrated HC1) was added and the dish was shaken for two minutes to
remove 3HB from the residue. The methanol solution was transferred into a test tube,
sealed, and heated at 1000C for 3 hours. After heating, the solution was allowed to cool
to room temperature. After cooling, 200 !L of the methanol solution was mixed with 1
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mL of pure isopropanol in a 1.7 mL tube, vortexed, and allowed to stand for 5 minutes.
Precipitate in this sample was removed by centrifugation at 13,200 x g for 10 minutes.
The supernatant was taken for chiral HPLC analysis.
Chiral HPLC Analysis of Methyl-3HB
Chiral HPLC analysis was performed on an Agilent 1100 Series instrument equipped
with a Chiralcel OD-H column (0.46 cm p x 25 cm) purchased from Daicel Chemical
Industries (West Chester, PA). The column temperature was maintained at 400C.
Methyl-3HB was detected on a diode array detector at 210 nm. The mobile phase was
9:1 n-hexane:isopropanol and the flow rate through the column was 0.7 mL min-.
Methyl-(R)-3HB and methyl-(S)-3HB purchased from Sigma-Aldrich (St. Louis, MO)
were used as standards and had retention times of 7.78 and 9.37 min, respectively.
Enzyme Assays
Samples of 5 mL culture broth were centrifuged at 5,000 x g and 4°C for 10 min. The
pellets were resuspended in 200 RL of lysing buffer (1 Roche protease inhibitor cocktail
tablet in 10.5 mL of 10 mM Tris-HCl supplemented with 1 mg mL-' lysozyme; pH =
8.0). Crude cell lysates were prepared by freeze-thaw lysis, carried out by subjecting
cells to five cycles of freezing in liquid nitrogen followed by thawing at 370 C. After
centrifugation at 14,000 x g and 4°C for 20 min, the supernatant was taken for enzyme
assays. The total protein concentration of this supernatant was determined by the method
of Bradford (1976) using bovine serum albumin as a standard.
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Activities of thiolases, including BktB, Thil, and PhaA, were assayed using acetoacetyl-
CoA and CoA as substrates, and the decrease in acetoacetyl-CoA concentration was
followed at 303 nm (Inui et al., 2008). Activities of PhaB and Hbd were assayed using
acetoacetyl-CoA as substrate and NADPH or NADH as cofactor, respectively. The
decrease of NADPH or NADH concentration resulting from 3-hydroxybutyryl-CoA
formation from acetoacetyl-CoA was measured at 340 nm (Inui et al., 2008; Schubert et
al., 1988).
Quantification of Intracellular Cofactor Levels
The NAD +, NADH, NADP +, and NADPH were each determined using Enzychrom TM
NAD+/NADH and NADP+/NADPH assay kits (Bioassay Systems, Hayward, CA).
Manufacturer's protocols were followed except that for sample preparation cells were
resuspended in 100 ld extraction buffer and sonicated for 10 seconds on ice before heat
extraction. The assays utilized alcohol dehydrogenase and glucose dehydrogenase for
NAD(H) and NADP(H) quantifications, respectively, and colorimetric changes in the
samples were measured at 565 nm.
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Chapter 6: Production of Higher Hydroxyacids in E. coli
In this chapter, the 3HB pathway developed in Chapter 5 is expanded to produce more
complex 3-hydroxyacids - specifically 3HV and DHBA. Also, the lactonization of
DHBA to 3-HBL is investigated in detail. These other products are made by supplying
the non-natural substrates propionate (for 3HV production) or glycolate (for DHBA and
3-HBL production) to the 3HB pathway. These non-natural substrates are thiolated by
propionyl-CoA transferase (pct) to form CoA thioesters capable of condensing with
acetyl-CoA to eventually form the novel hydroxyacid products. For 3HV production,
titers of 537 mg L-1' of (R)-3HB and 522 mg L' of (S)-3HV were achieved. For DHBA
production, 3.2 g L-1 of DHBA along with 230 mg L-' of 3-HBL were produced. The
DHBA/3-HBL product profile can be shifted towards 3-HBL in one of two ways - by
either removing the tesB gene and allowing for the auto-lactonization of DHBA-CoA or
by treating DHBA-rich culture supernatants with acid to chemically lactonize the DHBA
into 3-HBL. Removing the tesB gene resulted in an average improvement in 3-HBL
production of 52%. The latter method of chemically lactonizing the culture supernatant
with acid yielded 420 mg L'1 of DHBA and 2.17 g L' of 3-HBL, a 9-fold improvement
in 3-HBL titer.
Introduction
As discussed in Chapter 5, hydroxyacids are versatile, chiral compounds that contain both
a carboxyl and a hydroxyl moiety, readily allowing for their modification into several
useful derivatives (Lee et al., 2002; Chen and Wu, 2005) and making them suitable for
137
applications in the synthesis of antibiotics (Chiba and Nakai, 1985), P- and y-aminoacids
and peptides (Park, et al. 2001; Seebach et al., 2001), and as chiral synthetic building
blocks (Lee et al., 2002). Direct biological production of hydroxyacid monomers has
been successfully demonstrated for 3HB, and titers of 3 g L-' and 12 g L' on the shake
flask and fed-batch scales have been reported (Gao et al., 2002). In these reports, 3HB is
made from acetyl-CoA through the use of acetyl-CoA acetyltransferase (phbA), 3-
hydroxybutyryl-CoA dehydrogenase (phbB), phosphotransbutyrylase (ptb), and butyrate
kinase (buk) (Liu and Steinbiichel, 2000a; Liu and Steinbiichel, 2000b; Gao et al., 2002;
Figure 5.1). The last two of these enzymes were chosen to remove the CoA moiety from
3-hydroxybutyryl-CoA to yield free 3HB and were taken from Clostridium
acetobutylicum, where they participate in the production of butyrate from butyryl-CoA
(Liu and Steinbiichel, 2000b). Recently, thioesterase II (tesB) from Escherichia coli K12
(Naggert et al., 1991) was successfully employed to directly hydrolyze the acyl-thioester
of 3HB-CoA (Liu et al., 2007; Tseng et al., 2009; Figure 5.1).
The success of direct production of 3HB from the condensation of two acetyl-CoA
moieties opens up the possibility of producing more structurally diverse hydroxyacids
through generalizing this pathway to the condensation of an acyl-CoA molecule with
acetyl-CoA (Figure 6.1). In the generalized 3HB pathway, referred to as the 3-
hydroxyalkanoic acid pathway, one of the three acetoacetyl-CoA thiolases from Chapter
5 (thil, bktB, or phaA) is employed to perform the condensation reaction to yield a 3-
ketoacyl-CoA intermediate, which is subsequently reduced by either phaB or hbd to yield
a 3-hydroxyacyl-CoA compound. Finally, tesB is used to hydrolyze the CoA moiety
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from the 3-hydroxyacyl-CoA, liberating the free 3-hydroxyacid. These steps are exactly
identical to those used in 3HB biosynthesis (Figure 5.1). One additional complication in
the 3-hydroxyalkanoic acid pathway is that unlike acetyl-CoA, short chain acyl-CoA
compounds that would be candidate substrates for this pathway are not readily available
metabolites in E. coli. To circumvent this, propionyl-CoA transferase (pct), a broad
substrate-specificity enzyme from Megasphaera elsdenii (Schweiger and Buckel, 1984;
Taguchi et al., 2008) that exchanges CoA moieties between short-chain organic acids, is
employed. In the 3-hydroxyalkanoic acid pathway, pct in used to transfer CoA from
acetyl-CoA to an acid supplied to the cell (such as propionate), forming the acyl-CoA
required by the pathway. Table 6.1 summarizes the characteristics and sources for each
enzyme employed in the 3-hydroxyalkanoic acid pathway shown in Figure 6.1.
Glycolysis
% Acetyl-CoA
H3C SCoA
+ Step A StepB OH 0 tesBOH 0
O A SCoA A " SCoA A OH
Acyl-CoA Hydroxyacyl-CoA Hydroxyacid
A SCoA Product
A Step A: thil, bkB, or phaA
A OH Step B: phaB or hbd
Supplied Acid
Figure 6.1: Schematic of the 3-hydroxyalkanoic acid pathway, a generalized version of the 3HB pathway
shown in Figure 5.1. One key difference between these two pathways is the addition of pct to generate
acyl-CoA molecules used in the condensation reaction with acetyl-CoA.
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Table 6.1: General characteristics
shown in Figure 6.1.
and sources of enzymes used in the 3-hydroxyalkanoic acid pathway
The ultimate goal of this work was to use the 3-hydroxyalkanoic acid pathway to
synthesize 3-hydroxybutyrolactone (3-HBL) and/or its hydrolyzed form 3,4-
dihydroxybutyric acid (DHBA) from sugars and sugar-derived substrates. 3-HBL is
widely used in the pharmaceutical industry as a building block for the class of
cholesterol-reducing drugs called statins such as Crestor(R) and Lipitor(R) as well as the
antibiotic Zybox(R) and the anti-hyperlipidemic medication Ezetimibe(R) (Lee et al., 2008;
Lee and Park, 2009). Other pharmaceuticals derived from 3-HBL include HIV inhibitors
(Kim et al., 1995) and the nutritional supplement carnitine (Wang and Hollingsworth,
1999b). 3-HBL has been listed as one of the top ten value-added chemicals by the U.S.
Department of Energy (Werpy and Peterson, 2004). 3-HBL can readily be transformed
into a variety of three-carbon building blocks (Wang and Hollingsworth, 1999a), and
Figure 1.2 (taken from Werpy and Peterson, 2004) illustrates a variety of additional
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Organism of
Enzyme Origin Properties Reference
Acetyltransferase, broad substrate range
bktB R. eutropha H16 (C4-C6) Slater et al., 1998
C. acetobutylicum Dehydrogenase, forms S stereoisomer Boynton et al.,
hbd 824 product 1996
CoA-transferase, wide substrate range Schweiger and
pct M. elsdenii (C2 -C 4) Buckel, 1984
Acetyltransferase, high activity and Schubert et al.,
phaA R. eutropha H16 somewhat wide substrate range 1988
Dehydrogenase, forms R stereoisomer Schubert et al.,
phaB R. eutropha H 16 product 1988
Thioesterase, very broad substrate range Huisman et al.,
tesB E. coliK12 (C4 -C1 6) 1991
C. acetobutylicum Stim-Herndon et
thil 824 Acetyltransferase, high activity al., 1995
derivitization routes available for 3-HBL. In this work, the production of 3-
hydroxyvalerate (3HV) from glucose and propionate is first examined to test the 3-the
ability of the hydroxyalkanoic acid pathway to uptake free acids and convert them to
CoA thioesters. The work then progresses onto DHBA and 3-HBL biosynthesis from
glucose and glycolate and examines several factors controlling the titers of and ratio
between these two products.
Results
Production of 3HV from Glucose and Propionate
The 3-hydroxyalkanoic acid pathway was first tested using propionate as a substrate.
Neutralized propionate was supplied along with glucose to recombinant E. coli cells
expressing one of three acetoacetyl-CoA thiolases (thil, bktB, or phaA), one of two 3-
hydroxybutyryl-CoA reductases (phaB or hbd), tesB, and pct. These cultures were
incubated for 48 hours at 300C, and the resulting 3HV titers were measured by HPLC
(Figure 6.2). 3HV was detected in cultures expressing bktB-phaB (537 mg L), phaA-
phaB (142 mg L'), and bktB-hbd (522 mg L-'). No 3HV was detected in the other three
pathway gene combinations. The result that pathways with bktB yield the highest 3HV
titer is consistent with reports that BktB has high activity towards the condensation of a
C3 substrate with a C2 to form a C5 product (Slater et al., 1998). The choice of reductase
in the 3-hydroxyalkanoic acid pathway did not significantly influence 3HV production,
except in the case of phaA, where 3HV was only detected in the phaA-phaB gene
combination.
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Figure 6.2: Production of 3HV by recombinant E. coli expressing tesB, pct, one of three acetoacetyl-CoA
thiolases (thil, bktB, or phaA), and one of two 3-hydroxybutyryl-CoA reductases (phaB or hbd).
Chiral Analysis of Microbially-Produced 3HV
Recombinant E. coli expressing the 3-hydroxyalkanoic acid pathway expressing bktB and
either phaB or hbd as the 3-hydroxybutyryl-CoA reducase was grown at 300 C in 50 mL
LB supplemented with 20 g L- glucose and 20 mM propionate for 48 hours. The
stereochemistry of the resulting 3HV in the media from these cultures was determined by
methyl esterification of the 3HV present followed by chiral HPLC analysis as described
in the Materials and Methods section at the end of this Chapter. These spectra were
compared to a racemic 3HV standard. The results confirm that 3-hydroxyalkanoic acid
pathways expressing phaB make a different stereoisomer of 3HV than pathways
employing hbd (Figure 6.3). Unfortunately the lack of an enantiopure 3HV standard
prevents the assignment of absolute stereochemistry (e.g. R or S) to each sample, though
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it is clear that the phaB and hbd cultures produce different stereoisomers. However,
based on previous reports regarding the product stereochemistry of phaB and hbd (Lee et
al., 2008; Liu et al., 2007) and the observation that (R)-3HB has a faster retention time
relative to (S)-3HB (Figure 5.3), it is highly likely that here that the phaB pathway
sample is making (R)-3HV while the hbdpathway sample produces (S)-3HV.
143
Figure 6.3: HPLC spectra of methyl esters of 3HV. (A) represents a racemic 3HV standard with the two
stereoisomers eluting at 6.9 and 9.2 min, (B) is culture medium from E. coli expressing ptb-buk, phaB, and
bktB with a peak at 6.9 min, and (C) is culture medium from E. coli expressing ptb-buk, hbd, bktB, and
tesB with a peak at 9.2 min. The ptb-buk operon encodes a phosphotransbutyrase (ptb) and a butyrokinase
(buk) from Clostridium acetobuoylicum that functions to produce high levels of propionyl-CoA from
propionate, similar to pct. All samples were boiled in acidic methanol to form methyl-3HV esters prior to
HPLC analysis. Chiral 3HB experiments using this same chiral HPLC analysis protocol (Figure 5.3)
strongly suggests that the 6.9 and 9.2 min peaks represent (R)-3HV and (S)-3HV respectively.
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Production of DHBA and 3-HBL from Glucose and Glycolate
For the production of DHBA and 3-HBL, neutralized glycolate was supplied along with
glucose to recombinant E. coli MG1655(DE3) recA- endA- cells expressing one of three
acetoacetyl-CoA thiolases (thil, bktB, or phaA), one of two 3-hydroxybutyryl-CoA
reductases (phaB or hbd), tesB, and pct. These cultures were incubated for 96 hours at
30 0C, and the resulting DHBA and 3HBL titers were measured by HPLC (Figure 6.4).
The identity of DHBA was confirmed through LC/MS analysis (Figure 6.5). DHBA was
detected in all 3-hydroxyalkanoic acid pathway gene combinations, however 3-HBL was
only detected in pathways expressing phaB. The bktB-phaB combination yielded the
highest DHBA and 3-HBL titers of 573 ± 30 mg L and 178 ± 4 mg L respectively.
The phaA-phaB combination performed almost as well, yielding DHBA and 3-HBL
titers of 492 ± 19 mg L' and 107 ± 3 mg L' respectively. The thil-phaB combination
did not perform as well as the other phaB combinations, yielding only 247 ± 57 mg L~' of
DHBA and 96 ± 14 mg L' of 3-HBL. Pathway combinations using hbd made only
DHBA, and the maximum DHBA titer of 47 ± 10 mg L' was from bktB-hbd.
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Figure 6.4: Production of DHBA (blue bars) and 3-HBL (red bars) by recombinant MG1655(DE3) endA-
recA- E. coli expressing different 3-hydroxyalkanoic acid pathway genes. The specific genes used in each
pathway are shown on the x-axis.
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Figure 6.5: LC/MS analysis of DHBA produced by recombinant E. coli. The green line represents a
DHBA standard, while the red line is DHBA produced by recombinant E. coli expressing phaA, phaB, pct,
and tesB. The blue line is a negative control. The MS signal is an ion trace at m/z= 138, which represents
the ammonium adduct of protonated DHBA.
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Effect of tesB Expression on DHBA and 3-HBL Production
The production of DHBA and 3-HBL was tested with and without tesB in 3-
hydroxyalkanoic acid pathways co-expressing phaB, one of three acetoacetyl-CoA
thiolases (thil, bktB, or phaA), and pct. This experiment was conducted similar to the
one above, but now with the goal of understanding how 3-HBL is being produced by the
3-hydroxyalkanoic acid pathway. The resulting DHBA and 3-HBL titers are shown in
Figure 6.6. As is seen in this figure, pathways lacking tesB produced on average 57%
more 3-HBL, but 95% less DHBA. The bktB-phaB-pct combination yielded the highest
3-HBL titer of 270 + 3 mg L-. The performance of pathways with different acetoacetyl-
CoA thiolases followed that of Figure 6.4, with bktB reaching the highest product titers
and thil having the lowest titers.
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Figure 6.6: Production of DHBA (blue bars) and 3-HBL (red bars) by recombinant E. coli MG1655(DE3)
endA- recA expressing different 3-hydroxyalkanoic acid pathway genes in the presence or absence of tesB.
The specific genes used in each pathway are shown on the x-axis.
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Effect of Acidic Post-Treatment on DHBA and 3-HBL Titers
In organic chemistry, it is well documented that lactonization is acid-catalyzed (Carey,
2000). Since the phaB cultures shown in Figure 6.4 produced much DHBA but relatively
little 3-HBL, the 96-hour supernatants from these cultures were acidified with 50 mM of
hydrochloric acid, reducing the pH below 1.0. These culture supernatants were then
incubated at 37C overnight to allow for acid-catalyzed lactonization to occur. After this
overnight incubation, these samples were subjected to HPLC analysis, and the resulting
DHBA and 3-HBL titers are shown in Figure 6.7. The acid post-treatment of the culture
supernatants improved 3-HBL titers by 171% on average, and the highest 3-HBL titer
obtained was 497 ± 25 mg L' 1 for the bktB-phaB pathway combination. DHBA titers
dropped by 85% on average during the process due to the lactonization of DHBA to 3-
HBL. Approximately 80-85 mol% of the DHBA was converted to 3-HBL, with the
remaining 15-20 mol% being lost presumably to DHBA multimerization.
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Figure 6.7: Production of DHBA (blue bars) and 3-HBL (red bars) by recombinant E. coli MG1655(DE3)
endA recA- expressing different 3-hydroxyalkanoic acid pathway genes along with tesB and pct. The right
three samples represent product titers that result when the left three samples are treated with acid. The
specific acetoacetyl-CoA thiolase and 3-hydroxybutyryl-CoA reductase used in each pathway are shown on
the x-axis.
Strain Effects on DHBA and 3-HBL Production
The 3-hydroxyalkanoic acid pathway was further tested in E. coli MG1655(DE3) with
intact recA and endA genes to see if the titers of DHBA and 3-HBL could be further
improved in a more wild-type E. coli strain. The results of this experiment are shown in
Figures 6.8 and 6.9. In Figure 6.8, the total consumption of glucose and glycolate and the
production of acetate, 3HB, DHBA, and 3-HBL for 11 independent cultures is shown.
The relatively large sample size helps to counteract the natural variability in gene
expression that occurs in recA+ strains. In this experiment, 1.99 ± 0.36 g L- of DHBA
was produced along with 0.16 ± 0.04 g L 1of 3-HBL. This represents more than a 3-fold
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improvement in DHBA production over MG1655(DE3) recA endA- (Figure 6.4). The
highest DHBA producing culture made 3.20 g L' of DHBA and 0.23 g L-1 of 3-HBL
(Figure 6.9). This culture was subjected to overnight acid-catalyzed lactonization,
resulting in 2.17 g L-1 of 3-HBL with 0.42 g L-1 of DHBA. The exact reason why
MG1655(DE3) is a superior DHBA producer to MG1655(DE3) recA- endA- is
undetermined, but it is assumed that the increased genetic engineering that the latter
strain has been subjected to has negatively impacted its growth and metabolism.
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Figure 6.8: Production profile of the 3-hydroxyalkanoic acid
MG1655(DE3) expressing bktB, phaB, pct, and tesB after 96 hours.
glycolate consumed, along with the average levels of acetate, 3HB,
pathway in
The average
DHBA, and
recombinant E. coli
levels of glucose and
3-HBL produced are
shown for 11 independent cultures, with the error bars representing the standard deviation.
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Figure 6.9: Production of DHBA and 3-HBL in the highest-producing culture of recombinant E. coli
MG1655(DE3) expressing bktB, phaB, pct, and tesB after 96 hours. This culture was subjected to an
overnight acid treatment to catalyze lactonization, and the resulting DHBA and 3-HBL levels are shown on
the right side of this figure.
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Discussion
Controlling Product Profiles through Selection of Pathway Enzymes
The 3-hydroxyalkanoic acid pathway has the key advantage that it and its constituent
enzymes are flexible with respect to their substrates - the pathway is highly versitile. In
particular, TesB, PhaB, BktB, and Pct are all known to work with at least three different
substrates (Huisman et al., 1991; Schubert et al., 1988; Slater et al., 1998; Schweiger and
Buckel, 1984). Substrate flexibility was critical in realizing the production of 3HV,
DHBA, and 3-HBL from this pathway. Experimentally, the combination of the four most
flexible proteins (TesB, PhaB, BktB, and Pct) was found to yield the highest titers of
novel 3-hydroxyalkanoic acid pathway products (Figures 6.3, 6.4, 6.6, and 6.7).
Furthermore, the products obtained through the 3-hydroxyalkanoic acid pathway can be
precisely controlled through the substrates and genes supplied to the pathway. For
instance, 3HV is only produced in the presence of propionate, while DHBA and 3-HBL
are only made when glycolate is added. The pathway can also be modulated to produce
more DHBA or 3-HBL through the presence or absence of the thioesterase TesB. With
recombinant TesB, significantly more DHBA is made (573 mg L'1 for the bktB-phaB
pathway combination) than 3-HBL (178 mg L). Without TesB, more 3-HBL is made
(270 mg L-' for bktB-phaB) than DHBA (21 mg L-'). The small amount of DHBA
formed in the absence of recombinant tesB may be due to the expression of genomic
tesB, as this gene is native to E. coli (Huisman et al., 1991). Nonetheless, this result
suggests that without a thioesterase to hydrolyze the CoA thioester of DHBA (DHBA-
CoA), DHBA-CoA can self-lactonize into 3-HBL in vivo (Figure 6.10). While it is not
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known whether there is an enzyme in E. coli that catalyzes this reaction or whether this
reaction occurs spontaneously in vivo, it is clear that 3-HBL is produced from glucose
and glycolate and that tesB plays an important role in determining the fate of the DHBA-
CoA intermediate (Figure 6.6).
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Figure 6.10: 3-Hydroxyalkanoic acid pathway scheme for DHBA and 3-HBL production from glucose and
glycolate, highlighting the key branch point at DHBA-CoA. With the expression of recombinant tesB,
more DHBA is produced by the pathway than 3-HBL (Figure 6.6), however in the absence of tesB, more 3-
HBL is produced while little DHBA is made, suggesting that DHBA-CoA can self-lactonize into 3-HBL in
vivo. Here the pathway is shown with bktB and phaB as the acetoacetyl-CoA thiolase and 3-
hydroxybutyryl-CoA reductase, as this pair of genes was shown to yield the highest levels of DHBA and 3-
HBL (Figure 6.4).
Another interesting point is that in all of the 3HV, DHBA, and 3-HBL production
experiments done in this work in MG1655(DE3) recA- endA-, very little 3HB (< 100 mg
L-1 ) was detected (data not shown). Even in MG1655(DE3), there was twice as much
DHBA produced relative to 3HB (Figure 6.9), even though 3HB is the natural substrate
for the enzymes employed in the 3-hydroxyalkanoic acid pathway. 3HB is made from
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the condensation of two acetyl-CoA moieties (Figure 5.1) and should theoretically be a
major side product in the production of the other 3-hydroxyacids in this work since 3HB
is the natural product of the action of acetoacetyl-CoA thiolases with 3-hydroxybutyryl-
CoA reductases and 3HB has been produced at 2-3 g L-1 with these enzymes (Chapter 5
of this thesis; Tseng et al., 2009). The only difference between the 3HB and 3-
hydroxyalkanoic acid pathways is the presence of pct in the latter pathway. Pct is a CoA-
transferase that exchanges CoA moieties between short-chain organic acids, including
acetate and acetyl-CoA (Schweiger and Buckel, 1984). That very little 3HB is made in
the presence of recombinant pct suggests that the Pct protein may be removing CoA from
acetyl-CoA in the cell and transferring it onto other acids, including propionate for 3HV
production and glycolate for DHBA and 3-HBL production. This CoA transfer could
significantly reduce intracellular acetyl-CoA concentrations, making the second-order
condensation of two acetyl-CoA molecules much less likely than the condensation of
acetyl-CoA with another acyl-CoA (a first-order reaction with respect to acetyl-CoA). A
byproduct of removing CoA from acetyl-CoA would be increased acetate production, and
this effect was confirmed by HPLC in comparing the 3-hydroxyalkanoic acid pathway
with and without pct (Figure 6.11). The significant increase in acetate production
corroborates the hypothesis that Pct is harvesting CoA from acetyl-CoA for use in
thiolating other short-chain acids within the cell. This action likely reduces acetyl-CoA
levels to the point that 3HB biosynthesis is significantly inhibited.
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Figure 6.11: Acetate production after 48 hours from the 3-hydroxyalkanoic acid pathway in E. coB
MG1655(DE3) recA- endA- with and without pct. Experiments without the pct were performed in
triplicate, while those with pct represent single trials.
Controlling Stereochemistry via Choice of 3-Hydroxybutyryl-CoA Reductase
The 3-hydroxyalkanoic acid pathway's flexibility also extends to the stereochemistry of
its final product - by using phaB or hbd as the 3-hydroxybutyryl-CoA reductase in the
pathway, different stereochemical outcomes can be realized. It is well documented in the
literature that PhaB results in (R)-3-hydroxyacids while Hbd results in the (S)
stereoisomer (Lee et al., 2008; Liu et al., 2007). This phenomenon was experimentally
verified both in pathways producing 3HB (Figure 5.3; Tseng et al., 2009) and 3HV
(Figure 6.3). Unfortunately, the methyl esterification chiral analysis method used to
analyze the stereochemistry of 3HB and 3HV does not work on DHBA because of its
ability to lactonize and because of the inability of the 3-HBL lactone stereoisomers to
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resolve from one another during the analysis (data not shown). However, based on the
observation that PhaB and Hbd produce different and completely enantiopure 3HB and
3HV products, there is no reason to expect that they will not do the same for DHBA and
3-HBL. Interestingly, because DHBA has a hydroxyl group in the 8-position that
changes the stereochemical priority of the different parts of the molecule about its
stereocenter, the stereochemistry of DHBA formed by PhaB should be (S)-DHBA while
that formed by Hbd should be (R)-DHBA. This assignment of stereochemistry is based
on the absolute position of the y-hydroxyl group in DHBA relative to the carboxylate
group. Since PhaB is much better than Hbd at producing DHBA and 3-HBL in the 3-
hydroxyalkanoic acid pathway (Figure 6.4), the pathway is better suited for the
production of (S)-DHBA and (S)-3-HBL than the (R) stereoisomers. Fortunately, the (S)
stereoisomer is predominately used in the production of pharmaceuticals and high-value
compounds (Lee and Park, 2009). The screening of hbd homologs could identify a 3-
hydroxybutyryl-CoA reductase with identical stereochemical preference but with an
increased substrate range for the production of (R)-DHBA and (R)-3-HBL.
Conclusions
In this work, 3HV (0.54 g LU'), DHBA (3.2 g L'), and 3-HBL (2.2 g LU') were produced
using the 3-hydroxyalkanoic acid pathway (Figure 6.1) in E. coli. These compounds
have applications ranging from chiral building blocks to polymeric materials to high-
value pharmaceuticals. This work represents one of the first reports on 3HV biosynthesis
in E. coli, and is the first report on the complete biological production of DHBA and 3-
HBL from inexpensive sugar and sugar-derived substrates. Further screening of
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additional 3-hydroxyalkanoic acid pathway homologs should provide a rich resource of
pathway combinations for the production of other high value 3-hydroxyacids such as 3-
hydroxypropionate from formyl-CoA and acetyl-CoA. Molecular analogs of DHBA and
3-HBL could be made using the 3-hydroxyalkanoic acid pathway as well, such as 3,4-
dihydroxyvalerate and 4-methyl-3-HBL from the condensation of lactyl-CoA and acetyl-
CoA, potentially leading to new intermediates for more effective pharmaceuticals.
Product titers from the 3-hydroxyalkanoic acid pathway could be further enhanced by
additional optimization of culture conditions and host strain. The screening of
homologous pathway enzymes could improve titers in addition to broadening the
substrate range of the pathway. One promising route for increasing productivity is to
engineer E. coli to produce pathway substrates "in-house." For instance, glycolate could
be made intracellularly from glyoxylate through the action of the ycdW glyoxylate
reductase gene (Nufiez et al., 2001). Intracellular production of pathway substrates
would eliminate the need for substrate transport across the cellular envelope, accelerating
production. Intracellular production of substrates would also allow the feeding of just
glucose to E. coli for product formation, simplying the bioprocess while lowering
material costs.
Materials and Methods
Strains and Chemicals
E. coli DH10OB (Invitrogen, Carlsbad, CA) and ElectroTen-Blue (Stratagene, La Jolla,
CA) were used for transformation of cloning reactions and propagation of all plasmids.
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E. coli MG1655(DE3) was constructed from E. coli MG1655 using a XDE3
Lysogenization Kit (Novagen, Darmstadt, Germany). The recA and endA genes in E.coli
MG1655(DE3) were then knocked out by the method of Datsenko and Wanner (2000), to
yield E. coli MG1655(DE3) recA- endA- (Tseng et al., 2009). Both E.coli
MG1655(DE3) and E. coli MG1655(DE3) recA- endA- were used for the production of
3HV, DHBA, and 3-HBL. Luria-Bertani (LB) medium, D-glucose, propionic acid, and
glycolic acid were purchased from BD Biosciences (Sparks, MD), Mallinckrodt
Chemicals (Phillipsburg, NJ), Sigma-Aldrich (St. Louis, MO), and MP Biomedicals
(Solon, OH), respectively. Unless otherwise noted, all chemicals were purchased at the
highest grade available.
Plasmids and Primers
Genes derived from C. acetobutylicum ATCC 824 (thil and hbd), R. eutropha H16 (phaA,
bktB, and phaB), E. coli K-12 (tesB), and M. elsdenii (pct) were obtained by polymerase
chain reaction (PCR) using genomic DNA (gDNA) templates. All gDNAs were prepared
using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI). Custom
oligonucleotides (primers) were purchased for all PCR amplifications (Sigma-Genosys,
St. Louis, MO) and are shown in Table 6.2. In all cases, HotStar HiFidelity Polymerase
(Qiagen, Valencia, CA) was used for DNA amplification. Restriction enzymes and T4
DNA ligase were purchased from New England Biolabs (Ipswich, MA). DNA
digestions, ligations, and transformations were performed according to standard
procedures (Sambrook and Russell, 2001).
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Two co-replicable vectors, pETDuet-1 and pCDFDuet-1 (Novagen, Darmstadt,
Germany), were used for construction of the 3-hydroxyalkanoic acid pathways. Both
Duet vectors contain two multiple cloning sites (MCS), each of which is preceded by a
T7ac promoter and a ribosome binding site (RBS), affording high-level expression of
each individual gene. For cloning the pathway genes into these vectors, PCR products
were made using 5' and 3' primers with desired restriction sites incorperated within them.
These sites, used for cloning the genes, are underlined in Table 6.2. These PCR products
were digested with restriction enzymes corresponding to the restriction site incorporated
into them by their respective primers and ligated directly into similarly digested Duet
vector. Ligation reactions using pETDuet-l as the vector were transformed into DH10B
E. coli, while ligations using pCDFDuet-l were transformed into ElectroTen-Blue E.
coli. One of three acetoacetyl-CoA thiolases (thil, bktB, and phaA) and one of two 3-
hydroxybutyryl-CoA reductases (phaB and hbd) were cloned into pETDuet-1, resulting
in six pETDuet-based plasmids. The pCDFDuet-based plasmids contained either pct and
tesB or just pct alone. Once all plasmids were constructed, one pETDuet-based plasmid
and one pCDFDuet-based plasmid were co-transformed into E.coli MG1655(DE3) recA-
endA- or E.coli MG1655(DE3) to create a complete 3-hydroxyalkanoic acid pathway-
expressing production strain.
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Table 6.2: List of DNA oligonucleotide primers used in the cloning of genes for the 3-hydroxyalkanoic
acid project. Restriction sites used for cloning are underlined. Primer names correspond to the name of the
gene that the primer amplifies, whether the primer is the forward primer (FP) or reverse primer (RP) of that
gene, and the restriction site incorporated into the primer sequence for cloning.
Primer Sequence 5'-->3' Source
bktB-FP-NcoI GACACCATGGGCATGACGCGTGAAGTGGTAG Sigma-Genosys
bktB-RP-EcoRI GACAGAATTCTCAGATACGCTCGAAGATGG Sigma-Genosys
hbd-FP-NdeI TATCCATATGAAAAAGGTATGTGTTATAGGTGC Sigma-Genosys
hbd-RP-XhoI GACACTCGAGTTATTTTGAATAATCGTAGAAACCTTTTC Sigma-Genosys
phaA-FP-NcoI GACACCATGGGCATGACTGACGTTGTCATCGTATC Sigma-Genosys
phaA-RP-EcoRI GACAGAATTCTTATTTGCGCTCGACTGC Sigma-Genosys
phaB-FP-NdeI GACACATATGACTCAGCGCATTGC Sigma-Genosys
phaB-RP-XhoI GACACTCGAGTCAGCCCATGTGCAGG Sigma-Genosys
pct-FP-EcoRI GACAGAATTCATGAGAAAAGTAGAAATCATTACAGCTG Sigma-Genosys
pct-RP-PstI GACACTGCAGTTATTTTTTCAGTCCCATGGG Sigma-Genosys
tesB-FP-NdeI GACACATATGAGTCAGGCGCTAAAAAAAT Sigma-Genosys
tesB-RP-XhoI GACACTCGAGTTAATTGTGAATTACGCATCACC Sigma-Genosys
thil-FP-NcoI GACACCATGGGCATGAGAGATGTAGTAATAGTAAGTGC Sigma-Genosys
TGTAAGA
thil-RP-EcoRI GACAGAATTCTATTTAGTCTCTTTCAACTACGAGAGC Sigma-Genosys
Culturing Conditions
Recombinant E. coli harboring one of the acetoacetyl-CoA thiolases (thil, bktB, or phaA)
and one of two 3-hydroxybutyryl-CoA reductases (phaB or hbd) on the pETDuet-1
vector and tesB and/or pct on the pCDFDuet-1 vector were cultured in 50 mL LB
supplemented with 1% glucose in a 250 mL shake flask at 30 0C unless otherwise
indicated in the text. Ampicilin (50 mg LU) and streptomycin (50 mg L-1) were added to
provide selective pressure for plasmid maintenance. Additional supplemental
compounds, such as neutralized propionate or glycolate, were added to cultures where
indicated in the text from 2.OM stock solutions. Cultures were inoculated to an initial
optical density at 600 nm (OD600 ) of 0.05. Once the cells reached mid-exponential phase
(OD 600 ~ 0.5), 50 jiL of 1.0 M IPTG and 1 mL of 2.0 M neutralized propionate or
glycolate was added to the cultures for induction of gene expression and to provide the
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substrates needed for the 3-hydroxyalkanoic acid pathway. 1 mL of culture was
withdrawn daily for HPLC analysis.
Methyl Esterification of 3HV
50 mL of 3HV-containing LB microbial culture was centrifuged at 6000 x g for 10 min
and the supernatant was transferred to an evaporation dish for evaporating overnight in a
500C oven, resulting in a brown residue. To this residue, 2 mL of acidic methanol (4:1
methanol:concentrated HC1) was added and the dish was shaken for two minutes to
remove 3HV from the residue. The methanol solution was transferred into a test tube,
sealed, and heated at 1000C for 3 hours. After heating, the solution was allowed to cool
to room temperature. After cooling, 200 [tL of the methanol solution was mixed with 1
mL of pure isopropanol in a 1.7 mL tube, vortexed, and allowed to stand for 5 minutes.
Precipitate in this sample was removed by centrifugation at 13,200 x g for 10 minutes.
The supernatant was taken for chiral HPLC analysis.
HPLC Analyses
Achiral HPLC analysis was performed on an Agilent 1100 Series instrument equipped
with an Aminex HPX-87H column (0.7 cm x 30 cm) purchased from Bio-Rad
Laboratories (Hercules, CA). For all achiral analyses, the mobile phase was 5 mM
sulfuric acid, 5 gL of culture supernatant was injected for the analyses, and products were
quantified using a refractive index detector. For the achiral analysis of 3HV, the column
was operated at a temperature of 35.0 oC. The flowrate started at 0.55 mL min and was
linearly ramped up to 0.8 mL min' for the first 12 minutes and maintained at 0.8 mL
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min-' for an additional 8 minutes. 3HV purchased from Epsilon Chimie (Brest, France)
was used as a standard and had a retention time of approximately 14.5 min. For the
analysis of DHBA and 3-HBL, the column was operated at a temperature of 40.0 oC and
a constant flowrate of 0.75 mL min-'. 3-HBL purchased from Sigma-Aldrich (St. Louis,
MO) was used as a standard, and DHBA was prepared from 3-HBL by saponification
with 10 ON sodium hydroxide and used as a standard. The retention times for DHBA and
3-HBL were approximately 8.9 min and 13.7 min respectively.
Chiral HPLC analysis was performed on an Agilent 1100 Series instrument equipped
with a Chiralcel OD-H column (0.46 cm (p x 25 cm) purchased from Daicel Chemical
Industries (West Chester, PA). The column temperature was maintained at 400 C.
Methyl-3HV was detected on a diode array detector at 210 nm. The mobile phase was
9:1 n-hexane:isopropanol and the flow rate through the column was 0.7 mL min1.
Racemic 3HV purchased from Epsilon Chimie (Brest, France) was boiled in acidic
methanol as described above to form racemic methyl-3HV, which was used as a standard.
The retention times for the two enantiomers were 6.86 and 9.24 min. Prior chrial HPLC
analysis with 3HB suggests that the earlier retention time is (R)-3HV, while the latter is
(S)-3HV.
Mass spectrometry (MS) analysis was performed using an Agilent 6120 Quadrupole
LC/MS unit operated in positive ion electrospray mode. The LC mobile phase was 25
mM ammonium formate, pH 2, and the flowrate was 0.6 mL min-'. The unit was
operated downstream of the liquid chromatography column described above under the
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same chromatography conditions. Samples were vaporized at 1500C and nitrogen at
300'C, 60 psig, and 5.0 L min-1 was used as the carrier gas for MS analysis. The ion
detector was calibrated to scan for cations at an m/z of 138, representing the ammonium
adduct of DHBA.
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Chapter 7: Conclusions and Recommendations
Summary of Products and Titers
In this thesis, metabolic routes were developed for the production of hydroxyacids and
their lactones in two different microbial systems. The first system described in Chapters
3 and 4 was for the production of 3HV, 4HV, and 4VL from levulinate in P. putida. In
this work, the renewable carbon source levulinate was reduced by enzymes native to P.
putida to 4HV and 3HV, and the inclusion of a non-cytosolic lactonase enzyme allowed
for the production of 4VL under acidic conditions. This system allowed for the high-titer
production of five-carbon hydroxyacids and their lactones from feasible, renewable
substrates. The second system discussed in Chapters 5 and 6 depicted the production of
various y-hydroxyacids and lactones through the 3-hydroxyalkanoic acid pathway. This
pathway had the advantage of being flexible with regard to substrate and stereochemical
specificity, allowing for the production of a wide range of products of different and
controlled chiralities. 3HB, 3HV, DHBA, and 3-HBL were all synthesized using this
platform. The different products from each of these systems and their respective
maximum titers obtained are shown in Table 7.1 below.
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Table 7.1: Summary of products and titers of hydroxyacids and lactones
produced in this thesis. Stereochemistry is indicated where it is known.
P. putida Hydroxyvalerate System
(Chapters 3-4)
Product Maximum Titer
3HV 5.3 g L-
4HV 27.1 g L-1
4VL 8.2 g L1
E. coli 3-Hydroxyalkanoic Acid Pathway
System (Chapters 5-6)
Product Maximum Titer
(R)-3HB 2.9 g L1
(S)-3HB 2.1 g L-1
(R)-3HV 537 mg L-
(S)-3HV 522 mg L-
DHBA 3.2 g L-1
3-HBL 2.2 g L1
Experimental Observations of Key Pathway Design Parameters
In Chapter 2 of this thesis, there was an extensive discussion on pathway design, with
emphasis on theoretical or database tools available to aid in this endeavor. Chapters 3-6
however provide several important experimental design parameters or "rules-of-thumb"
for pathway design as well. Chief among these is the strategic choice of enzymes and
enzyme homologs for metabolic pathways. The 3-hydroxyalkanoic acid pathway
illustrates this point extensively. By examining multiple homologs of acetoacetyl-CoA
thiolases and 3-hydroxybutyryl-CoA reductases, the array of products from the pathway
was broadened. For instance, Figure 6.2 shows that only half of the combinations of
acetoacetyl-CoA thiolases and 3-hydroxybutyryl-CoA reductases were able to produce
3HV. Had not multiple enzymes been screened, 3HV might not have been detected, and
had not different 3-hydroxybutyryl-CoA reductases been screened, the production of
different product enantiomers would not have been realized (Figures 5.3 and 6.3). This
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observation indicates that the availability of homologous enzymes is a key parameter in
the design and construction of novel metabolic pathways.
Another key design "rule-of-thumb" was found to be using enzymes with broad substrate
specificities in building unnatural pathways. Completely non-natural biosynthetic
products like DHBA and 3-HBL were only possible when several enzymes with wide
substrate ranges were assembled together. Figure 6.4 illustrates this point well. Here,
PhaB was shown to give much higher DHBA and 3-HBL titers than Hbd. PhaB was
cloned from the polyhydroxyalkanoate synthesis pathway in R. eutropha, a pathway that
is designed to store a wide range of hydroxyacids as a carbon-storage polymer (Schubert
et al., 1988). Because this polymer is used for energy, the cell is not particularly picky
about the nature of the carbon stored (otherwise it would not store as much carbon as it
could, resulting in an evolutionary disadvantage), and the PhaB enzyme consequently has
very loose substrate specificity. Hbd on the other hand evolved as part of a very specific
butyrate production pathway designed as a sink for electrons generated during the
anaerobic C. acetobutylicum fermentations on glucose (Boynton et al., 1996). Because
there is no evolutionary advantage for Hbd to have broad substrate specificity, there has
been no pressure for it to perform catalysis on anything other than 3-ketobutyryl-CoA.
Consequently Hbd does not tolerate the 5-hydroxyl group in 3-keto-4-hydroxybutyryl-
CoA (a precursor to DHBA) as well as PhaB and DHBA titers are much lower with Hbd
than PhaB. This substrate specificity effect on product titers is also seen amongst the
acetoacetyl-CoA reductases, with BktB and PhaA having much higher titers than Thil
(Figure 6.4), again due to the same evolutionary pressure argument on BktB and PhaA
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(also used for carbon storage in R. eutropha; Schubert et al., 1988; Slater et al., 1998)
versus the lack of that pressure on Thil (which is also used in the butyrate pathway in C.
acetobutylicum; Stim-Herndon et al., 1995). Having broad substrate range "auxiliary"
enzymes for the 3-hydroxyalkanoic acid pathway - Pct and TesB - also made 3HV,
DHBA, and 3-HBL production possible (Schweiger and Buckel, 1984; Huisman et al.,
1991). By examining the known substrate tolerances of candidate enzymes for a pathway
and understanding those substrate tolerances in the evolutionary context of the enzymes'
native functions, one can identify those enzymes that are most likely to accept non-
natural substrates in de novo biosynthetic pathways for the production of novel products.
Another interesting observation is that sometimes simply expressing an enzyme that
catalyzes a known reaction is not enough to achieve product. For instance, it was known
that 4HV was a substrate for PON1 (Draganov et al., 2005), yet simply expressing PON1
does not result in substantial 4VL accumulation (Figures 4.3 - 4.5). Enzymes must be
expressed in the proper context to realize their true catalytic potential. Intracellularly,
PON 1 could not produce significant quantities of 4VL due to the unfavorable equilibrium
between 4HV and 4VL. At an acidic pH, however, PON1 can better catalyze 4HV
lactonization, because at reduced pH values the equilibrium between 4HV and 4VL
shifted more towards 4VL production. Because the cytosol pH is slightly basic (Wilks
and Slonczewski, 2007), PON1 had to be localized outside of the cell to take advantage
of a more acidic medium pH for catalysis. Just as not all enzymes in nature are cytosolic,
all recombinantly-expressed enzymes need not be cytosolic as well. In this particular
case, relocating the PON1 lactonase outside of the cytosol where the conditions under
167
which it performed catalysis could be controlled allowed for an order of magnitude
improvement in lactone titer (Figure 4.5). This strategy is generalizable to bottleneck
enzymes in other metabolic pathways that do not perform well under cytosolic
conditions.
Analysis of Lactonization Strategies
Lactonization in aqueous biological systems is challenging for two reasons: (1) water
hydrolyzes lactone rings and (2) lactonization generally does not occur without an acid
catalyst (Carey, 2000). Aqueous culture media has water concentrations in excess of 50
molar, strongly encouraging the hydrolysis of lactones while suppressing the formation of
lactone rings. Ironically, functional group contribution theory calculations show that
lactonization should have a standard free energy change of -2.7 kcal mol', indicating that
lactonization under standard thermodynamic conditions is spontaneous (Mavrovouniotis,
1991). Unfortunately, aqueous solution is anything but "standard thermodynamic
conditions", and the high concentration of water drives lactone equilibrium towards the
hydrolyzed state. Since microbial cells must be cultured in aqueous solution, removing
the water during the culturing phase is not an option. Removing the water after the
culture is done would result in lactonization, but the energy cost for evaporating the water
would be very high. Enzymes like PON1 exist that can catalyze the lactonization
reaction (Aharoni et al., 2004), however as enzymes are catalysts, they only speed the
reaction along to equilibrium and cannot produce more lactone than would otherwise be
present at equilibrium. In this case, that equilibrium lies far in favor of lactone
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hydrolysis, and in the case of the P. putida 4VL lactone production system described in
Chapter 4, the equilibrium was approximately 4 mol% lactone (Figures 4.3 and 4.4).
One strategy for overcoming this thermodynamic reality is to drive the lactonization
reaction forward with acid. Acid accelerates the lactonization reaction by counteracting
the net alkaline generation that occurs when a deprotonated carboxylate group condenses
with a hydroxyl group. Unfortunately inside a microbial cell where biocatalysis normally
occurs, the pH is maintained at a relatively high value of approximately 7.5 (Wilks and
Slonczewski, 2007). In this thesis (Chapter 4), this problem was overcome by localizing
a lactonase outside of the cytosol, where the enzyme is exposed to the medium pH. This
allowed for control of the pH of lactonization by manipulation of the medium pH, and
consequently by lowering the medium pH, lactonization was substantially enhanced
(Figure 4.4). However, the medium pH cannot be reduced below the threshold at which
the cells would die due to acid toxicity. In the P. putida system where this technique was
employed, that threshold was approximately pH 6.0, where the equilibrium amount of
lactone (4VL) was approximately 30-35 mol% (Figure 4.6). While this strategy is a solid
improvement over the original 4 mol% lactone, this approach still leaves 65-70 mol% of
the lactone in the hydrolyzed state.
A much better approach was to circumvent the lactone-hydroxyacid equilibrium entirely
by starting with a higher-energy substrate. In the case of the 3-hydroxyalkanoic acid
pathway biosynthesis of 3-HBL (Chapter 6), 3-HBL was made spontaneously from
DHBA-CoA through a type of auto-lactonization reaction (Figure 6.10). DHBA-CoA
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has substantially more energy than DHBA due to the activation of its carboxylate group
by a CoA thioester (Mavrovouniotis, 1991). This additional energy helps drive
lactonization to completion by using the CoA moiety as a leaving group. When tesB was
removed from the 3-hydroxyalkanoic acid pathway to allow auto-lactonization of DHBA-
CoA to occur, 89-94 mol% of the product obtained was in the lactone (3-HBL) form
(Figure 6.6). Furthermore these numbers are a conservative estimate as genomic tesB
(which hydrolyzes DHBA-CoA into DHBA) was still active in this experiment. This
near-complete degree of lactonization indicates that using high-energy substrates for
lactonization is a highly effective option, though it may be difficult to find systems where
such a strategy is possible. For instance, 4HV-CoA in theory can lactonize, however this
spontaneous lactonization was never observed experimentally.
A more general strategy for lactonization is the post-treatment of culture broths
containing large amount of hydroxyacid precursor with copious amounts of acid, driving
the lactonization reaction forward chemically. When this method was employed for 3-
HBL production from DHBA, lactone fractions were improved from 20-31 mol% to 84-
88 mol%, though admittedly with some loss of DHBA to multimerization (Figures 6.7
and 6.9). While this method essentially terminates the microbial cell culture and requires
the purchase and addition of acid, it is a quick and simple culture post-treatment that is
broadly applicable to any microbial production system so long as that system can produce
the hydroxyacid precursor.
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Outlook and Recommendations
The P. putida 4VL production system (Chapters 3 and 4) has already shown tremendous
promise in producing 4VL, a potientally valuable next generation biofuel and bioprocess
plant chemical (Horvith et al., 2007), from levulinate, a renewable biomass-derived
feedstock listed as one of the top ten value-added chemicals derived from biomass
(Werpy and Peterson, 2004). This process, the first of its kind, allows for the utilization
of levulinate made from the processing of agricultural waste. The hydroxyvalerates
produced as an intermediate in 4VL production can be polymerized into "green"
biopolyesters with favorable physical properties (Gorenflo et al., 2001). Shake-flask and
bioreactor scale experiments done in this thesis have shown that high titers of
hydroxyvalerates (Figures 3.1 and 3.2) and 4VL (Figures 4.5 and 4.6) are possible even
without any strain or enzyme engineering. Future efforts to improve upon the titers of
3HV, 4HV, and 4VL reported in this work should focus first on identifying the enzyme(s)
in P. putida responsible for levulinate metabolism so that the pathway can be
reconstituted in a more accessible microorganism such as E. coli. This would allow for
metabolic and enzyme engineering of these enzymes in order to improve pathway
productivity. Alternatively, P. putida could be engineered directly if the levulinate
metabolism pathway was known.
The integrated bioprocessing effect for 4VL production in P. putida in acidic media,
while making 4VL production possible, only converts 30-35 mol% of 4HV into 4VL.
This means that 4VL titers could be improved by up to three-fold simply by finding a
way to achieve complete lactonization. One quick and easy way of doing this is by
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acidifying 4HV-rich culture media to pH < 1, however the addition of so much acid could
render the process economically unattractive. A viable alternative to this would be to
operate this bioprocess in two-phases. If the 4VL produced in the aqueous phase could
be sequestered away from the PON1 lactonase, the equilibrium between 4HV and 4VL
would shift even further towards 4VL production through a Le Chatelier-type effect. As
of the writing of this thesis this experiment is being tested using two solid phase
polymeric resins: DowexTM Optipore TM L493 and DowexTM OptiporeTM SD-2 (Dow
Chemical Company (Midland, MI). Preliminary results indicate that the equilibrium
level of lactonization at pH 6 in the presence of these two resins increases from
approximately 30 mol% to 55 mol% (data not shown). This result shows that
implementation of a two-phase system has excellent potential for driving lactonization
forward while recovering and purifying the 4VL product.
The 3-hydroxyalkanoic acid pathway also shows tremendous promise as a general
platform for the biosynthesis of a wide range of 3-hydroxyacids and their derivatives.
While this thesis focused on the production of 3HB, 3HV, DHBA, and 3-HBL, it is
certainly possible to produce other products through the condensation of acetyl-CoA with
different acyl-CoA molecules. The main challenges in realizing broader production of 3-
hydroxyacids with this pathway are thiolating the necessary organic acids so that they
may be substrates for condensation and finding additional acetoacetyl-CoA thiolases and
3-hydroxybutyryl-CoA reductases capable of working with different and ever more
divergant substrates. In this work, only one pct homolog was cloned and screened, and
fortunately it was tolerant of a wide range of substrates. Examining other pct homologs,
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such as one from Clostridium propionicum (Selmer et al., 2002) may lead to new
substrates and new discoveries with the 3-hydroxyalkanoic acid pathway. Similarly, the
screening of new acetoacetyl-CoA thiolase and 3-hydroxybutyryl-CoA reductase
homologs should enable the condensation and reduction of an even more diverse array of
pathway intermediates. Finally as with the P. putida 4VL work, enzyme and strain
engineering is always a viable option for further improving pathway productivity and
achieving higher titers. Scale-up of the 3-hydroxyalkanoic acid pathway in a bioreactor
is also another option, as this was not explored in this work. Given the value of 3-HBL
(currently $20-50 per gram depending on quantity and enantiopurity) and its large market
as a substrate in the production of many high-value compounds and pharmaceuticals (Lee
and Park, 2009), efforts should be focused in bringing 3-HBL titers to commercially
viable levels.
Concluding Thoughts
Fundamentally this thesis was an exercise in metabolic exploration. As stated in Chapter
2, there are many enzymes out there - both known and unknown - and there are many
potential and productive combinations of these enzymes that result in the creation of new
and/or useful chemical compounds. Currently this metabolic terrain remains largely
unmapped, and opportunities for revolutionizing how chemicals are made are out in that
terrain somewhere. The work done here represents only one homestead in this vast
metabolic wilderness. Nonetheless, the metabolic wilderness, the author hopes, is one
step closer to being tamed.
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Even in the much more mature field of chemistry, new reactions and processes are being
discovered daily. Every month or so one can read through the many chemistry journals
that are published - each one full of new discoveries and new knowledge. Today the
chemistry landscape is much better colonized than the biochemical one. With chemistry,
whole broad classes of reactions have been worked out to obtain desired products. For
instance, reducing agents such as lithium aluminum hydride have been found to react
with and reduce many different compounds on demand. This kind of reaction is well
worked out in chemistry, so much so that the chemist can be confident that the reaction
has an excellent chance of working on completely untested substrates. In the biochemical
production of compounds, figuring out how to develop and construct a pathway for the
production of a desired chemical is a daunting and laborious process. Enzymes are all
too often "black-box catalysts" that, while powerful, are poorly understood.
Biotechnology is not yet developed to the point where enzyme behavior can be predicted
when enzymes are challenged by non-natural substrates in novel metabolic pathways.
The development of the P. putida hydroxyvalerate and the E. coli 3-hydroxyalkanoic acid
pathways has this author thinking that the future and promise of metabolic pathway
engineering lies not in the construction of individual pathways but in the creation of
whole biocatalytic platforms. The building of individual pathways, while helping to map
the metabolic wilderness, only sheds light on the smallest of areas. Just as in chemistry,
there is a great need to develop biocatalysts and pathways for the production of whole
classes of compounds rather than single molecular targets. How nice it would be to pull a
tube of reductase enzyme out of a freezer and to be able to use that enzyme on a vast
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array of substrates with the confidence that this enzyme will catalyze their reduction.
The 3-hydroxyalkanoic acid pathway (Chapters 5 and 6) was a small example of one
broad biochemical system. Still, this pathway has its limits - the further away the
pathway substrate is from acetyl-CoA the lower the product titer becomes. However, the
3-hydroxyalkanoic acid pathway is a seed - a starting point from which a more
generalized, broader reaching 3-hydroxyalkanoic acid pathway can be engineered.
Through the examination of enzyme homologs and the power of protein engineering, this
seed can indeed sprout into a plant with many leaves and branches - with many different
pathways substrates and valuable products. The ReBiT database discussed in Chapter 2
depicts the construction of pathways based on changes in functional group structure, but
it disregards enzyme substrate specificity to simplify the problem of computational
pathway design. Yet ReBiT highlights the need for enzymes that are not picky with their
substrates. Just as lithium aluminium hydride is not picky with what it reacts with, so too
is there a need for enzymes that can be chosen for a reaction only on the chemical
reactions they catalyze and not the substrates they prefer.
Beyond building generalized metabolic pathways, there is a need for constructs, systems,
or otherwise "bags of tricks" for those difficult systems that do not lend themselves to
biocatalysis. The integrated bioprocessing work (Chapter 4) was one such broadly
applicable system. Other engineered systems, such as the recent metabolic pathway
scaffolding work (Dueber et al., 2009) have been developed to solve specific challenges
in metabolic pathway construction. The 4VL production work made clear that simply co-
expressing enzymes in a pathway is often not enough to truly realize the potential of that
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pathway. Enzymes must be expressed in context - in the right location, in the right
amount, and at the right time - in order to maximize their effect and impact on product
titers. The key message in integrated bioprocessing is to integrate the pathway into the
context and environment of its host. This is not simply host strain engineering, but true
integration of the pathway through the use of tools that weld a recombinant pathway to
the cell in a manner that maximizes pathway productivity. This is not to say that host
engineering is not important - indeed host engineering is one very critical component of
the weld. But to meet the challenge of generalized biocatalysis, not only must pathways
be composed correctly and the host engineered for optimium productivity, but strategies
and tools must be developed and applied to mesh a recombinant pathway with its host.
Biotechnology is the clear choice for clean, renewable chemical production. From
medicines to fuels to materials, the human world is made of chemicals, and chemicals
dramatically enhance the human quality of life. In today's world, oil is the source of
most chemicals. Through oil wealth is made, national agendas are set, and humanity
lives in relative comfort. Oil however is not eternal, and this fact is the primary driver of
innovation within biotechnology. The metabolic wilderness is still thick, and most
biochemical pathways cannot currently compete with their oil-derived counterparts, but
ultimately the leap to renewable resources must be made. Ultimately, the metabolic
wilderness will be colonized and tamed, the only question is when.
If there was a mantra for this thesis, it would be "Where there's an enzyme, there's a
way." The author is a firm believer that any compound can be made through
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biocatalysis, though finding the right way remains quite the challenge. Enzymes are truly
remarkable catalysts, yet so little is known about how they do what they do. Today,
science struggles to understand native enzymatic function - predicting unnatural enzyme
function is an educated guess at best. If no way exists to make a desired product, this
only means that efforts should be focused on making the enzyme. While the wilderness
is vast, it is not truly infinite. Yet it will not be tamed through the engineering of
individual pathways, but through the creation of broader biocatalytic platforms. Rather
than making one pathway at a time, efforts should be concentrated on developing the
tools needed to make more pathways within a given period of time. Today's jungles are
cut down not with axes, but with bullbozers.
The author truly hopes that this thesis inspires and empowers others to claim their stake,
their homestead, on the frontier that is metabolic pathway engineering. Though the work
is hard, the field is young, and the potential is great. Today the engineering of successful
pathways is luck, but tomorrow it will be skill. A teacher very dear to the author once
said that fortune favors the prepared mind. Today is the day to work hard and prepare,
for biotechnology's best days have yet to come.
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